BD to Present at Investor Healthcare Conferences
- FRANKLIN LAKES, N.J. , Feb. 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following healthcare conferences: Citi's 2025 Unplugged Medtech and Life Sciences Access Day February 27, 2025 8:45 a.m.
- 02/13/2025
|
Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™.
- DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. The increased incidence of emerging infectious diseases and antibiotic-resistant infections leads to greater demand for accurate and reliable diagnostics. In addition, there are rapid advances in the efficiency of molecular testing techniques, such as PCR and next-generation sequencing, which have improved diagnostic capabilities. These provide results that are more sensitive and at a faster speed, and allow for the simultaneous identification of multiple pathogens, which becomes vital in handling complex and continually changing infectious disease threats. These are some of the major contributors to the growing market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40667482 Browse in-depth TOC on "Molecular Infectious Disease Testing Market" 539 - Tables61 - Figures448 - Pages An advancement in multiplex testing which could transform the molecular infectious disease testing market, is the integrated, fully automated multiplex diagnostic platforms. It will combine testing for multiple pathogens in a single reaction with the advantage of full automation, right from sample preparation to result interpretation. The automation of multiplex testing minimizes the chance of human error, enhances throughput, and accelerates the diagnostic process. These are the factors why this technology will thrive in environments of high demand such as hospitals, urgent care centers, and public health labs. The more these systems become user-friendly and affordable, the greater their potential will be to enhance access to multiplex tests in more rapid and comprehensive infectious disease surveillance and management across a range of healthcare settings. Based on product & service, the global molecular infectious disease testing market has been segmented into reagents & kits, instruments, and services & software. The fastest-growing segment within the molecular infectious disease testing market is the reagents and kits, mainly due to their critical role in making it possible for an accurate and efficient diagnosis. The growing use of molecular testing in clinical practices has caused the demand for good quality reagents and kits since they are indispensable in PCR, next-generation sequencing, and other molecular assays. The expansion of testing volumes within diagnostic laboratories and hospitals further propels the growth. Moreover, increased accessibility to ready-to-use, standardized kits and reagents that enhance sensitivity and reduce the turnaround time accelerate their demand in the molecular infectious disease testing market. Categorized by type, the molecular infectious disease testing market is segmented into single plex testing and multiplex testing. The multiplex testing segment is expected to witness the highest growth rate in the molecular infectious disease testing market because of its ability to test for more than one pathogen in a single test. Such capability can considerably reduce the testing time and cost while improving efficiency and accuracy of diagnostics. This is very helpful in complex infections, which could be due to multiple pathogens. The increasing demand for this type of testing in healthcare settings having high patient numbers is further due to the need for comprehensive, timely diagnostic solutions. Technological advancements in multiplex assay platforms have made this testing become indispensable in improving the clinical outcome, enhancing infection control measures. Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). These companies have a diversified product portfolio and a good geographic presence also. With growing global burden of infectious diseases and increasing need for accurate diagnostics, such players are well-positioned to develop novel diagnostic technologies and further expand their offerings. They expand their market share through subsidiaries across the world based on the strength of their R&D capabilities and diversified product and services portfolios. Their product launches, agreements, acquisitions, and partnerships further enhance their portfolio while expanding the reach of their global business. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=40667482 The key players operating in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). The market players have adopted several strategies such as advanced product development, partnerships, expansions, and acquisitions to strengthen their market position. The organic and inorganic strategies have allowed the market players to expand across geographies through the provision of advanced molecular infectious disease tests. Danaher emerged as the leader in the molecular infectious disease testing market in 2023. Its position as the leader in the market across the US serves as a platform from where it can penetrate more into the developing economies and build its global presence across more geographies. The company is also responsible for innovation in its products to cater to the varied needs of customers worldwide. This has assisted the company in building on its leadership position in the market. Additionally, the company also adopts certain organic growth strategies by launching new products and seeking relevant regulatory clearances. For example, in March 2024, the US FDA cleared the Xpert Xpress GBS test. In November 2022, it launched the Xpert Xpress MVP, a multiplexed PCR test. Such strategic steps have helped the company stay continuously in the lead in the molecular infectious disease testing market. F. Hoffmann-La Roche Ltd is a significant global player in the molecular infectious disease testing market. Its broad portfolio and presence in all parts of the world have helped it sustain its competitive advantage. Roche has a very good direct and indirect distribution network around the world, which enables it to balance out demand fluctuations in the different markets. Its strategic emphasis on organic as well as inorganic growth strategies makes the company stronger in the marketplace. For example, in September 2024, Roche launched the cobas Respiratory flex test. This is the first test by Roche using Roche's innovative and proprietary TAGS (Temperature-Activated Generation of Signal) technology. This technology identifies as many as 15 pathogens in a single PCR test by using multiplex polymerase chain reaction testing combined with color, temperature, and data processing. All these strategies, coupled with its strong presence in the market, have given Roche further opportunities to enhance its position within the molecular infectious disease testing market. bioMérieux is a prominent player in the molecular infectious disease testing market. Its robust position in the market is due to extensive distribution networks in America, Europe, the Middle East & Africa, and Asia Pacific. High investment in research & development, coupled with organic growth strategies, also helps bioMérieux strengthen its position in the market. Such initiatives include the launching of products and gaining appropriate regulatory approvals in order to extend its market shares. In December 2024, bioMérieux announced that the company's BIOFIRE FILMARRAY Tropical Fever (TF) Panel has achieved USD FDA Special 510(k) clearance. This new, innovative PCR-based testing solution brings fast and accurate pathogen identification in patients suffering from unexplained fever to clinicians, optimizing the treatment overall. For more information, Inquire Now! Related Reports: Molecular Diagnostics Market Veterinary Diagnostics Market Molecular Quality Controls Market IVD Contract Manufacturing Market Genetic Testing Market Get access to the latest updates on Molecular Infectious Disease Testing Companies and Molecular Infectious Disease Testing Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
- 02/13/2025
|
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 02/12/2025
|
Starboard pushes an open door at Becton Dickinson as company seeks to separate its biosciences unit
- Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The company aims to do just that.
- 02/08/2025
|
Compared to Estimates, Becton Dickinson (BDX) Q1 Earnings: A Look at Key Metrics
- While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 02/05/2025
|
Becton Dickinson (BDX) Tops Q1 Earnings and Revenue Estimates
- Becton Dickinson (BDX) came out with quarterly earnings of $3.43 per share, beating the Zacks Consensus Estimate of $2.98 per share. This compares to earnings of $2.68 per share a year ago.
- 02/05/2025
|
Becton Dickinson looks to separate life sciences unit
- Becton Dickinson said on Wednesday its board has authorized a plan to separate its life sciences unit as the medical device maker aims to focus on its core business.
- 02/05/2025
|
BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value
- Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market valuation "New BD," built on momentum of BD 2025 strategy, will be well-positioned as a scaled, pure-play MedTech leader focused on attractive categories shaping the future of health care Biosciences and Diagnostic Solutions to realize its full market potential as differentiated leader in Life Sciences Tools and Diagnostics, with robust innovation pipeline and headroom for growth in key sectors FRANKLIN LAKES, N.J. , Feb. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD's Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus and growth-oriented investments and capital allocation for both BD and the separated business and enhance value creation for shareholders.
- 02/05/2025
|
BD Reports First Quarter Fiscal 2025 Financial Results
- Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organic GAAP and adjusted diluted EPS of $1.04 and $3.43 grew 8.3% and 28.0%, respectively BD completes $750 million share repurchase to date in FY25 Company increases FY25 adjusted diluted EPS guidance at the midpoint while absorbing translational currency1 FRANKLIN LAKES, N.J. , Feb. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 first quarter which ended December 31, 2024.
- 02/05/2025
|
Can Sustained Product Demand Drive BDX Stock Before Q1 Earnings?
- The continued solid uptake of BD's products is expected to have driven fiscal first-quarter revenues despite transitory market dynamics.
- 02/03/2025
|
Insights Into Becton Dickinson (BDX) Q1: Wall Street Projections for Key Metrics
- Besides Wall Street's top -and-bottom-line estimates for Becton Dickinson (BDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
- 02/03/2025
|
Starboard Value pushes Becton Dickinson to sell life sciences unit, FT reports
- Activist investor Starboard Value has taken a stake in Becton Dickinson and is pushing the medical technology company to sell its life sciences unit, the Financial Times reported on Monday.
- 02/03/2025
|
Becton Dickinson (BDX) Reports Next Week: Wall Street Expects Earnings Growth
- Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/30/2025
|
BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $750 Million Repurchase to Date in FY25
- FRANKLIN LAKES, N.J. , Jan. 28, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, payable on March 31, 2025 to holders of record on March 10, 2025.
- 01/28/2025
|
BD Stock Rises on Biosero Deal for AI-Powered Robotic Cytometry Tech
- BD and Biosero collaborate to integrate robotic automation with flow cytometry technology, aiming to accelerate drug discovery.
- 01/24/2025
|
What Can The Dividend Kings Deliver In 2025?
- The Dividend Kings underperformed the broad U.S. equity market in 2024, achieving a 5.53% total return compared to the S&P 500's 24.89%. 2024 returns for the Dividend Kings were primarily driven by earnings growth and dividends, with the change in P/E ratio being a detractor. I breakdown the components of total return for each Dividend King by sector to gain insights into current valuation.
- 01/24/2025
|
BD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and Development
- FRANKLIN LAKES, N.J. and SAN DIEGO , Jan. 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, today announced a framework collaboration agreement to enable and facilitate robotic arm integration with BD flow cytometry instruments to accelerate drug discovery and development.
- 01/23/2025
|
BD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and Development
- FRANKLIN LAKES, N.J. & SAN DIEGO--(BUSINESS WIRE)--BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, today announced a framework collaboration agreement to enable and facilitate robotic arm integration with BD flow cytometry instruments to accelerate drug discovery and development. Together, the companies intend to develop new software capabilities within.
- 01/23/2025
|
Carilion Clinic First in Virginia to Offer Needle-free In-patient Blood Draws, Redefining Patient Standard of Care
- ROANOKE, Va. and FRANKLIN LAKES, N.J.
- 01/22/2025
|
Masimo names Becton Dickinson's Katie Szyman CEO
- Masimo said on Tuesday it has named Becton Dickinson executive Katie Szyman as chief executive officer after a bitter proxy battle with activist hedge fund Politan Capital Management led to the ouster of founder Joe Kiani from the medical device maker's board last year.
- 01/21/2025
|
BDX or MMSI: Which Is the Better Value Stock Right Now?
- Investors interested in Medical - Dental Supplies stocks are likely familiar with Becton Dickinson (BDX) and Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now?
- 01/17/2025
|
BD to Announce Financial Results for its First Quarter of Fiscal 2025
- FRANKLIN LAKES, N.J. , Jan. 16, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.
- 01/16/2025
|
Bet on 5 Top-Ranked Stocks With Rising P/E for Soild Gains
- Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Land's End, Humana, Rent the Runway, Becton, Dickinson and Company and ATI.
- 01/15/2025
|
BD Boosts U.S. Manufacturing of Critical Medical Devices
- FRANKLIN LAKES, N.J. , Jan. 15, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced additional investments in its U.S. manufacturing network to add capacity for critical medical devices, including syringes, needles and IV catheters, to meet the ongoing needs of the nation's health care system.
- 01/15/2025
|
New ASCCP Guidelines Include More Precise Method of Cervical Cancer Screening
- BD Onclarity™ HPV assay adheres to new guidelines by identifying more individual types of HPV than any other test on the market FRANKLIN LAKES, N.J. , Jan. 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the BD Onclarity™ HPV Assay has officially been added to the American Society for Colposcopy and Cervical Pathology (ASCCP) Enduring Risk-Based Management Guidelines, due to its ability to individually identify more high-risk types of HPV.
- 01/13/2025
|
BD Names Pamela Spikner as Chief Accounting Officer and Controller
- FRANKLIN LAKES, N.J., Jan. 10, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Pamela Spikner has been named senior vice president, chief accounting officer and controller, effective January 20.
- 01/10/2025
|
Here's Why Becton Dickinson (BDX) is a Strong Growth Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 01/09/2025
|
New Survey Finds Women Are Skipping Their OB/GYN Exams, Increasing Risks for Cervical Cancer
- Women Are Seeking More Convenience and Less Discomfort in Testing Options FRANKLIN LAKES, N.J., Jan. 9, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the results of a new survey, revealing that 72% of women in the United States have delayed having a gynecology visit, with many highlighting the need for greater convenience, comfort and ease for this critical cervical cancer screening process.
- 01/09/2025
|
BD To Host Virtual 2025 Annual Meeting of Shareholders
- FRANKLIN LAKES, N.J. , Jan. 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will host its virtual 2025 Annual Meeting of Shareholders (the "Annual Meeting") on Tuesday, January 28, 2025, at 1:00 p.m.
- 01/07/2025
|
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
- Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/07/2025
|
Here's Why You Should Retain BDX Stock in Your Portfolio for Now
- BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns.
- 01/07/2025
|
Becton Dickinson (BDX) is a Top-Ranked Value Stock: Should You Buy?
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 01/03/2025
|
BDX vs. MMSI: Which Stock Is the Better Value Option?
- Investors interested in Medical - Dental Supplies stocks are likely familiar with Becton Dickinson (BDX) and Merit Medical (MMSI). But which of these two companies is the best option for those looking for undervalued stocks?
- 01/01/2025
|
My Best Dividend Aristocrats For January 2025
- The ProShares S&P 500 Dividend Aristocrat ETF rocked a cool 4.85% gain in November, but it's giving up nearly half of its return this year in December. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 41 months of tracking these strategies, two strategies are generating a CAGR superior to NOBL.
- 12/31/2024
|
5 Top AI-in-MedTech Stocks for Big Gains in 2025: MDT, BSX & More
- Here we discuss five medical stocks - MDT, BSX, BDX, GEHC and TEM - incorporating AI in their workflows. These are likely to gain in 2025 as AI helps cut costs and improve patient care.
- 12/30/2024
|
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 12/20/2024
|
BDX Stock Down Despite New Expansion to Boost Fingertip Blood Testing
- The blood testing process integrating BD's MiniDraw System with Babson's BetterWay technologies is likely to lower common barriers to testing and improve patient outcomes.
- 12/18/2024
|
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 12/18/2024
|
Why Becton Dickinson (BDX) is a Top Momentum Stock for the Long-Term
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 12/17/2024
|
BD and Babson Diagnostics Launch Innovative Fingertip Blood Testing to Health Care Organizations
- FRANKLIN LAKES, N.J. and AUSTIN, Texas , Dec. 17, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Babson Diagnostics, a science-first health care technology company, today announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems and other large provider networks in settings like urgent cares, doctor offices and other ambulatory care settings.
- 12/17/2024
|
Becton Dickinson settles charges over infusion pump risks, SEC says
- The U.S. Securities and Exchange Commission said on Monday that it had settled charges with Becton Dickinson and Co. over allegations it misled investors about risks associated with its Alaris infusion pump.
- 12/16/2024
|
Becton Dickinson to Pay $175 Million for Misleading Investors About Alaris Infusion Pump
- Washington, D.C.--(Newsfile Corp. - December 16, 2024) - The Securities and Exchange Commission today announced settled charges against Becton, Dickinson and Company, a New Jersey-based medical device manufacturer known as BD, for repeatedly misleading investors about risks associated with its continued sales of its Alaris infusion pump and for overstating its income by failing to record the costs of fixing multiple software flaws with the pump.
- 12/16/2024
|
BD Resolves Previously Disclosed SEC Investigation
- FRANKLIN LAKES, N.J. , Dec. 16, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement: BD has reached an agreement with the U.S. Securities and Exchange Commission (SEC) to resolve the previously disclosed investigation related to prior public disclosures and SEC reporting regarding the BD Alaris™ System, which was acquired by BD from CareFusion in 2015 and is part of the BD Medication Management Solutions business.
- 12/16/2024
|
Zacks Industry Outlook Becton, Dickinson, BD, McKesson, Cardinal Health and Merit Medical Systems
- Becton, Dickinson, BD, McKesson, Cardinal Health and Merit Medical Systems have been highlighted in this Industry Outlook article.
- 12/13/2024
|
4 Stocks to Watch Amid Dental Supplies Industry Challenges
- Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are BDX, MCK, CAH and MMSI.
- 12/12/2024
|
Santa's Stunning Stocking Surprises: 5 High Yield Blue-Chip Bargains For 2025
- Investing in blue-chip stocks at 52-week lows can potentially yield significant returns if fundamentals are strong. Avoid value traps by focusing on companies with solid fundamentals, like Elevance Health, Becton, Dickinson, LyondellBasell, Rogers Communications and Rexford Industrial Realty. These companies offer a 3.7% yield and a 27% discount to fair value, and they have historically outperformed the market with 27% less volatility.
- 12/12/2024
|
12 High-Yield Dividend Aristocrats To Weather The Coming 2025 Storm In Style
- The S&P is up almost 28% in 2024, and many investors worry about a melt-up followed by a sharp correction like in 2022 or 2018. A 2025 market correction is likely, but low-volatility, high-yield Dividend Aristocrats offer a better alternative to the traditional 60-40 portfolio and S&P. These 12 Aristocrats provide a 3.2% yield, 14% discount, 22% upside potential next year, and 10% long-term income growth consensus, while being 54% lower volatility than the S&P.
- 12/07/2024
|
These 5 Stocks Have 50 Years of Dividend Growth—Here's How to Find More
- With a new presidential administration set to take office on Jan. 20, 2025, some investors may be uncertain about how new policies and personnel will affect the stock market and interest rates. Will tariffs, discarded trade deals, and frayed alliances help or hurt the market?
- 12/06/2024
|
17 Upcoming Dividend Increases, Including A King
- With the holiday season underway, I present 17 companies with dividend increases for 2024, including Becton, Dickinson, and Company, a dividend king with a 52-year streak. My strategy focuses on buying, holding, and adding to companies with consistent dividend growth and outperforming benchmarks, using data from U.S. Dividend Champions and NASDAQ. I prioritize companies with strong historical returns and high 10-year dividend growth rates, comparing them against the Schwab U.S. Dividend Equity ETF.
- 12/05/2024
|
Becton, Dickinson and Company (BDX) 7th Annual Evercore ISI HealthCONx Conference (Transcript)
- Becton, Dickinson and Company (NYSE:BDX ) 7th Annual Evercore ISI HealthCONx Results Conference December 3, 2024 10:50 AM ET Company Participants Richard Byrd - EVP and President of Interventional Business Chris DelOrefice - Executive Vice President & Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Thanks, everyone, for joining us this morning. A pleasure to have with us Becton, Dickinson.
- 12/03/2024
|
Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 12/02/2024
|
Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps
- On Tuesday, Embecta Corp EMBC posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents and down from 59 cents reported a year ago.
- 11/26/2024
|
My Best Dividend Aristocrats For December 2024
- The ProShares S&P 500 Dividend Aristocrat ETF is up 10.26% year-to-date through October. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 40 months of tracking these strategies, two strategies are generating a CAGR superior to NOBL.
- 11/26/2024
|
First of Its Kind HPV Self-Collection Study Launched to Improve Cervical Cancer Screening in Underserved Communities
- BROWNSVILLE, Texas , Nov. 20, 2024 /PRNewswire/ -- A first of its kind Human Papillomavirus (HPV) self-collection screening pilot program aimed at improving cervical cancer screening in underserved communities has officially launched in Texas. HPV is the cause of virtually all cervical cancers.
- 11/20/2024
|
BD to Present at the 7th Annual Evercore ISI HealthCONx Conference
- FRANKLIN LAKES, N.J. , Nov. 19, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 10:50 am Eastern Time.
- 11/19/2024
|
Becton, Dickinson and Company Q4: Shifting To High-Growth Areas
- Becton, Dickinson and Company is projected to achieve 8.8%-9.3% revenue growth in FY25, driven by new product launches and the APM business. The acquisition of Edwards Lifesciences' Critical Care product group is expected to significantly boost BD's Advanced Patient Monitoring segment. BD plans to reduce debt leverage to 2.5x and repurchase $1 billion in shares, enhancing financial stability and shareholder value.
- 11/12/2024
|
Are Investors Undervaluing Becton, Dickinson and Company (BDX) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 11/11/2024
|
Looking for a Growth Stock? 3 Reasons Why Becton Dickinson (BDX) is a Solid Choice
- Becton Dickinson (BDX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 11/07/2024
|
BDX or MMSI: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Becton Dickinson (BDX) or Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now?
- 11/07/2024
|
Becton, Dickinson and Company (BDX) Q4 2024 Earnings Call Transcript
- Becton, Dickinson and Company (NYSE:BDX ) Q4 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Greg Rodetis - Senior Vice President, Treasurer & Head of Investor Relations Tom Polen - Chairman, Chief Executive Officer & President Chris DelOrefice - Executive Vice President & Chief Financial Officer Mike Garrison - President of Medical Segment Conference Call Participants Vijay Kumar - Evercore ISI Larry Biegelsen - Wells Fargo Travis Steed - Bank of America Robbie Marcus - JPMorgan Patrick Wood - Morgan Stanley David Roman - Goldman Sachs Matt Miksic - Barclays Matt Taylor - Jefferies Rick Wise - Stifel Operator Hello and welcome to BD's Fourth Quarter and Full Year Fiscal 2024 Earnings Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com, or by phone at 800-839-1337 for domestic calls and area code +1-402-220-0489 for international calls.
- 11/07/2024
|
BDX Stock Gains Following Q4 Earnings Beat and Higher Margins
- BD's overall topline in the fourth quarter of fiscal 2024 benefits from revenue growth in all segments.
- 11/07/2024
|
Becton Dickinson (BDX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
- The headline numbers for Becton Dickinson (BDX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 11/07/2024
|
Becton Dickinson (BDX) Q4 Earnings and Revenues Surpass Estimates
- Becton Dickinson (BDX) came out with quarterly earnings of $3.81 per share, beating the Zacks Consensus Estimate of $3.77 per share. This compares to earnings of $3.42 per share a year ago.
- 11/07/2024
|
Becton Dickinson beats quarterly estimates on strength in drug-delivery devices
- Becton Dickinson surpassed analysts' expectations for fourth-quarter results on Thursday, helped by strong demand for its drug-delivery devices.
- 11/07/2024
|
BD Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
- Strong Growth and Margin Execution Drives Performance in Quarter Q4 revenue of $5.4 billion increased 6.9% as reported, 7.4% currency-neutral and 6.2% organic Q4 GAAP and adjusted diluted EPS from continuing operations of $1.45 and $3.81 grew 173.6% and 11.4%, respectively FY24 revenue of $20.2 billion increased 4.2% as reported and currency neutral, 4.6% adjusted currency-neutral, and 5.0% organic FY24 GAAP and adjusted diluted EPS from continuing operations of $5.93 and $13.14 grew 16.3% and 7.6%, respectively FY24 cash from continuing operations grew 28.5% to $3.8 billion and Free Cash Flow grew 47.4% to $3.1 billion, increasing $0.9 billion and $1.0 billion since the prior year, respectively Company issues FY25 revenue guidance including GAAP growth of 8.9% to 9.4%, adjusted currency-neutral growth of 8.8% to 9.3% and organic growth of 4.0% to 4.5% Company issues FY25 adjusted diluted EPS guidance of $14.25 to $14.60 1, which reflects growth of about 10% at the midpoint FRANKLIN LAKES, N.J. , Nov. 7, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2024 fourth quarter and full year which ended September 30, 2024.
- 11/07/2024
|
BD Board Increases Dividend for 53rd Consecutive Year
- FRANKLIN LAKES, N.J. , Nov. 7, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $1.04 per common share, an increase of 9.5% from the previous quarter.
- 11/07/2024
|
Can Sustained Product Demand Drive BDX Stock Before Q4 Earnings?
- Continued solid uptake of BD's products is expected to have driven fiscal fourth-quarter revenues.
- 11/04/2024
|
Insights Into Becton Dickinson (BDX) Q4: Wall Street Projections for Key Metrics
- Get a deeper insight into the potential performance of Becton Dickinson (BDX) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
- 11/04/2024
|
Becton, Dickinson And HP Among 13 Companies To Announce Annual Dividend Increases In First Half Of November
- This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. I expect 13 companies to announce their annual increases in the first half of November, including double-digit increases from Automatic Data Processing, Roper Technologies, and Snap-on. Investors saw good 10%+ increases from insurer Brown & Brown, payment processor Visa, and specialty chemical company RPM in October.
- 11/03/2024
|
BDX Stock Declines Despite Launching BD IO Vascular Access System
- BD announces the BD Intraosseous Vascular Access System to enable quick vascular access for critical care situations.
- 11/01/2024
|
Becton Dickinson (BDX) Earnings Expected to Grow: Should You Buy?
- Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/31/2024
|
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 10/30/2024
|
BD Launches Enhanced Intraosseous System, Enabling Vascular Access in Seconds for Critical Care Situations
- FRANKLIN LAKES, N.J. , Oct. 30, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched the new BD® Intraosseous Vascular Access System, enabling access for rapid delivery of fluids or medication in critical emergency situations.
- 10/30/2024
|
My Best Dividend Aristocrats For November 2024
- The ProShares S&P 500 Dividend Aristocrats ETF went on a great run during Q3, gaining 11.6% during the quarter. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 39 months of tracking these strategies, all 3 strategies are generating a CAGR superior to NOBL while also offering a higher dividend yield.
- 10/29/2024
|
Here's Why Becton Dickinson (BDX) is a Strong Growth Stock
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 10/29/2024
|
BD Named Among the 100 Best Corporate Citizens of 2024
- FRANKLIN LAKES, N.J. , Oct. 25, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has been named as one of the 100 Best Corporate Citizens of 2024 by 3BL, ranking second in the health care equipment and services industry for its second consecutive year.
- 10/25/2024
|
3 Reasons Why Becton Dickinson (BDX) Is a Great Growth Stock
- Becton Dickinson (BDX) possesses solid growth attributes, which could help it handily outperform the market.
- 10/22/2024
|
BDX vs. MMSI: Which Stock Is the Better Value Option?
- Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Becton Dickinson (BDX) and Merit Medical (MMSI). But which of these two companies is the best option for those looking for undervalued stocks?
- 10/22/2024
|
Why These 2 Dividend Aristocrats Look Like Buys Today
- Twenty-five consecutive years of dividend growth and economic moats work in these undervalued stocks' favor. 00:00 Introduction 01:02 Chevron CVX 01:37 Becton Dickinson BDX Susan Dziubinski: I'm Susan Dziubinski with Morningstar.
- 10/22/2024
|
BDX Stock Up on Robotics Solution Launch to Boost Single-Cell Research
- BD aims to automate the complex library preparation process to aid researchers get consistent results and minimize the variability stemming from manual procedures.
- 10/15/2024
|
Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 10/14/2024
|
BD Announces New Robotics Solution to Automate, Standardize Single-Cell Research
- Automation-Ready Reagents Used with the Hamilton Robotics Liquid-Handler Streamlines and Helps Accelerate Lab Work Leading to Genomic Sequencing FRANKLIN LAKES, N.J. , Oct. 14, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial launch of the first in a family of high-throughput, robotics-compatible reagent kits that will enable automation to ensure greater consistency and increased efficiency of large-scale, single-cell discovery studies.
- 10/14/2024
|
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
- Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/11/2024
|
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 10/11/2024
|
BD to Announce its Fiscal 2024 Fourth Quarter and Full Year Financial Results
- Announces Dates for Fiscal 2025 Quarterly Earnings Webcasts FRANKLIN LAKES, N.J. , Oct. 10, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results for its fiscal 2024 fourth quarter and full year on Thursday, Nov. 7, 2024.
- 10/10/2024
|
Undervalued Dividend Kings: October 2024
- Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank Dividend Kings by quality score and highlight undervalued stocks for potential investment. The article provides tables and charts presenting quality scores, key metrics, and fair value estimates.
- 10/08/2024
|
Here's Why Becton Dickinson (BDX) is a Strong Momentum Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 10/07/2024
|
Three Reasons Why You Should Hold BDX Stock in Your Portfolio Now
- BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns.
- 10/03/2024
|
BD Reaches Agreement to Resolve Vast Majority of Hernia Litigation
- No admission of liability or wrongdoing; settlement structured to eliminate uncertainty for all stakeholders related to settled cases. Settlement amount within current product litigation reserve and will be paid out over a multi-year period.
- 10/02/2024
|
My Best Dividend Aristocrats For October 2024
- The ProShares S&P 500 Dividend Aristocrats ETF extends it's good form in the second half of 2024, adding a gain of 3.69% in August. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 38 months of tracking these strategies, all 3 strategies are generating a CAGR superior to NOBL while also offering a higher starting dividend yield.
- 09/27/2024
|
New Data Reveals BD's Artificial Intelligence Software Highly Effective in Detecting Indicators of Controlled Substance Diversion
- FRANKLIN LAKES, N.J. , Sept. 26, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new data that highlights how its advanced artificial intelligence technology can help health systems better identify incidents of controlled substance diversion in the operating room.
- 09/26/2024
|
Why Matrix CIO is chasing Becton Dickinson and US Bancorp
- David Katz, chief investment officer at Matrix Asset Advisors, joins 'The Exchange' to discuss his picks in the markets, how to position for the future, and more.
- 09/24/2024
|
4 Stocks to Buy Amid Dental Supplies Industry Challenges
- Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include BDX, MCK, COO and STAA.
- 09/20/2024
|
BD Stock Rises as Neopak XtraFlow Syringe Expands in Biologics
- BDX launches the Neopak XtraFlow Glass Prefillable Syringe, enhancing drug delivery for biologics and expanding capacity with new high-volume production lines.
- 09/19/2024
|
BD Expands Capacity for Advanced Prefillable Syringes and Enhances Injection Experience for the Next Generation of Biologics
- LE PONT-DE-CLAIX, France , Sept. 18, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe and the latest capacity expansion of the BD Neopak™ Glass Prefillable Syringe platform to serve the growing market for biologic therapies.
- 09/18/2024
|
Becton, Dickinson and Company: Future Benefit From GLP-1 Drug Delivery
- I reiterate a 'Buy' rating for BDX with a fair value of $265 per share, driven by growth in GLP-1 drug delivery and the acquisition of Edwards Lifesciences' Critical Care. BDX's strong market position in prefilled syringes and self-administered injection systems positions it to benefit significantly from the fast-growing GLP-1 market, potentially adding $1 billion in revenue by 2030. The acquisition of Edwards Lifesciences' Critical Care product group for $4.2 billion is expected to accelerate BDX's revenue growth and expand margins, enhancing its smart connected care solutions.
- 09/13/2024
|
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 09/10/2024
|
Here's Why Becton Dickinson (BDX) is a Strong Growth Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 09/09/2024
|
BD Stock Falls After Acquisition of Edwards' Critical Care Group
- BDX expands its smart care portfolio by acquiring Edwards Lifesciences' Critical Care group, now BD Advanced Patient Monitoring, strengthening AI-driven health solutions.
- 09/05/2024
|
Becton, Dickinson and Company (BDX) Wells Fargo 2024 Healthcare Conference
- Becton, Dickinson and Company (NYSE:BDX ) Wells Fargo 2024 Healthcare Conference September 4, 2024 8:45 AM ET Company Participants Tom Polen - Chairman, President & CEO Conference Call Participants Lawrence Biegelsen - Wells Fargo Lawrence Biegelsen Welcome back. Good morning.
- 09/04/2024
|
BD Completes Acquisition of Critical Care from Edwards Lifesciences
- Expands BD's portfolio of smart connected care solutions with leading monitoring technologies, including advanced AI-enabled clinical decision tools Combination of leading monitoring and infusion platforms enables future innovation opportunities for closed–loop monitoring and treatment, integrating combined company data sets and interoperability capabilities Business renamed as BD Advanced Patient Monitoring, will be based in Irvine, Calif. and become part of BD Medical segment Katie Szyman will continue to lead BD Advanced Patient Monitoring as worldwide president FRANKLIN LAKES, N.J.
- 09/03/2024
|
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 08/23/2024
|
BD Celebrates 75 years of U.S. Manufacturing Excellence in Nebraska
- Emphasizes Value of Domestic Production of Critical Medical Devices FRANKLIN LAKES, N.J. , Aug. 22, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today celebrated the 75th anniversary of its manufacturing operations in Columbus, Neb.
- 08/22/2024
|
Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 08/22/2024
|
Why Becton Dickinson (BDX) is a Top Momentum Stock for the Long-Term
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 08/21/2024
|
BD Names Michael Feld as President of Life Sciences Segment
- FRANKLIN LAKES, N.J. , Aug. 12, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Michael Feld has been named executive vice president and president of the Life Sciences segment for BD, effective Aug. 20, 2024, and will serve as a member of the Executive Leadership Team.
- 08/12/2024
|
10 High-Yield Dividend Aristocrats That Could Be Perfect For What's Coming Next
- Market volatility recently hit the 3rd highest levels ever recorded, and extreme fear grips Wall Street. The yen carry trade unwind is likely not over yet; US recession risks remain elevated, and the market decline might still have another 8%. Dividend aristocrats are down just 0.9% in this downturn, and many aristocrats are up modestly.
- 08/10/2024
|
BD to Present at Wells Fargo 2024 Healthcare Conference
- FRANKLIN LAKES, N.J. , Aug. 8, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 2024 Healthcare Conference on Wednesday, September 4, 2024 at 8:45 am Eastern Time.
- 08/08/2024
|
The 3 Best Dividend Aristocrats to Buy for Sustainable Income: August 2024
- Dividends have played a significant role in the total returns of equity investments. The practice of consistently increasing dividends can be seen in the S&P 500 Dividend Aristocrats.
- 08/08/2024
|
Becton, Dickinson And Company: Somewhat Undervalued, A Very Moderate Buy
- Becton, Dickinson is overwhelmingly considered undervalued by Wall Street analysts, with an average price target of ~$280 and highs of $312-$330. This is supported by my extensive DCF and comps models. BDX benefits from innovative products, strategic partnerships, and ongoing trends. The company boasts high margins and a reliable, growing dividend. However, the price is already pretty close to its all-time high and most price targets, so significant further appreciation is unlikely, making BDX a very moderate "Buy".
- 08/06/2024
|
BD (BDX) Q3 Earnings Surpass Estimates, Margins Expand
- BD's (BDX) overall topline benefits from revenue growth in all segments in the fiscal third quarter.
- 08/01/2024
|
Becton, Dickinson and Company (BDX) Q3 2024 Earnings Call Transcript
- Becton, Dickinson and Company (NYSE:BDX ) Q3 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Greg Rodetis - Senior Vice President, Treasurer & Head of Investor Relations Tom Polen - Chairman, Chief Executive Officer & President Chris DelOrefice - Executive Vice President & Chief Financial Officer Mike Garrison - President of the Medical Segment Conference Call Participants Robbie Marcus - JPMorgan Travis Steed - Bank of America David Roman - Goldman Sachs Patrick Wood - Morgan Stanley Larry Biegelsen - Wells Fargo Rick Wise - Stifel Vijay Kumar - Evercore ISI Operator Hello and welcome to BD's Third Quarter Fiscal 2024 Earnings Conference Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website at investors.bd.com or by phone at 800-839-2385 for domestic calls and area code +1 402-220-7203 for international calls.
- 08/01/2024
|
Compared to Estimates, Becton Dickinson (BDX) Q3 Earnings: A Look at Key Metrics
- Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 08/01/2024
|
Becton Dickinson (BDX) Q3 Earnings Beat Estimates
- Becton Dickinson (BDX) came out with quarterly earnings of $3.50 per share, beating the Zacks Consensus Estimate of $3.31 per share. This compares to earnings of $2.96 per share a year ago.
- 08/01/2024
|
Becton Dickinson tops profit estimates on demand for drug-delivery devices
- Becton Dickinson reported a better-than-expected third-quarter profit on Thursday, helped by strong demand for its drug-delivery devices.
- 08/01/2024
|
BD Reports Third Quarter Fiscal 2024 Financial Results
- Strong Margin Execution Drives Performance in Quarter Revenue of $5.0 billion as reported, adjusted revenue of $5.1 billion, driven by strong organic revenue growth GAAP and adjusted diluted EPS of $1.68 and $3.50 grew 23.5% and 18.2%, respectively Year-to-date Cash from Continuing Operations grew 60% to $2.7 billion and Free Cash Flow grew over 100% to $2.2 billion, increasing $1.0 billion and $1.2 billion since the prior year, respectively The company updated its fiscal 2024 GAAP revenue growth guidance to approximately 3.7%, and its organic revenue growth guidance to 5.0% to 5.25% The company increased its fiscal 2024 adjusted diluted EPS guidance by 5 cents at the midpoint to $13.05 to $13.15 1 FRANKLIN LAKES, N.J. , Aug. 1, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its third quarter of fiscal 2024, which ended June 30, 2024.
- 08/01/2024
|
Sustained Product Demand Likely to Aid BD's (BDX) Q3 Earnings
- Continued solid uptake of BD's (BDX) products is expected to have driven fiscal third-quarter revenues.
- 07/29/2024
|
Countdown to Becton Dickinson (BDX) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
- Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Becton Dickinson (BDX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
- 07/29/2024
|
BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases
- Collaboration on Flow Cytometry-Based Companion Diagnostics to Advance Personalized Health Care FRANKLIN LAKES, N.J. and SECAUCUS, N.J.
- 07/25/2024
|
BD Board Declares Dividend
- FRANKLIN LAKES, N.J. , July 23, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on September 9, 2024.
- 07/23/2024
|
What Makes Becton Dickinson (BDX) a New Buy Stock
- Becton Dickinson (BDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 07/23/2024
|
BDX vs. MMSI: Which Stock Should Value Investors Buy Now?
- Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Becton Dickinson (BDX) or Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now?
- 07/23/2024
|
BD (BDX) Up on Efforts to Tackle Blood Culture Vial Shortage
- BD (BDX) faces a shortage of blood culture vials due to supplier issues. It is ramping up production and collaborating with the FDA to ensure patient care remains unaffected.
- 07/16/2024
|
3 Healthcare Stocks to Buy Now to Profit From Aging Population Trends
- If you can count, you may find healthcare stocks focused on the aging population to be a compelling opportunity. What do I mean?
- 07/11/2024
|
US FDA flags shortage of Becton Dickinson's blood test tubes
- The U.S. Food and Drug Administration issued an alert on Wednesday to laboratories and healthcare providers of a shortage of Becton Dickinson' blood test tubes used in diagnosing bacterial and fungal infections.
- 07/10/2024
|
BD Statement on Supplier Issue Impacting BD BACTEC™ Blood Culture Vials
- Company Committed to Support Global Health and Customers BD Taking all Available Measures to Mitigate Supplier Issue FRANKLIN LAKES, N.J. , July 10, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement related to a U.S. FDA letter to health care providers regarding the supply of blood culture vials: Nikos Pavlidis, worldwide president of BD Diagnostic Solutions said, "BD is experiencing reduced availability of blood culture vials from our supplier.
- 07/10/2024
|
BD Surpasses Scope 1 and 2 Reduction Milestones for FY 2023
- FRANKLIN LAKES, N.J. , July 10, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has surpassed its Scope 1 and 2 science-based greenhouse gas (GHG) emissions reduction targets for FY 2023 by 5 percentage points and received approval for near and long-term science-based emissions reduction targets from the Science Based Target initiative (SBTi)[1].
- 07/10/2024
|
The Highest Quality Dividend Growth Stocks In 2024
- This article updates one I wrote in August 2022, which was based on a template article by David Van Knapp published in June 2020. I use an adapted quality scoring system to assess the quality of dividend growth stocks. The system employs six quality indicators from independent sources and assigns 0-5 points to each quality indicator, for a maximum of 30 points.
- 07/09/2024
|
Three Reasons to Hold BD (BDX) Stock in Your Portfolio Now
- BD's (BDX) robust product portfolio raises optimism about the stock.
- 07/05/2024
|
BD to Announce Financial Results for its Third Quarter of Fiscal 2024
- FRANKLIN LAKES, N.J. , July 3, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results for its third quarter of fiscal year 2024 on Thursday, August 1, 2024.
- 07/03/2024
|
Boing! 7 Undervalued Stocks That Could Surprise the Skeptics.
- Undervalued stocks, let's talk about them. Typically, when you come across a list of equities that are supposedly discounted, you're dealing with industry comparisons.
- 07/01/2024
|
BD's (BDX) New Research Tool to Aid Single-Cell Analysis
- BD (BDX) announces the commercial launch of its new single-cell research tool, BD Rhapsody ATAC-Seq Assay, to help researchers understand DNA regulation.
- 06/27/2024
|
New BD Research Tool Helps Scientists Study Cells that are Often Key Culprits in the Development of Cancer and Infectious Diseases
- BD Rhapsody™ ATAC-Seq Assay Helps Researchers Understand DNA Regulation and Enable Advancements in Precision Medicine FRANKLIN LAKES, N.J. , June 26, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases.
- 06/26/2024
|
BD Announces Dates for Third Quarter and Fourth Quarter Fiscal 2024 Earnings Webcasts
- FRANKLIN LAKES, N.J. , June 20, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it plans to host webcasts to discuss quarterly financial results on the following dates: Third Quarter Fiscal 2024 —Thursday, August 1, 2024 at 8:00 a.m.
- 06/20/2024
|
Time Sensitive - Reminder from Levi & Korsinsky, LLP to File Claim for Share of Becton, Dickinson and Company (BDX) Settlement Fund Before Deadline
- NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Becton, Dickinson and Company (NYSE: BDX). The settlement provides for a fund of $85,000,000 to benefit class members.
- 06/11/2024
|
Time Sensitive - Reminder from Levi & Korsinsky, LLP to File Claim for Share of Becton, Dickinson and Company (BDX) Settlement Fund Before Deadline
- NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Becton, Dickinson and Company (NYSE: BDX). The settlement provides for a fund of $85,000,000 to benefit class members.
- 06/06/2024
|
BD (BDX) Inks Buyout Deal to Expand Smart Connected Care Suite
- BD's (BDX) latest agreement is likely to unlock new future value-creation opportunities and expand its portfolio of smart connected care solutions.
- 06/05/2024
|
Looming Deadline - Levi & Korsinsky Encourages Shareholders of Becton, Dickinson and Company (BDX) to File a Share in Class Action Recovery
- NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Becton, Dickinson and Company (NYSE: BDX). The settlement provides for a fund of $85,000,000 to benefit class members.
- 06/04/2024
|
Becton Dickinson Buys Critical Care Unit From Edwards Lifesciences for $4.2B
- Shares of Becton Dickinson (BDX) advanced close to 3% Monday as the maker of syringes and other medical devices announced it was buying the Critical Care product unit of Edwards Lifesciences (EW) for $4.2 billion in cash.
- 06/03/2024
|
Three Reasons to Retain BD (BDX) Stock in Your Portfolio Now
- BD's (BDX) robust product portfolio raises optimism about the stock.
- 06/03/2024
|
Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash
- The buyer intends to fund deal with a combination of $1 billion in cash and $3.2 billion of new debt in a transaction that is one of its largest of many.
- 06/03/2024
|
Edwards Lifesciences to sell critical care products unit to Becton Dickinson for $4.2 bln
- Edwards Lifesciences on Monday said it has agreed to sell its Critical Care products unit to Becton Dickinson in an all-cash transaction valued at $4.2 billion.
- 06/03/2024
|
Edwards Lifesciences to sell its critical care product group for $4.2 billion to Becton Dickinson
- Shares of Edwards Lifesciences Corp. EW, -1.14% rallied 3% in premarket trading Monday, after the company announced an agreement to sell its critical care product group to Becton Dickinson & Co. BDX, +2.29% in a cash deal valued at $4.2 billion. Edwards said it plans to use the proceeds from the sale to fund investments for growth, such as in technologies for technologies for aortic, mitral, tricuspid and pulmonic patients, and in therapeutic areas for interventional heart failure.
- 06/03/2024
|
BD to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to Expand Smart Connected Care Solutions and Become an Advanced Monitoring Technology Leader
- Combination unlocks new future value-creation opportunities and is expected to be immediately accretive to BD revenue growth, adjusted gross margin, adjusted operating margin and adjusted EPS Expands BD's portfolio of smart connected care solutions with complementary and broad set of leading monitoring technologies, advanced AI-enabled clinical decision tools and robust innovation pipeline Critical Care to operate as a separate business unit within BD's Medical segment, based in Irvine, Calif. and led by Katie Szyman FRANKLIN LAKES, N.J.
- 06/03/2024
|
Edwards Lifesciences to Sell Critical Care to BD
- IRVINE, CA--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE: BDX), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care. Edwards will use the after-tax cash proceeds to fund strategic growth investments. The sale enhances Edwards' balance sheet flexibilit.
- 06/03/2024
|
Becton, Dickinson And Polaris: The Market Is Dead Wrong About These Dividend Aristocrat Bargains
- Value investing may be out of favor due to the success of tech darlings like Nvidia and Amazon. However, value investing can still be done safely and responsibly, and generate exceptional returns, including 15% to 25% annual returns over several years. Dividend aristocrats like Becton, Dickinson and Polaris are trading at 52-week lows and present potentially attractive buying opportunities.
- 06/01/2024
|
Levi & Korsinsky, LLP Notifies Shareholders of Becton, Dickinson and Company (BDX) an Upcoming Claims Deadline in a Class Action Settlement
- NEW YORK, NY / ACCESSWIRE / May 30, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Becton, Dickinson and Company (NYSE:BDX). The settlement provides for a fund of $85,000,000 to benefit class members.
- 05/30/2024
|
My Best Dividend Aristocrats For June 2024
- The ProShares S&P 500 Dividend Aristocrats ETF hits its first speed bump in April, dropping by 4.69%. Some of this loss has been recovered in May. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 34 months of tracking these strategies, one strategy is outperforming NOBL, while 2 remain relatively close.
- 05/28/2024
|
Panagora Asset Management Inc. Sells 276 Shares of Becton, Dickinson and Company (NYSE:BDX)
- Panagora Asset Management Inc. trimmed its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 2.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,432 shares of the medical instruments supplier’s stock after selling 276 shares during the quarter. Panagora Asset Management Inc.’s holdings in Becton, Dickinson and Company were worth $3,031,000 at the end of the most recent quarter. A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. DiNuzzo Private Wealth Inc. bought a new position in Becton, Dickinson and Company in the fourth quarter worth $30,000. Fortitude Family Office LLC purchased a new position in Becton, Dickinson and Company during the 4th quarter valued at about $35,000. Venturi Wealth Management LLC boosted its stake in Becton, Dickinson and Company by 552.0% during the fourth quarter. Venturi Wealth Management LLC now owns 163 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 138 shares in the last quarter. Arlington Trust Co LLC purchased a new stake in Becton, Dickinson and Company in the fourth quarter worth about $41,000. Finally, MCF Advisors LLC increased its stake in shares of Becton, Dickinson and Company by 51.4% during the fourth quarter. MCF Advisors LLC now owns 212 shares of the medical instruments supplier’s stock valued at $52,000 after purchasing an additional 72 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock. Becton, Dickinson and Company Trading Down 0.1 % Shares of NYSE BDX opened at $236.30 on Monday. The firm’s 50 day moving average price is $238.15 and its 200-day moving average price is $238.93. Becton, Dickinson and Company has a 52-week low of $229.40 and a 52-week high of $287.32. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41. The company has a market cap of $68.29 billion, a PE ratio of 52.05, a P/E/G ratio of 2.07 and a beta of 0.45. Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. The firm’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.86 EPS. On average, equities research analysts expect that Becton, Dickinson and Company will post 13.04 EPS for the current fiscal year. Becton, Dickinson and Company Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be issued a $0.95 dividend. The ex-dividend date is Monday, June 10th. This represents a $3.80 annualized dividend and a yield of 1.61%. Becton, Dickinson and Company’s payout ratio is 83.70%. Wall Street Analyst Weigh In Separately, Barclays boosted their price target on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research report on Monday, May 6th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $281.40. Get Our Latest Research Report on BDX Insiders Place Their Bets In other news, EVP Michael David Garrison sold 1,715 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at $542,348.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,597 shares of company stock valued at $2,028,786. 0.31% of the stock is owned by insiders. Becton, Dickinson and Company Profile (Free Report) Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. Read More Five stocks we like better than Becton, Dickinson and Company 3 Small Caps With Big Return Potential JD’s Earnings Could Mean Chinese Stocks Making a Comeback Roth IRA Calculator: Calculate Your Potential Returns Canada Goose Flies Higher Driven By DTC Growth Insider Selling Explained: Can it Inform Your Investing Choices? CVS Health Stock Has a Silver Lining Called Value Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
- 05/20/2024
|
BD's (BDX) FDA-Approved Test to Offer Wider Testing Access
- BD's (BDX) receipt of the FDA's clearance for the use of self-collected vaginal specimens for HPV testing is likely to improve screening access to a wider female population.
- 05/17/2024
|
Levi & Korsinsky, LLP Notifies Shareholders of Becton, Dickinson and Company (BDX) an Upcoming Claims Deadline in a Class Action Settlement
- NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Becton, Dickinson and Company (NYSE:BDX). The settlement provides for a fund of $85,000,000 to benefit class members.
- 05/16/2024
|
Women in U.S. Can Now Collect Their Own Sample for Cervical Cancer Screening
- FRANKLIN LAKES, N.J. , May 15, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) approval for the use of self-collected vaginal specimens for human papillomavirus (HPV) testing when cervical specimens cannot otherwise be obtained.
- 05/15/2024
|
Levi & Korsinsky, LLP Notifies Shareholders of Becton, Dickinson and Company (BDX) an Upcoming Claims Deadline in a Class Action Settlement
- NEW YORK, NY / ACCESSWIRE / May 14, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Becton, Dickinson and Company (NYSE:BDX). The settlement provides for a fund of $85,000,000 to benefit class members.
- 05/14/2024
|
Cramer's Mad Dash: Becton Dickinson and Co. and Owens & Minor
- CNBC's Jim Cramer delivers his daily Mad Dash.
- 05/14/2024
|
Levi & Korsinsky, LLP Notifies Shareholders of Becton, Dickinson and Company (BDX) an Upcoming Claims Deadline in a Class Action Settlement
- NEW YORK, NY / ACCESSWIRE / May 7, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Becton, Dickinson and Company (NYSE: BDX). The settlement provides for a fund of $85,000,000 to benefit class members.
- 05/07/2024
|
Becton, Dickinson Beats Estimates in Q2
- Adjusted diluted EPS came in at $3.17, surpassing analysts' estimates. Q2 revenue reached just over $5 billion, edging past expectations.
- 05/05/2024
|
10 Sleep-Well-At-Night Dividend Aristocrats Perfect For Whatever's Coming Next
- The stock market is unpredictable, and even professionals struggle to understand it. Stocks have historically been the best-performing asset, but short-term returns are influenced by sentiment, momentum, and luck. According to JPMorgan, 96% of stocks don't beat bonds, and almost half of US stocks suffer "permanent, catastrophic" declines of 70+%.
- 05/03/2024
|
Levi & Korsinsky, LLP Notifies Shareholders of Becton, Dickinson and Company (BDX) an Upcoming Claims Deadline in a Class Action Settlement
- NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Becton, Dickinson and Company (NYSE:BDX). The settlement provides for a fund of $85,000,000 to benefit class members.
- 05/02/2024
|
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 05/02/2024
|
Compared to Estimates, Becton Dickinson (BDX) Q2 Earnings: A Look at Key Metrics
- The headline numbers for Becton Dickinson (BDX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 05/02/2024
|
BD (BDX) Q2 Earnings Surpass Estimates, FY24 View Revised
- BD's (BDX) overall top line benefits from revenue growth in all segments and both geographic regions in the fiscal second quarter.
- 05/02/2024
|
Becton Dickinson (BDX) Surpasses Q2 Earnings and Revenue Estimates
- Becton Dickinson (BDX) came out with quarterly earnings of $3.17 per share, beating the Zacks Consensus Estimate of $2.96 per share. This compares to earnings of $2.86 per share a year ago.
- 05/02/2024
|
Becton Dickinson lifts profit view on strong surgical equipment demand
- Becton Dickinson raised its annual profit forecast and beat second-quarter profit estimates on Thursday, as the group banks on strong demand for its surgical equipment and syringes.
- 05/02/2024
|
BD Reports Second Quarter Fiscal 2024 Financial Results
- Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024 Q2 revenue of $5.0 billion increased 4.6% as reported, 4.7% currency-neutral and 5.7% organic Q2 GAAP and adjusted diluted EPS of $1.85 and $3.17 grew 20.9% and 10.8%, respectively Year-to-date Cash from Continuing Operations of $1.4 billion and Free Cash Flow of $1.1 billion increased $785 million and over $900 million, respectively Company raises full-year adjusted EPS guidance and affirms organic revenue growth guidance FRANKLIN LAKES, N.J. , May 2, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its second quarter of fiscal 2024, which ended March 31, 2024.
- 05/02/2024
|
BD Board Declares Dividend
- FRANKLIN LAKES, N.J. , April 30, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on June 28, 2024 to holders of record on June 10, 2024.
- 04/30/2024
|
BD to Present at Bank of America Securities Health Care Conference 2024
- FRANKLIN LAKES, N.J. , April 29, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Bank of America Securities Health Care Conference 2024 on Tuesday, May 14, 2024 at 11:00 am Eastern Time.
- 04/29/2024
|
Sustained Product Demand Likely to Aid BD's (BDX) Q2 Earnings
- Continued solid uptake of BD's (BDX) products is expected to have driven fiscal second-quarter revenues.
- 04/29/2024
|
Unveiling Becton Dickinson (BDX) Q2 Outlook: Wall Street Estimates for Key Metrics
- Get a deeper insight into the potential performance of Becton Dickinson (BDX) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
- 04/29/2024
|
How Much Will $10k Invested in These Dividend Aristocrats Grow to by 2025?
- Investors don't have to look far to find justification for investing in dividend aristocrats. Generally speaking, dividends are an excellent way to secure stable returns and compound one's wealth.
- 04/26/2024
|
Levi & Korsinsky, LLP Notifies Shareholders of Becton, Dickinson and Company (BDX) an Upcoming Claims Deadline in a Class Action Settlement
- NEW YORK, NY / ACCESSWIRE / April 25, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Becton, Dickinson and Company (NYSE:BDX). The settlement provides for a fund of $85,000,000 to benefit class members.
- 04/25/2024
|
Top 5 U.S. Giants at Lucrative Valuations Amid April Turmoil
- We have narrowed our search to five U.S. bigwigs (market capital > $70 billion) with attractive valuations. These are: NVDA, MU, BDX, ANET, EQIX.
- 04/22/2024
|
BDX or MMSI: Which Is the Better Value Stock Right Now?
- Investors interested in Medical - Dental Supplies stocks are likely familiar with Becton Dickinson (BDX) and Merit Medical (MMSI). But which of these two companies is the best option for those looking for undervalued stocks?
- 04/19/2024
|
Here's Why You Should Hold BD (BDX) Stock in Your Portfolio
- BD's (BDX) slew of product launches and strategic deals raises optimism about the stock.
- 04/12/2024
|
BD's (BDX) Latest Product to Offer Wider Access to Researchers
- The latest worldwide commercial availability of BD's (BDX) cell sorters is set to expand researchers' capabilities to transform research and cell-based therapeutic development across numerous fields.
- 04/08/2024
|
Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 04/04/2024
|
Rich Returns at a Discount: 3 Dividend Aristocrats Trading at 52-Week Lows
- Looking for Dividend aristocrats trading at their 52-week lows? If so, you've come to the right place.
- 04/03/2024
|
BDX vs. MMSI: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical - Dental Supplies sector have probably already heard of Becton Dickinson (BDX) and Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now?
- 04/03/2024
|
Becton Dickinson to increase domestic production of syringes
- Becton Dickinson said on Thursday that it will increase domestic production of medical syringes.
- 03/21/2024
|
BD's (BDX) ADC System Favored by New Study for Long-Term Care
- BD's (BDX) ADC system is likely to result in improvements in clinical workflow, operational efficiency and financial savings in long-term care facilities.
- 03/14/2024
|
7 Robotic Surgery Stocks to Buy for the Future of Healthcare
- There are some robotic surgery stocks for investors to buy in March this year. The growth of robotic-assisted surgery has been driven by its potential benefits, such as smaller incisions, reduced pain and scarring, quicker recovery times, and improved clinical outcomes.
- 03/13/2024
|
Here's Why You Should Retain BD (BDX) to Your Portfolio
- BD's (BDX) slew of product launches raises optimism about the stock.
- 03/12/2024
|
3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March
- Johnson & Johnson's stellar fundamentals make it a no-brainer. Becton, Dickinson is an underrated compounder with decades of excellence.
- 03/11/2024
|
BD (BDX) Initiates IDE Study to Aid Treatment of Artery Disease
- BD (BDX) commences the enrollment of the first patient in the IDE study for the assessment of the company's Vascular Covered Stent for the treatment of Peripheral Arterial Disease.
- 03/05/2024
|
3 Stocks to Buy at 52-Week Lows: March 4 Edition
- Dumpster diving can be fun! One man's trash is another's treasure, particularly when investing.
- 03/04/2024
|
Becton, Dickinson And Company: Growth Starts To Normalize (Rating Upgrade)
- Becton, Dickinson and Company (BD) experienced weak growth in China, with a decline of 5.3% year-over-year. BD's major challenges, including the Alaris pump and Covid comparisons, are starting to normalize. The stock price is undervalued, leading to an upgrade in rating from 'Hold' to 'Buy' with a fair value of $250 per share.
- 03/04/2024
|
Get Paid While You Wait: 7 Dividend Aristocrats to Buy Now
- The stock market bulls are charging right now. The Federal Reserve appears set to lower interest rates this year, which could stoke equity markets.
- 02/27/2024
|
BD (BDX), Camtech Health Unite to Aid Cervical Cancer Screening
- BD (BDX) collaborates with Camtech Health to improve the rate of cervical cancer screening in Singapore by offering women an option to self-collect samples in the privacy of their own homes.
- 02/23/2024
|
BDX or WST: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Becton Dickinson (BDX) or West Pharmaceutical Services (WST). But which of these two stocks is more attractive to value investors?
- 02/13/2024
|
BD to Present Next Installment of BD Innovates Series: Spotlight on Peripheral Vascular Disease
- FRANKLIN LAKES, N.J. , Feb. 12, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next installment of its BD Innovates series — which will highlight BD solutions that help clinicians treat Peripheral Vascular Disease — on Monday, February 26, 2024, at 3:00 PM Eastern Time.
- 02/12/2024
|
Three Reasons to Retain BD (BDX) Stock in Your Portfolio
- BD's (BDX) slew of product launches raises optimism about the stock.
- 02/06/2024
|
Becton, Dickinson and Company (BDX) Q1 2024 Earnings Call Transcript
- Becton, Dickinson and Company (BDX) Q1 2024 Earnings Call Transcript
- 02/01/2024
|
BD (BDX) Q1 Earnings Surpass Estimates, Margins Contract
- BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal first quarter.
- 02/01/2024
|
Becton Dickinson (BDX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
- While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 02/01/2024
|
Becton Dickinson (BDX) Q1 Earnings Surpass Estimates
- Becton Dickinson (BDX) came out with quarterly earnings of $2.68 per share, beating the Zacks Consensus Estimate of $2.39 per share. This compares to earnings of $2.98 per share a year ago.
- 02/01/2024
|
Becton Dickinson lifts 2024 profit forecast on surgical devices strength
- Becton Dickinson beat first-quarter profit estimates and raised its full-year earnings forecast on Thursday as it benefits from strong demand for its surgical equipment.
- 02/01/2024
|
BD's (BDX) Tie-Up to Offer AI-Based Digital System for Pap Test
- BD's (BDX) latest partnership is likely to aid cytotechnologists and pathologists to efficiently identify evidence of cervical cancer and pre-cancerous lesions.
- 01/31/2024
|
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
- Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited fiscal first-quarter sales.
- 01/29/2024
|
BD (BDX) Collaborates With Hamilton to Benefit Researchers
- Becton, Dickinson and Company (BDX) partners with Hamilton to boost its portfolio of single-cell multiomics solutions, enabling researchers to perform more confident experiments.
- 01/25/2024
|
Earnings Preview: Becton Dickinson (BDX) Q1 Earnings Expected to Decline
- Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/25/2024
|
Becton, Dickinson: 4 Reasons To Buy This Growth At A Reasonable Price Play
- Becton, Dickinson and Company has underperformed the market and healthcare sector in recent years. The company's balance sheet has improved significantly which I believe will allow for increased returns of capital to shareholders going forward. BDX's recent guidance for FY 2024 has lowered earnings expectations, but the company has a history of beating consensus estimates.
- 01/22/2024
|
Becton Dickinson CEO: Solutions that drive automation and efficiency are a big need in healthcare
- Becton Dickinson Chairman, President and CEO Tom Polen joins 'Mad Money' host Jim Cramer to talk inflation's impact on healthcare, the prefilled syringe market and more.
- 01/11/2024
|
There's a big focus on efficiency as hospitals feel inflationary pressures: Becton Dickinson CEO
- Becton Dickinson Chairman, President and CEO Tom Polen joins 'Mad Money' host Jim Cramer to talk inflation's impact on healthcare, the prefilled syringe market and more.
- 01/11/2024
|
BD Announces Webcast of Annual Meeting of Shareholders
- FRANKLIN LAKES, N.J. , Jan. 5, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 23, 2024, at 1:00 p.m.
- 01/05/2024
|
BD to Announce Financial Results for its First Quarter of Fiscal 2024
- FRANKLIN LAKES, N.J., Jan. 4, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results for its first quarter of fiscal year 2024 on Thursday, February 1, 2024.
- 01/04/2024
|
29 Undervalued Dividend Aristocrats: December 2023
- The S&P 500 Dividend Aristocrats Index contains 67 dividend growth stocks called the Dividend Aristocrats.
- 12/22/2023
|
BD to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- FRANKLIN LAKES, N.J., Dec. 22, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 42nd Annual J.P.
- 12/22/2023
|
Bear of the Day: Becton, Dickenson and Co (BDX)
- Earnings have been retreating on this Bear of the Day.
- 12/12/2023
|
New Strong Sell Stocks for December 11th
- DG, BDX and CIGI have been added to the Zacks Rank #5 (Strong Sell) List on December 11, 2023.
- 12/11/2023
|
BD's (BDX) Novel Blood Collection System MiniDraw Gets FDA Nod
- BD's (BDX) FDA approval for MiniDraw will likely reshape diagnostic testing by providing a unique design that offers blood collection at any convenient location with reduced volume.
- 12/08/2023
|
US FDA clears Becton Dickinson's blood collection device
- Becton Dickinson said on Thursday the U.S. Food and Drug Administration (FDA) had cleared its less invasive blood collection device.
- 12/07/2023
|
BD (BDX) Launches Advanced Vascular Access Management System
- BD's (BDX) SiteRite 9 Ultrasound System is likely to revolutionize vascular care by enhancing clinician efficiency and setting a new standard in first-attempt success.
- 12/05/2023
|
7 Compelling Stocks to Buy That are Sitting at 52-Week Lows
- In arguably most circumstances, when you see stocks at 52-week lows, you should avoid them. Based on prevailing market theory, equity valuations culminate from the most recent publicly available information.
- 12/05/2023
|
BD to Present Next Installment of BD Innovates Series: Spotlight on Pharmaceutical Systems
- FRANKLIN LAKES, N.J. , Dec. 4, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next installment of its BD Innovates series, which will highlight its Pharmaceutical Systems business on Monday, December 11, 2023, at 11:30 am Eastern Time.
- 12/04/2023
|
Dividend Champion, Contender, And Challenger Highlights: Week Of December 3
- A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
- 12/03/2023
|
9 Upcoming Dividend Increases, Including A King
- Dividend growing companies perform better than those that don't increase their payouts consistently. Becton, Dickinson and Company is a dividend king, while UBSI and ADP are approaching king status. December is the last opportunity for companies to announce their yearly dividend increase.
- 11/30/2023
|
Top 4 Health Care Stocks That Could Blast Off This Quarter - Acutus Medical (NASDAQ:AFIB), Becton Dickinson (NYSE:BDX)
- The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
- 11/17/2023
|
BD to Present at the 6th Annual Evercore ISI HealthCONx Conference
- FRANKLIN LAKES, N.J. , Nov. 14, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023 at 8:20 am Eastern Time.
- 11/14/2023
|
Following The Q4 Results, Becton, Dickinson and Company Is Still A Hold
- Becton, Dickinson, and Company is a healthcare company with strong fundamentals and a history of dividend growth. The company has shown robust execution of its 2025 strategy, positioning it for sustained growth and innovation in the medical technology space. However, there are risks to the investment, including slower EPS growth, competition, and a lack of margin of safety in the current valuation.
- 11/13/2023
|
BD (BDX) Q4 Earnings In-Line With Estimates, Margins Contract
- BD's (BDX) overall top line benefits from revenue growth in all its segments and both geographic regions in the fiscal fourth quarter.
- 11/09/2023
|
Midday Movers: Disney Rises, Tesla and Becton Dickinson Fall
- U.S. equities fell midday ahead of comments from Fed Chair Jerome Powell that could offer clues about the future of monetary policy. The Dow, S&P 500, and Nasdaq were all lower.
- 11/09/2023
|
Becton, Dickinson and Company (BDX) Q4 2023 Earnings Call Transcript
- Becton, Dickinson and Company (NYSE:BDX ) Q43 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Greg Rodetis - Senior Vice President, Treasurer and Head of Investor Relations Tom Polen – Chairman, President and Chief Executive Officer Chris DelOrefice – Executive Vice President and Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Vijay Kumar - Evercore ISI Larry Biegelsen - Wells Fargo Travis Steed - Bank of America Matt Miksic - Barclays Operator Hello, and welcome to BD's Fourth Quarter and Full Year Fiscal 2023 Earnings Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at (800) 688-7339 for domestic and area code 1-40220-1347 for International.
- 11/09/2023
|
Here's What Key Metrics Tell Us About Becton Dickinson (BDX) Q4 Earnings
- Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 11/09/2023
|
Three value stock picks from a veteran manager with a good performance record
- For many years through 2022, it was becoming more difficult for active fund managers to make the case for their services, when broad index funds, with lower fees, were performing so well. But the tech-driven market decline for 2022 might have made some investors think again about different investment styles for the long term.
- 11/08/2023
|
Unlocking Q4 Potential of Becton Dickinson (BDX): Exploring Wall Street Estimates for Key Metrics
- Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Becton Dickinson (BDX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.
- 11/06/2023
|
Becton, Dickinson And HP Among 13 Companies Announcing Annual Dividend Increases In The First Half Of November
- Visa and Exxon Mobil announced dividend increases in October, with Visa increasing its dividend by 15.6% and Exxon Mobil increasing its dividend by 4.4%. Several companies, including AbbVie, American Electric Power, and McDonalds, met or exceeded dividend increase predictions in October. Dividend growth slowed for companies like Amphenol, Black Hills, and Tompkins Financial due to various factors such as the current economic slowdown and flat or lower earnings.
- 10/30/2023
|
Dividend Income Update September 2023
- With the start of the final quarter of 2023, it's time to take a look back at my previous month of dividend income. Getting close to that $2,000 milestone in a month sure looks amazing. I know, those end of quarter months are always the big payers but it's still nice to see.
- 10/17/2023
|
Becton, Dickinson Stock Is A Hold, Here's Why
- Becton, Dickinson and Company is a global healthcare company specializing in medical supplies, devices, and diagnostic products. BDX saw solid growth in Q3 driven by strong demand for pharmacy automation systems and medical devices. The company raised its revenue guidance for FY23 and expects continued profitability improvement in the near future.
- 10/04/2023
|
Here's Why You Should Hold BD (BDX) Stock in Your Portfolio
- BD's (BDX) slew of product launches raises optimism about the stock.
- 09/19/2023
|
BD's (BDX) Tie-Up to Explore Flow Cytometry for Clinical Outcomes
- BD's (BDX) latest partnership is likely to accelerate the delivery of innovative personalized therapies to patients who need them the most.
- 09/08/2023
|
Beyond Pills: 3 Non-Pharma Healthcare Stocks for Healthy Gains
- When you consider healthcare stocks, do you automatically think of pharmaceutical companies? Most people do.
- 08/30/2023
|
BD to Present at Investor Healthcare Conferences
- FRANKLIN LAKES, N.J. , Aug. 23, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following healthcare conferences: 2023 Wells Fargo Healthcare Conference September 6, 2023 8:45 a.m.
- 08/23/2023
|
BD (BDX) Q3 Earnings Surpass Estimates, Margins Contract
- BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal third quarter.
- 08/03/2023
|
Becton Dickinson (BDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 08/03/2023
|
Becton Dickinson beats quarterly profit estimates on strong medical device sales
- Becton Dickinson beat Wall Street estimates for third-quarter profit on Thursday, helped by strong demand for its drug delivery devices and surgical equipment.
- 08/03/2023
|
BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?
- Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q3 sales.
- 07/28/2023
|
7 Stocks Getting a Huge Vote of Confidence From Wall Street Analysts
- While discrediting the acumen of experts seems to be a popular exercise on the Internet, investors can potentially gain handsomely from top analyst stocks. Of course, you'll find some research on this topic that implies that celebrated market gurus don't always get it right.
- 07/27/2023
|
Why Becton Dickinson (BDX) is Poised to Beat Earnings Estimates Again
- Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/26/2023
|
Becton Dickinson (BDX) Surges 5.7%: Is This an Indication of Further Gains?
- Becton Dickinson (BDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- 07/25/2023
|
S&P 500 Gains and Losses Today: Oil Industry Stocks Surge as Oil Prices Rise
- U.S. equities gained after better-than-expected second quarter earnings reports, with the S&P 500 rising 0.4% on Monday, July 24, 2023.
- 07/24/2023
|
Becton Dickinson Shares Jump After FDA Decision on Its Infusion System
- Shares of Becton Dickinson rose to their highest level since 2020 after the FDA gave 501(k) clearance to Becton Dickinson's updated BD Alaris Infusion System.
- 07/24/2023
|
Markets Higher at Midday as Rising Crude Prices Boost Oil Industry Stocks
- The earnings-fueled stock market rally continued at midday on Monday, July 24, 2023.
- 07/24/2023
|
BD (BDX) Receives FDA Nod to Address Critical Infusion Needs
- The latest regulatory clearance for BD's (BDX) Alaris Infusion System is expected to improve healthcare system efficiency via better care coordination and utilization of actionable information.
- 07/24/2023
|
Becton Dickinson shares hit record high after US FDA clears return of drug infusion system
- Shares of Becton Dickinson hit an all-time high on Monday and were last up 6.1% after the medical device maker received U.S. Food and Drug Administration clearance late on Friday for the market return of its drug infusion system.
- 07/24/2023
|
Why Shares of Becton, Dickinson Rose Monday
- The company filed a 501(k) resubmission for its new BD Alaris Infusion System two years ago. The company said it will begin immediately distributing the new Alaris Infusion System, and will remediate older versions of the device.
- 07/24/2023
|
BDX or ALGN: Which Is the Better Value Stock Right Now?
- Investors interested in Medical - Dental Supplies stocks are likely familiar with Becton Dickinson (BDX) and Align Technology (ALGN). But which of these two stocks is more attractive to value investors?
- 07/07/2023
|
BD to Announce Financial Results for its Third Quarter of Fiscal 2023
- FRANKLIN LAKES, N.J. , July 6, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results for its third quarter of fiscal year 2023 on Thursday, August 3, 2023.
- 07/06/2023
|
The 7 Most Undervalued Blue-Chip Stocks to Buy Now: June 2023
- Looking for undervalued blue-chip stocks to buy? This is a great time to be doing so.
- 06/27/2023
|
Dividend Champion, Contender, And Challenger Highlights: Week Of June 25
- A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
- 06/25/2023
|
Becton, Dickinson and Company: Still Not Very Healthy
- Becton, Dickinson and Company has seen another year of relative stagnation. Following the spinoff of the Diabetes Care unit, sales and earnings have taken a small setback. Valuations remain full at around 20 times adjusted earnings amidst some leverage still being apparent and with structural growth hard to come by.
- 06/20/2023
|
BD's (BDX) Latest Product to Automate Clinical Flow Cytometry
- The latest worldwide commercial availability of BD's (BDX) product is expected to lead to increased automation in clinical lab workflow.
- 06/15/2023
|
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
- Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and product launches.
- 06/13/2023
|
Becton, Dickinson: Business Should Beat H2 2023 Expectations
- I expect Becton, Dickinson and Company to beat 2H23 estimates due to reduced expectations and margin improvements. BDX's management has made progress in SKU rationalizations, workforce reduction, and enhancing the company's structural margin profile. The stable operating environment, procedure volume recovery, and hospital capital spending appetite support revenue growth for BDX.
- 06/08/2023
|
BD's (BDX) Latest Product Launch to Boost Research Outcome
- BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting and allow researchers to answer complex biological questions.
- 05/22/2023
|
BD's (BDX) New FDA Approval to Improve MRSA Diagnostics
- BD's (BDX) receipt of the latest FDA approval is likely to improve laboratory workflow.
- 05/18/2023
|
Becton Dickinson CEO: Q2 ‘was another quarter of exceeding expectations'
- Becton, Dickinson and Company CEO and President Tom Polen joins Yahoo Finance Live to discuss company earnings, growth opportunities in the home test kit market, biotech drugs, strong demand in the weight loss market, and the outlook for Becton Dickinson.
- 05/04/2023
|
BD (BDX) Q2 Earnings Surpass Estimates, FY23 View Revised
- BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal second quarter.
- 05/04/2023
|
BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?
- Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q2 sales.
- 05/03/2023
|
Becton, Dickinson and Company: This Serial-Acquirer Is A Buy
- The medical devices industry has grown steadily for many decades, driven by people living longer and increased adoption of technologically advanced healthcare devices. Given the predictability of the revenues, this industry lends itself well to industry consolidators who can deploy excess free cash flow into additional revenue streams.
- 04/15/2023
|
BDX vs. WST: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical - Dental Supplies sector have probably already heard of Becton Dickinson (BDX) and West Pharmaceutical Services (WST). But which of these two stocks presents investors with the better value opportunity right now?
- 04/14/2023
|
3 Stocks Worth a Buy for Solid Earnings Acceleration
- Invest in stocks like Becton, Dickinson and Company (BDX), Raytheon Technologies (RTX) & Palantir Technologies (PLTR) as of now for superb earnings acceleration.
- 04/14/2023
|
BD's (BDX) New Launch to Result in Optimal IV Placement
- BD's (BDX) latest launch is expected to advance its vision of a One-Stick Hospital Stay by improving the first-stick success in IV placements.
- 04/12/2023
|
DivHut Portfolio Update: March 2023
- The system is clearly broken, and has been for a while; however, I could find comfort in one thing, my dividends. Four figures in a month is a win in my book. Earning $1,893.81 represents 12.6% year over year increase in passive income.
- 04/12/2023
|
My Dividend Growth Portfolio - Q1 2023 Summary
- In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its correlation with my writing.
- 04/06/2023
|
BDX or WST: Which Is the Better Value Stock Right Now?
- BDX vs. WST: Which Stock Is the Better Value Option?
- 03/29/2023
|
7 Dividend Aristocrats to Buy for Consistent Income Growth
- I'd argue there's never been a better time to consider investing in dividend aristocrats. Volatility remains very high in the overall market, with a destabilized banking sector.
- 03/28/2023
|
Dividend Champion, Contender, And Challenger Highlights: Week Of March 26
- A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.
- 03/25/2023
|
2 Unique Dividend Aristocrats to Diversify the Portfolio
- Here are two Dividend Aristocrats that are top-rated Zacks stocks at the moment and can offer unique exposure and diversification to investors' portfolios.
- 03/23/2023
|
BD's (BDX) New FDA Approval to Improve Vaginitis Testing
- BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of vaginitis.
- 03/17/2023
|
Healthcare Stocks With at Least 30 Years of Dividend Increases
- While it is not the only factor to consider, the annual dividend can solidify whether a stock will benefit you financially. And among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield.
- 03/14/2023
|
3 Stocks to Buy for Consistent Dividend Growth
- Some of these companies have been around for over 100 years and have seen all imaginable economic environments
- 03/10/2023
|
Three Reasons to Add BD (BDX) Stock to Your Portfolio Now
- Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and product launches.
- 03/08/2023
|
BDX or ALGN: Which Is the Better Value Stock Right Now?
- BDX vs. ALGN: Which Stock Is the Better Value Option?
- 03/06/2023
|
Dividend Champion, Contender, And Challenger Highlights: Week Of March 5
- A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.
- 03/05/2023
|
BD to Present at Barclays Global Healthcare Conference
- FRANKLIN LAKES, N.J. , March 1, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Barclays Global Healthcare Conference on Wednesday, March 15, 2023 at 9:00 am Eastern Time.
- 03/01/2023
|
Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11
- Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its combination at-home COVID-19 and a flu test. The over-the-counter (OTC) 30-minute at-home rapid test can detect influenza A and B and the SARS-CoV-2 virus using nasal swabs.
- 03/01/2023
|
BD's (BDX) New FDA Approval to Improve Cervical Cancer Testing
- BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of cervical cancer.
- 02/27/2023
|
The 7 Best Dividend Growth Stocks for Long-Term Investors
- When faced with myriad market ambiguities, investors may be well served to target the best dividend growth stocks to buy. In many ways, this investment category represents the best of both worlds.
- 02/22/2023
|
The Dividend Aristocrats Ranked By Quality Scores
- The annual rebalancing and subsequent changes to the S&P 500 Dividend Aristocrats Index have produced a new list of 67 dividend growth stocks called the Dividend Aristocrats. I rank the Dividend Aristocrats using Quality Snapshots, an elegant and effective system for assessing the quality of dividend growth stocks.
- 02/11/2023
|
BD's (BDX) Latest Combination Test Receives the FDA's EUA
- BD's (BDX) new combination test is likely to significantly aid clinicians in treating patients in the current and future respiratory virus seasons.
- 02/10/2023
|
BDX vs. WST: Which Stock Is the Better Value Option?
- BDX vs. WST: Which Stock Is the Better Value Option?
- 02/07/2023
|
BD (BDX) Q1 Earnings and Revenues Beat Estimates, Margins Down
- The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.
- 02/02/2023
|
Becton, Dickinson and Company (BDX) Q1 2023 Earnings Call Transcript
- Becton, Dickinson and Company (NYSE:BDX ) Q1 2023 Earnings Conference Call February 2, 2023 8:00 AM ET Company Participants Francesca DeMartino – Senior Vice President and Head-Investor Relations Tom Polen – Chairman, Chief Executive Officer and President Chris DelOrefice – Executive Vice President and Chief Financial Officer Dave Hickey – President-Life Sciences Segment Mike Garrison – President-Medical Segment Conference Call Participants Vijay Kumar – Evercore ISI Matt Taylor – Jefferies Larry Biegelsen – Wells Fargo Robbie Marcus – JPMorgan Matt Miksic – Barclays Rick Wise – Stifel Operator Hello, and welcome to BD's First Fiscal Quarter of 2023 Earnings Call. At the request of BD, today's call is being recorded, and a replay of the call will be made available on BD's Investor Relations website on bd.com.
- 02/02/2023
|
Becton Dickinson (BDX) Tops Q1 Earnings and Revenue Estimates
- Becton Dickinson (BDX) delivered earnings and revenue surprises of 11.61% and 0.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/02/2023
|
Should You Buy Becton Dickinson (BDX) Ahead of Earnings?
- Becton Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/01/2023
|
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
- Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have driven up Q1 sales.
- 01/30/2023
|
Why Becton Dickinson (BDX) Could Beat Earnings Estimates Again
- Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/24/2023
|
The Dividend Kings Ranked By Quality Score
- Dividend Kings have an astounding track record of 50 or more years of higher dividend payouts. I rank the Dividend Kings using Quality Snapshots, a simple yet elegant system for assessing the quality of dividend growth stocks.
- 01/24/2023
|
Ranking The Diversified Healthcare Giants
- The Top Six Healthcare Products and Service companies are some of the most popular investments in the market. However, they offer varying financial profiles.
- 01/22/2023
|
The 7 Best Dividend Stocks to Buy for 2023
- If you're looking for the best dividend stocks to buy in 2023, an excellent place to start is with the Vanguard Dividend Appreciation Index Fund (NYSEARCA: VIG ). VIG is one of the largest U.S.-listed dividend ETF with $65.4 billion in share class total net assets.
- 01/18/2023
|
My Dividend Growth Portfolio - Q4 2022 Summary
- In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its correlation with my writing.
- 01/18/2023
|
Dividend Income Update: December 2022
- Dividend investing can work over time and anyone can create an ever growing passive income stream. My year over year progress is moving at a nice clip.
- 01/10/2023
|
Final Trades: GXO, Becton Dickinson, Freeport-McMoRan & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 01/09/2023
|
BD Announces Webcast of Annual Meeting of Shareholders
- FRANKLIN LAKES, N.J. , Jan. 6, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 24, 2023, at 1 p.m.
- 01/06/2023
|
BD to Announce Financial Results for its First Quarter of Fiscal 2023
- FRANKLIN LAKES, N.J. , Jan. 5, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results for its first quarter of fiscal year 2023 on Thursday, February 2, 2023.
- 01/05/2023
|
2 Medical Stocks to Watch Heading Into 2023
- The two healthcare companies easily outdid the S&P 500 this year.
- 12/31/2022
|
Michael Farr: These are 2023's top stock picks for what could be a rocky year
- Lower lows could be ahead for investors. Here are Michael Farr's picks for the new year.
- 12/27/2022
|
Becton, Dickinson: A Quality Defensive Pick For 2023
- Becton, Dickinson had a flat year in 2022. Compared to the market, that was a strong result. Over the longer-term, Becton, Dickinson has been a solid compounder, but returns have lost some steam over the past five years.
- 12/20/2022
|
BD to Present at the 41st Annual J.P. Morgan Healthcare Conference
- FRANKLIN LAKES, N.J. , Dec. 20, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 41st Annual J.P.
- 12/20/2022
|
The 10 Best Dividend Stocks of All Time
- Discussions regarding the best dividend stocks of all time often start with the Dividend Aristocrats. They are S&P 500 companies that have increased their annual dividend payment for at least 25 consecutive years.
- 12/02/2022
|
8 Upcoming Dividend Increases
- All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 6% and a median increase of 3.8%.
- 12/01/2022
|
Is There More Room For Growth In Becton Dickinson Stock?
- Becton Dickinson stock (NYSE: BDX) has seen a 7% fall this year, faring better than the broader S&P500 index, down 17%.
- 11/23/2022
|
BD to Present at Evercore ISI 5th Annual HealthCONx Conference
- FRANKLIN LAKES, N.J. , Nov. 15, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present virtually at the Evercore ISI 5th Annual HealthCONx Conference on Tuesday, November 29, 2022 at 8:00 am Eastern Time.
- 11/15/2022
|
Merck, Nike Among 14 Companies To Announce Annual Dividend Increases In The Second Half Of November
- There were a few double-digit boosts in the first half of November. Most notably, ADP came through with a 20% increase and Snap-On Tools with a 14% increase. Emerson extended its dividend growth streak to 66 years with a 1% boost and Lancaster Colony started its 7th decade of dividend growth with a 6% increase.
- 11/13/2022
|
BD (BDX) Q4 Earnings and Revenues Beat Estimates, Margins Up
- The majority of BD's (BDX) core units witness strong revenue growth in the fiscal fourth quarter.
- 11/10/2022
|
Becton, Dickinson and Company (BDX) Q4 2022 Earnings Call Transcript
- Becton, Dickinson and Company (NYSE:BDX ) Q4 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Francesca DeMartino - SVP & Head, IR Thomas Polen - President, CEO & Chairman Christopher DelOrefice - EVP & CFO Mike Garrison - President of the Medical Segment Dave Hickey - President of Life Sciences Segment Rick Byrd - President of Interventional Segment Conference Call Participants Lawrence Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Robert Marcus - JPMorgan Matthew Taylor - Jefferies Josh Jennings - Cowen and Company Frederick Wise - Stifel Operator Hello, and welcome to BD's Earnings Call for the Fourth Quarter and Full Year Fiscal 2022. At the request of BD, today's call is being recorded and will be available for replay through November 17, 2022 on BD's Investor Relations website on bd.com or via phone at 866-342-8591 for domestic calls, and area code +1 (203) 518-9713 for international calls.
- 11/10/2022
|
Becton Dickinson (BDX) Tops Q4 Earnings and Revenue Estimates
- Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.73% and 1.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2022
|
Becton Dickinson stock down 1.3% premarket as Q4 earnings beat tempered by soft fiscal 2023 guidance
- Becton Dickinson & Co. stock BDX, -0.55% slid 1.3% in premarket trade Thursday, after the medical tech and diagnostics company beat estimates for its fiscal fourth quarter but offered guidance that lagged. The Franklin Lakes, N.J.
- 11/10/2022
|
Becton Dickinson raises quarterly dividend by 4.6% to 91 cents a share
- Becton Dickinson & Co. BDX, -0.55% said Thursday its board has approved a 4.6% increase in its quarterly dividend to 91 cents a share. The medical tech and diagnostics company said the new dividend is payable Dec. 30 to shareholders of record as of Dec. 9.
- 11/10/2022
|
3 Dental Supplies Stocks to Watch Amid Industry Headwinds
- Here we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors - BDX, MCK and ABC.
- 11/09/2022
|
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
- Continued strength in BD's (BDX) Interventional segment and Life Sciences segment's base business is expected to have driven Q4 sales.
- 11/07/2022
|
BD (BDX)-Biocorp's Latest Deal to Enhance Tracking Adherence
- BD's (BDX) newest agreement is expected to enable the care provision to transition to alternate settings and improve chronic disease outcomes.
- 10/18/2022
|
BD TO ANNOUNCE FISCAL 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
- FRANKLIN LAKES, N.J. , Oct. 13, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will report its fiscal 2022 fourth quarter and full year financial results on Thursday, November 10, 2022.
- 10/13/2022
|
Becton, Dickinson: Buy In Now While You Can
- Market is undervaluing growth and margin optimization. Recent spinoff of its diabetic line is beneficial.
- 10/12/2022
|
2 Dividend Kings Outperforming the S&P 500 Index
- The Dividend King index is a collection of just 45 companies with at least 50 consecutive years of dividend growth. These companies have raised payments to shareholders through multiple recessions, showing the strength of their respective business models.
- 10/06/2022
|
BD's (BDX) New Cloud Software Solution to Boost Lab Workflow
- BD's (BDX) latest launch is expected to provide scientists with an integrated ecosystem that enables optimization of panel design, collaboration and analysis.
- 10/04/2022
|
This Healthcare Company Is Likely To Offer Better Returns Over Eli Lilly Stock
- There is more to the comparison, and in the sections below, we discuss why we believe BDX stock will offer better returns than LLY stock in the next three years.
- 09/15/2022
|
BD's (BDX) Latest PFS Launch to Boost Production Efficiencies
- BD's (BDX) newest product offering is expected to set a new standard in performance for vaccine PFS with new and strict specifications for improved production efficiencies.
- 09/14/2022
|
BD Chases End-To-End Supply Chain Visibility
- BD had a supply chain risk management solution. It provided good visibility to their Tier 1 suppliers.
- 09/02/2022
|
BD to Present at the Wells Fargo 2022 Healthcare Conference
- FRANKLIN LAKES, N.J. , Aug. 24, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 2022 Healthcare Conference on Wednesday, September 7, 2022 at 12:30pm Eastern Time.
- 08/24/2022
|
3 Top Dividend Kings to Buy for the Long Haul
- You'll need to hold these stocks for many years to get the full benefit of their consistent dividend growth.
- 08/18/2022
|
7 Blue-Chip Stocks That Will Survive 2022
- Buying high-quality blue-chip stocks in a bear market could be a solid path to generating lucrative long-term returns. Blue-chip stocks are typically large-cap businesses in the mature stage of their business cycle.
- 08/09/2022
|
Should You Really Care About This Company's Short-Term Success?
- Abbott Laboratories' growth looks much less impressive after removing sales from COVID-19 diagnostics.
- 08/05/2022
|
Becton Dickinson and Co (BDX) CEO Thomas Polen on Q3 2022 Results - Earnings Call Transcript
- Becton Dickinson and Co (NYSE:BDX ) Q3 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Francesca DeMartino - SVP & Head, IR Thomas Polen - President, CEO & Chairman Christopher DelOrefice - EVP & CFO Simon Campion - EVP, President, Medical Segment & Interim President, Interventional Segment David Hickey - Executive VP & President, Life Sciences Segment Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Vijay Kumar - Evercore ISI Robert Marcus - JPMorgan Chase & Co. Frederick Wise - Stifel, Nicolaus & Company Travis Steed - Bank of America Merrill Lynch Operator Hello, and welcome to BD's Earnings Call for the Third Quarter of Fiscal 2022. At the request of BD, today's call is being recorded and will be made available for replay through August 11, 2022 on BD's Investor Relations website on bd.com or by phone at 866-342-8591 for domestic calls and area code +1-203-518-9713 for international calls.
- 08/04/2022
|
Becton Dickinson (BDX) Surpasses Q3 Earnings and Revenue Estimates
- Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.83% and 4.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2022
|
Becton, Dickinson and Company Is A Hold At The Current Valuation
- Becton, Dickinson and Company is one of my favorite dividend growth investments. I am constantly looking for opportunities to add to my position.
- 08/02/2022
|
3 Dental Supplies Stocks to Buy Amid Industry Headwinds
- Here we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors - BDX, PDCO and SDC.
- 08/01/2022
|
Becton, Dickinson: Acquisitions Underwhelming
- We believe the healthcare sector's strong growth momentum with average revenue growth of 3.8% QoQ indicates a positive outlook, with the equipment industry forecasted at a market CAGR of 5.5%. For the healthcare equipment industry, we believe the outlook is supported by the average guidance of 9.4% but see Becton, Dickinson lagging behind its peers in Q1 with below-industry average growth (0.5%).
- 07/27/2022
|
BDX or ALGN: Which Is the Better Value Stock Right Now?
- BDX vs. ALGN: Which Stock Is the Better Value Option?
- 07/25/2022
|
A Debt-Free and Fairly Valued Medical Devices Company
- LeMaitre Vascular Inc. ( LMAT , Financial) has been on a roll—it has generated robust financial results and metrics that produced a high GF Score. But the share price has been in a slump.
- 07/20/2022
|
3 Reasons Why BD (BDX) is a Great Pick For Your Portfolio Now
- Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.
- 07/15/2022
|
BDX vs. ALGN: Which Stock Is the Better Value Option?
- BDX vs. ALGN: Which Stock Is the Better Value Option?
- 07/08/2022
|
BD TO ANNOUNCE FINANCIAL RESULTS FOR ITS THIRD QUARTER OF FISCAL 2022
- FRANKLIN LAKES, N.J. , July 7, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report financial results for its third quarter of fiscal year 2022 on Thursday, August 4, 2022.
- 07/07/2022
|
BD's (BDX) New Combination Test to Boost Patient Outcome
- BD's (BDX) latest combination test is expected to speed up the detection of the infection-causing viruses, thereby accelerating the implementation of the appropriate treatment plan.
- 07/01/2022
|
BD (BDX) Integrates Innovative Solution to Boost Patient Care
- BD's (BDX) announcement of the implementation of BD HealthSight brings together timely monitoring to support the early detection of emerging healthcare infections, thereby improving patient care.
- 06/23/2022
|
BD's (BDX) Latest Collaboration to Enhance Patient Care
- BD's (BDX) new partnership is expected to increase efficiency for new clinical trials, generate evidence, support new claims for its products and streamline medical device regulatory submissions.
- 06/15/2022
|
7 ‘Strong Buy' Dividend Kings to Own Now If the Fed Rate Increase This Week Is Huge
- One thing has become painfully obvious, after Friday's consumer price index reading came in at a scorching 8.6% year over year, the highest reading since 1981.
- 06/13/2022
|
BD's (BDX) New Tie-Up to Develop Detection Kit for Monkeypox
- BD's (BDX) partnership with CerTest is expected to aid in advancing the understanding of the monkeypox virus' global spread.
- 06/09/2022
|
BD entering the new pharmacy automation solutions space via the Parata Systems acquisition
- Becton, Dickson and Company (NYSE: BDX), a top medical tech corporation also known as BD, and leading private equity company, Frazier Healthcare Partners, announced they had entered into a definitive merger agreement whereby BD is to acquire Parata for a consideration price of about $1.5 billion. Parata System's portfolio of new and exciting pharmacy automation […] The post BD entering the new pharmacy automation solutions space via the Parata Systems acquisition appeared first on Invezz.
- 06/08/2022
|
BD to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
- FRANKLIN LAKES, N.J. , June 2, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Goldman Sachs 43rd Annual Global Healthcare Conference on Thursday, June 16, 2022 at 11:00 a.m.
- 06/02/2022
|
3 Top Dividend Kings to Buy for the Long Haul
- A bear market can test investors' patience, but these companies can help you survive.
- 05/28/2022
|
New Strong Sell Stocks for May 27th
- ACER, BBWI, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2022.
- 05/27/2022
|
New Strong Sell Stocks for May 25th
- ALGN, AUD, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 25, 2022.
- 05/25/2022
|
Becton, Dickinson: Strong Defensive Name In Today's Volatile Market
- BDX is a defensive play with numerous actionable growth opportunities. BDX has a robust pipeline of products to further catalyze returns.
- 05/23/2022
|
3 Dividend Kings Trading for Bargain Prices
- This suggests that ABM Industries, Becton, Dickinson & Company, and Dover could be good options for investors looking for high levels of total returns and secure income. The post 3 Dividend Kings Trading for Bargain Prices appeared first on InvestorPlace.
- 05/19/2022
|
BD (BDX) Introduces New Molecular Diagnostic Platform in US
- BD's (BDX) new fully-automated, high-throughput infectious disease molecular diagnostics platform in the United States to aid lab technicians in prioritizing higher value work.
- 05/18/2022
|
BD (BDX) Extends Partnership to Boost Diagnostic Blood Collection
- BD (BDX) expands strategic partnership with Babson Diagnostics that will enable less invasive blood sample collection easier and patient-centric.
- 05/16/2022
|
New Strong Sell Stocks for May 13th
- DDD, AMRN, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2022.
- 05/13/2022
|
7 Stock Picks to Play the Post-Pandemic Return of Dental Visits
- Although Covid-19 allowed people the excuse to not see their dentist, the necessary return could benefit these dental stocks to buy. The post 7 Stock Picks to Play the Post-Pandemic Return of Dental Visits appeared first on InvestorPlace.
- 05/09/2022
|
Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q2 2022 Results - Earnings Call Transcript
- Becton, Dickinson and Company (NYSE:BDX ) Q2 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Francesca DeMartino - SVP, IR Thomas Polen - President, CEO & Chairman Christopher DelOrefice - EVP & CFO Simon Campion - EVP & President, Interventional Segment Conference Call Participants Vijay Kumar - Evercore ISI Travis Steed - Bank of America Robbie Marcus - JPMorgan Lawrence Biegelsen - Wells Fargo Securities Rick Wise - Stifel Operator Hello, and welcome to BD's Earnings Call for the Second Quarter of Fiscal 2022. At the request of BD, today's call is being recorded and will be available for replay through May 12, 2022, on BD's Investor Relations website at bd.com or by phone at 866-342-8591 for domestic calls and list the Area Code +1-203-518-9713 for international calls.
- 05/05/2022
|
BD (BDX) Beats on Q2 Earnings and Revenues, Revises FY22 View
- The majority of BD's (BDX) core units witness strong revenue growth in the fiscal second quarter.
- 05/05/2022
|
Becton Dickinson (BDX) Q2 Earnings and Revenues Surpass Estimates
- Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.71% and 3.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2022
|
Why Becton (BDX) Might Surprise This Earnings Season
- Becton (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 05/04/2022
|
BD to Present at the BofA Securities 2022 Healthcare Conference
- FRANKLIN LAKES, N.J. , April 29, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 12:00 p.m.
- 04/29/2022
|
BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?
- Continued strength in BD's (BDX) Interventional segment is expected to have driven up Q2 sales.
- 04/27/2022
|
Why Becton Dickinson (BDX) is Poised to Beat Earnings Estimates Again
- Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/20/2022
|
Dividend Income Update March 2022
- The start of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated.
- 04/11/2022
|
Bet on These 4 Low-Beta, High-Dividend MedTech Stocks for 2022
- Stocks like Becton, Dickinson and Company (BDX), Phibro Animal Health (PAHC), McKesson Corporation (MCK) and UnitedHealth Group Inc (UNH) are right picks with strong fundamentals.
- 04/08/2022
|
ICU Medical: There Is Still Upside Here As Management Goes Big To Drive Value
- ICU Medical: There Is Still Upside Here As Management Goes Big To Drive Value
- 03/25/2022
|
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
- Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and strategic deals.
- 03/24/2022
|
7 Reddit Stocks Likely to Withstand Any Recession in 2022
- These Reddit stocks come from a range of industries, including pharmaceuticals and retailers, and can easily withstand market turmoil. The post 7 Reddit Stocks Likely to Withstand Any Recession in 2022 appeared first on InvestorPlace.
- 03/22/2022
|
Becton, Dickinson: Low Volatility Is A Strength In The Current Market
- We expect the interventional segment to continue maintaining its high growth as Becton, Dickinson focuses on transformational solutions.
- 03/17/2022
|
5 Low-Vol Dividend Aristocrats to Survive a Stormy Market
- Turmoil in the stock market has many investors looking for ways to manage risk. If your goal is safety and reliable income, a great starting point is the Dividend Aristocrats, a group of high-quality S&P 500 stocks known for delivering at least 25 straight years of dividend growth.
- 03/16/2022
|
IHI: A Standout Performer With Equally Strong Future Growth Prospects
- IHI: A Standout Performer With Equally Strong Future Growth Prospects
- 03/05/2022
|
Scared of a Bear Market? Buy This Rock-Solid Stock Now
- It's holding up without breaking a sweat.
- 02/26/2022
|
Upcoming Ex-Dividend Dates: March 1-9, 2021
- Upcoming Ex-Dividend Dates: March 1-9, 2021
- 02/26/2022
|
Becton Dickinson (BDX) Crossed Above the 20-Day Moving Average: What That Means for Investors
- Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
- 02/24/2022
|
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
- Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.
- 02/23/2022
|
Riding The Stock Waves: Update On The Medical Devices Sector
- Riding The Stock Waves: Update On The Medical Devices Sector
- 02/21/2022
|
Diamond Hill Capital Makes New Tech Bets, Sells Charles Schwab
- Diamond Hill Capital (Trades, Portfolio) recently disclosed its 13F portfolio updates for the fourth quarter of 2021, which ended on Dec. 31.
- 02/08/2022
|
Becton Dickinson (BDX) Crossed Above the 20-Day Moving Average: What That Means for Investors
- Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
- 02/04/2022
|
These 2 Stock Winners Are Defying the Market's Downturn
- It was another bad day for the market, but these companies are looking strong.
- 02/03/2022
|
BD (BDX) Beats on Q1 Earnings and Revenues, Raises FY22 View
- The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.
- 02/03/2022
|
Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q1 2022 Results - Earnings Call Transcript
- Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q1 2022 Results - Earnings Call Transcript
- 02/03/2022
|
Becton Dickinson Q1 Earnings Top Estimates, Raises FY22 Guidance On Higher COVID-19 Related Sales
- Becton Dickinson and Co BDX reported Q1 FY22 revenues of $4.9 billion, down 6% Y/Y (-5.9% on a currency-neutral basis), better than the consensus of $4.76 billion. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
- 02/03/2022
|
Becton Dickinson (BDX) Surpasses Q1 Earnings and Revenue Estimates
- Becton Dickinson (BDX) delivered earnings and revenue surprises of 27.27% and 4.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/03/2022
|
Should You Buy Becton, Dickinson and Company (BDX) Ahead of Earnings?
- Becton, Dickinson and Company (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/02/2022
|
Becton Dickinson Strengthens Post-Treatment Monitoring For Blood Cancers With Cytognos Acquisition
- Becton, Dickinson and Co (NYSE: BDX) has acquired Cytognos, a unit of Vitro SA, a Spanish diagnostics company that develops, produces, and sells fully integrated reagents, hardware, and software platforms. Deal terms were not disclosed.
- 02/01/2022
|
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
- Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q1 sales.
- 01/28/2022
|
Becton Dickinson (BDX) Expected to Beat Earnings Estimates: Should You Buy?
- Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/27/2022
|
2 Top Dividend Kings to Buy for the Long Haul
- The Dividend King club is an exclusive one. It takes good management to grow a dividend for 50 or more years, and these two healthcare stocks offer that.
- 01/26/2022
|
BD (BDX) Hits a New 52-Week High: What's Behind the Rally?
- A slew of strategic acquisitions are driving the top line for BD (BDX).
- 01/21/2022
|
Why the Earnings Surprise Streak Could Continue for Becton Dickinson (BDX)
- Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/14/2022
|
Becton, Dickinson And Company: Stable, Profitable, And Offering At-Home COVID-19 Testing
- Beckton, Dickinson and Company is a Profitable Dividend Aristocrat that generates tons of cash.
- 01/12/2022
|
Best Dividend Kings For January 2022
- The 35 Dividend Kings finished 2021 on a bright note adding 8.79% in December. The 8 best dividend kings based on forecasted growth and valuation trailed the average dividend king return by 161 bps in December.
- 01/12/2022
|
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
- Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic buyouts.
- 01/11/2022
|
4 Stocks to Watch Out For as MedTech Rides on Buyout Frenzy
- Here are some MedTech stocks - Quidel (QDEL), Thermo Fisher (TMO), Baxter (BAX) and BD (BDX) - that have been quite active in the acquisition front and therefore worth investor attention.
- 01/06/2022
|
BD TO ANNOUNCE FINANCIAL RESULTS FOR ITS FIRST QUARTER OF FISCAL YEAR 2022
- FRANKLIN LAKES, N.J., Jan. 5, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report financial results for its first quarter of fiscal year 2022 on Thursday, Feb. 3, 2022.
- 01/05/2022
|
BD (BDX) Partners With Retailers for At-Home COVID-19 Test
- BD (BDX) collaborates with retail partners and distributors to make the BD Veritor At-Home COVID-19 Test widely accessible.
- 12/27/2021
|
Options Income Series: Earn High Income Safely And Consistently - December 2021
- We explain why selling the cash-covered puts and covered calls is a safer choice and earns a high income. We will discuss how to formulate an options income strategy that's sustainable and repeatable.
- 12/25/2021
|
BD's (BDX) Latest Buyout to Enhance its Digital Capabilities
- BD's (BDX) acquisition of Scanwell is expected to significantly transform its at-home solutions both at present and in the future.
- 12/23/2021
|
BD to Present at the 40th Annual J.P. Morgan Healthcare Conference
- FRANKLIN LAKES, N.J., Dec. 22, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will virtually present at the 40th Annual J.P.
- 12/22/2021
|
Fed Tomfoolery: 5 Top Stocks - 3 Pure-Growth, 2 Dividend-Growth
- We review 5 top stock ideas that have been created by the Fed's tomfoolery (3 are pure-growth stocks and 2 are dividend-growth stocks). We also discuss a big reason why cryptocurrency popularity continues to grow (hint: more Fed tomfoolery).
- 12/12/2021
|
BD's (BDX) Tissuemed Buyout to Boost its Surgical Solutions Arm
- BD's (BDX) latest acquisition is expected to complement its currently used products and help to support minimally invasive surgeries.
- 12/10/2021
|
Best Dividend Kings For December 2021
- The 32 Dividend Kings lost 1.68% in November, underperforming the broad market once more this year.
- 12/09/2021
|
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
- Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.
- 12/08/2021
|
BD's (BDX) Buyout of Venclose to Improve Patient Outcome
- BD's (BDX) acquisition of Venclose is expected to deliver a patient-centric approach to care.
- 12/06/2021
|
Upcoming Ex-Dividend Dates: December 12-20, 2021
- Upcoming Ex-Dividend Dates: December 12-20, 2021
- 12/06/2021
|
Becton Dickinson to name diabetes care spinoff 'embecta'
- Becton Dickinson & Co. BDX, +0.90% said Monday that the spinoff of its diabetes care business will be named "embecta." The previously announced spinoff, into an independent publicly traded company, is expected to be completed in the second quarter of 2022.
- 12/06/2021
|
Dividend Champions For December 2021
- Monthly update of the Dividend Champions List. 75 companies declared higher dividends in the past month, with an average increase of 8.55% over their previous payouts.
- 12/02/2021
|
11 Upcoming Dividend Increases
- All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List.
- 12/02/2021
|
Becton, Dickinson & Co. Is Trading at a Discount
- Shares of Becton, Dickinson and Co. ( BDX , Financial) reported earnings results earlier this month that came in above Wall Street analysts' estimates. Covid-19 remains a tailwind to the company's business, but the core segments also performed well.
- 11/29/2021
|
Rapid Covid-19 tests in high demand ahead of Thanksgiving
- CNBC's Meg Tirrell joins 'Squawk Box' to report on the increased demand for Covid-19 tests ahead of the Thanksgiving holiday.
- 11/23/2021
|
Becton, Dickinson Is A Strong Buy At $250
- Becton, Dickinson is one of the most stable predictable low-volatility health care stocks out there.
- 11/18/2021
|
Second Half Of November Brings Dividend Increases From Merck, Nike And 12 Others
- Investors saw a few very good dividend increases in the first half of November, with ADP, Snap-on, and Roper Technologies announcing double-digit boosts, and a massive 29% boost from HP. The second half of November will bring double-digit boosts from a few more companies including Nike, Motorola Solutions, Aflac, and Agilent Technologies.
- 11/15/2021
|
Dividend Increases: October 30-November 5, 2021
- In this article series, we provide a weekly summary of dividend changes. A summary table presents relevant data and key statistics of dividend increases.
- 11/11/2021
|
IMF October Buys: The 13 Stocks Added To My Fund
- IMF October Buys: The 13 Stocks Added To My Fund
- 11/09/2021
|
Qiagen, Becton Dickinson Settle Patent Infringement Lawsuit For $53M
- Qiagen N.V. (NYSE: QGEN) settled with Becton Dickinson & Co (NYSE: BDX) a patent infringement lawsuit related to Qiagen's NeuMoDx 96 and NeuMoDx 288 clinical PCR systems.
- 11/08/2021
|
Becton, Dickinson and Company's (BDX) CEO Tom Polen on Q4 2021 Results - Earnings Call Transcript
- Becton, Dickinson and Company's (BDX) CEO Tom Polen on Q4 2021 Results - Earnings Call Transcript
- 11/04/2021
|
Becton Dickinson (BDX) Q4 Earnings and Revenues Beat Estimates
- Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.58% and 4.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/04/2021
|
Is a Surprise Coming for BD (BDX) This Earnings Season?
- BD (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 11/03/2021
|
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
- Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q4 sales.
- 10/27/2021
|
Becton Dickinson Starts Selling New At-Home Rapid COVID-19 Tests
- Becton Dickinson and Co (NYSE: BDX) has partnered with Amazon.com Inc (NASDAQ: AMZN) to begin shipment of a new at-home rapid COVID-19 test that can confirm results using an entirely automated smartphone app. The BD Veritor At-Home COVID-19 Test, which U.S. regulators authorized in August, also automatically reports results to federal and state public health authorities.
- 10/26/2021
|
Can Becton Dickinson (BDX) Keep the Earnings Surprise Streak Alive?
- Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/26/2021
|
3 Must-Buy Efficient Stocks to Boost Portfolio Returns
- Becton, Dickinson and Company (BDX), Ternium (TX) & AutoNation (AN) are three must-buy efficient stocks that can enrich your portfolio now.
- 10/25/2021
|
BD Launches New 'Together We Advance' Environmental, Social, Governance Strategy; Announces 2030+ Goals to Enhance Stewardship of Human Health, Communities and the Planet
- FRANKLIN LAKES, N.J., Oct. 18, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new strategy to advance environmental, social and governance (ESG) initiatives, as well as a suite of goals for 2030 and beyond that focus on enhancing stewardship of the company, the planet, community and human health.
- 10/18/2021
|
BD Unveils Nebraska-Based Manufacturing Capacity to Support U.S. Vaccination Agility and Preparedness
- FRANKLIN LAKES, N.J., Oct. 7, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has strengthened the U.S. government's access to safety injection devices through increased manufacturing capacity and domestic supply.
- 10/07/2021
|
BD Announces 510(k) Clearance of Expanded Indications for the Rotarex™ Atherectomy System
- FRANKLIN LAKES, N.J., Oct. 6, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance for expanded indications from the U.S. Food and Drug Administration (FDA) for the Rotarex™ Atherectomy System.
- 10/06/2021
|
Bear Of The Day: Becton, Dickinson and Co (BDX)
- Despite a beating the number in the most recent report, this stock has fallen to the lowest Zacks Rank
- 10/05/2021
|
Best Dividend Aristocrats For October 2021
- NOBL's momentum fades in September hindering its chances of having a record-breaking return this year. I present 3 strategies that theoretically can beat the dividend aristocrat index in the long term.
- 09/29/2021
|
Dividend Champion And Contender Highlights: Week Of September 26
- A weekly summary of dividend activity for Dividend Champions and Contenders.
- 09/26/2021
|
2 Safe Dividend Growth Stocks You Can Buy and Forget About
- These yields may seem low, but you'll likely be earning much more on your initial investment over time.
- 09/25/2021
|
BD Joins the Race to Zero: Largest Alliance Dedicated to Achieving Net Zero Emissions by 2050
- FRANKLIN LAKES, N.J., Sept. 22, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, with support from a number of partners including Global Citizen, is proud to announce the company has officially signed on to the Race to Zero via the most ambitious Science Based Targets initiative (SBTi), the Business Ambition for 1.5⁰C , and this milestone will be celebrated on September 25, 2021 at Global Citizen LIVE.
- 09/22/2021
|
BD Partners with Washington State in Back-to-School Testing Effort
- FRANKLIN LAKES, N.J., Sept. 21, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has been selected by the state of Washington as a digitally read, rapid antigen test option for COVID-19 testing and screening in K-12 schools across the state.
- 09/21/2021
|
Cybersecurity Gains Prominence in MedTech: 3 Stocks to Focus on
- Technology-based healthcare stocks like Henry Schein (HSIC), Veeva Systems (VEEV) and BD (BDX) are expected to continue their rally over the next few months.
- 09/17/2021
|
Becton Dickinson CEO on first Covid smartphone test and how it works
- Thomas Polen, Becton Dickenson CEO, joins Closing Bell to talk about his company's smartphone Covid test.
- 09/10/2021
|
Why Biden's Action Plan Is Bullish For COVID-19 Testing Stocks
- On Thursday, President Joe Biden revealed his new COVID-19 action plan, which includes $2 billion in government spending on 280 million rapid point of care and at-home COVID-19 tests. On Friday, Bank of America analyst Bob Hopkins said Biden's new plan is good news for test manufacturers, including Becton Dickinson and Co (NYSE:BDX) and Abbott Laboratories (NYSE:ABT).
- 09/10/2021
|
Becton, Dickinson And Company: One Of The Best Dividend SWANs You Can Buy Today
- Becton, Dickinson And Company: One Of The Best Dividend SWANs You Can Buy Today
- 09/10/2021
|
Notable Becton Dickinson Insider Trades $5.72 Million In Company Stock
- James Lim, Executive Vice President at Becton, Dickinson (NYSE:BDX), made a large buy and sell of company shares on September 3, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that James Lim purchased 14,584 Becton, Dickinson shares at a price of $134.73 per share for a total of $1,964,902 on September 3.
- 09/07/2021
|
BD's (BDX) Latest Diagnostic System to Improve Lab Efficiency
- BD's (BDX) new system is expected to address labs' needs for high-volume processing and increases in efficiency.
- 08/31/2021
|
BD to Present at Two Upcoming Virtual Healthcare Investor Conferences in September
- FRANKLIN LAKES, N.J., Aug. 26, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will present at the following upcoming virtual investor conferences: The Wells Fargo Securities 2021 Healthcare Conference on Thursday, September 9, 2021, at 8:00 a.m.
- 08/26/2021
|
BD (BDX) Veritor At-Home COVID-19 Test Receives EUA From FDA
- EUA for BD's (BDX) At-Home COVID-19 test is expected to boost home testing to prevent outbreaks and limit the rise in COVID-19 cases from the Delta variant.
- 08/26/2021
|
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
- Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and regulatory approvals.
- 08/26/2021
|
BD Locks FDA Emergency Use Nod For At-Home COVID-19 Antigen Test
- The FDA has issued an Emergency Use Authorization (EUA) for Becton Dickinson and Co's (NYSE: BDX) BD Veritor At-Home COVID-19 Test. Also Read: BD's Automated Molecular Diagnostics Platform Wins FDA Approval, Initial Test For HPV
- 08/26/2021
|
BD Receives Emergency Use Authorization for First At-Home COVID-19 Test to Use Smartphone to Interpret, Deliver Results
- FRANKLIN LAKES, N.J., Aug. 25, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the BD Veritor™ At-Home COVID-19 Test — the first at-home COVID-19 rapid antigen test to use computer vision technology in a smartphone to interpret and provide a digital display of testing results.
- 08/25/2021
|
BD's Automated Molecular Diagnostics Platform Wins FDA Approval, Initial Test For HPV
- Becton Dickinson and Co (NYSE: BDX) has received FDA approval for its automated, sample-to-answer, high-throughput BD Cor system along with the BD Onclarity HPV Assay for extended genotyping of human papillomavirus (HPV). The modular and scalable BD Cor includes an automated sample preparation system, BD Cor PX, and an instrument that automates the BD Onclarity HPV assay, BD Cor GX.
- 08/25/2021
|
BD Launches Fully Automated High-Throughput Molecular Diagnostic Platform for U.S. Laboratories
- FRANKLIN LAKES, N.J., Aug. 25, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has launched a new, fully automated high-throughput diagnostic system using robotics and sample management software algorithms to set a new standard in automation for infectious disease molecular testing in core laboratories and other centralized laboratories in the United States.
- 08/25/2021
|
BD Announces Pricing of Tender Offers
- FRANKLIN LAKES, N.J., Aug. 19, 2021 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the consideration payable in connection with its previously announced tender offers to purchase for cash (i) any and all of the Company's 2.894% senior notes due 2022 and 3.300% senior notes due 2023, each listed in the first table below (the "Any and All Notes"), and (ii) in the order of priority set forth in the second table below, up to the applicable Maximum Tender SubCap, if any, of each of the Company's 3.875% senior notes due 2024, 3.734% senior notes due 2024 and 3.363% senior notes due 2024, each listed in the second table below (collectively, the "Maximum Tender Offer Notes" and together with the Any and All Notes, the "Securities" and each a "series"), subject to an aggregate maximum tender cap of $1,285,000,000 for all tendered series of Maximum Tender Offer Notes (the "Aggregate Maximum Tender Cap").
- 08/19/2021
|
Becton, Dickinson and Company Announces Early Tender Results
- FRANKLIN LAKES, N.J., Aug. 19, 2021 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the early tender results for its previously announced tender offers to purchase for cash (i) any and all of the Company's 2.894% senior notes due 2022 and 3.300% senior notes due 2023, each listed in the first table below (the "Any and All Notes"), and (ii) in the order of priority set forth in the second table below, up to the applicable Maximum Tender SubCap of each of the Company's 3.875% senior notes due 2024, 3.734% senior notes due 2024 and 3.363% senior notes due 2024, each listed in the second table below (collectively, the "Maximum Tender Offer Notes" and together with the Any and All Notes, the "Securities" and each a "series"), subject to an aggregate maximum tender cap of $1,285,000,000 (the "Aggregate Maximum Tender Cap").
- 08/19/2021
|
BD's (BDX) New Offering to Boost Labs' Flow Cytometry Abilities
- BD's (BDX) latest product offering is expected to help improve access to instrumentation for complex scientific research to more laboratories.
- 08/16/2021
|
New BD Benchtop Cell Analyzer Enhances Laboratory Access and Accelerates Scientific Research
- FRANKLIN LAKES, N.J., Aug. 11, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of a new benchtop cell analyzer that brings sophisticated flow cytometry capabilities to laboratories of all sizes.
- 08/11/2021
|
Christopher DelOrefice to Join BD as Chief Financial Officer
- FRANKLIN LAKES, N.J., Aug. 11, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Christopher DelOrefice has been named executive vice president and chief financial officer (CFO), effective Sept.
- 08/11/2021
|
BD Announces Upsizing of Tender Offers
- FRANKLIN LAKES, N.J., Aug. 10, 2021 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced that it has amended its previously announced tender offers to purchase for cash each of its 3.875% Senior Notes due 2024, 3.734% Senior Notes due 2024 and 3.363% Senior Notes due 2024 (collectively, the "Maximum Tender Offer Notes") to (i) increase the previously announced maximum principal amount to be purchased by the Company of its 3.734% Senior Notes due 2024 from $300,000,000 to $500,000,000 and (ii) increase the previously announced maximum principal amount to be purchased by the Company of all series of Maximum Tender Offer Notes in the tender offers from $715,000,000 to $1,285,000,000.
- 08/10/2021
|
JPMorgan Downgrades Becton Dickinson On Muffled FY22 Outlook
- JPMorgan downgraded Becton Dickinson and Co (NYSE:BDX) to Neutral from Overweight with a price target of $265, down from $280. While Becton reported better than expected top and bottom-line Q3 results, analyst Robert Marcus tells investors that this was overshadowed by the company's "muted" Q4 and FY22 outlook.
- 08/06/2021
|
Becton Dickinson and Company (BDX) CEO Tom Polen on Q3 2021 Results - Earnings Call Transcript
- Becton Dickinson and Company (BDX) CEO Tom Polen on Q3 2021 Results - Earnings Call Transcript
- 08/05/2021
|
Becton Dickinson (BDX) Q3 Earnings and Revenues Surpass Estimates
- Becton Dickinson (BDX) delivered earnings and revenue surprises of 11.38% and 8.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2021
|
BDX Stock Plunges Despite Q3 Earnings Topping Estimates On Recovery In Elective Volumes; Raised FY21 Guidance
- Becton Dickinson and Co (NYSE: BDX) reported Q3 revenues of $4.9 billion, +26.9% Y/Y, better than the consensus of $4.51 billion. The increase is primarily driven by the strong base business performance as overall healthcare utilization levels recover from the initial impact of COVID-19.
- 08/05/2021
|
Becton, Dickinson: Q3 Earnings Insights
- Shares of Becton, Dickinson (NYSE:BDX) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were up 24.55% year over year to $2.74, which beat the estimate of $2.44.
- 08/05/2021
|
BD Announces Third Fiscal Quarter Results; Strong Base Growth Drives Better Performance In Quarter And Higher Guidance For Fiscal 2021
- FRANKLIN LAKES, N.J., Aug. 5, 2021 /PRNewswire/ -- Third fiscal quarter revenues of $4.9 billion grew 26.9% on a reported basis.
- 08/05/2021
|
BD to Present at UBS Genomics 2.0 and MedTech Innovations Summit
- FRANKLIN LAKES, N.J., July 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that management will be presenting at the UBS Genomics 2.0 and MedTech Innovations Summit on Wednesday, August 11, 2021, at 4:00 p.m.
- 07/29/2021
|
BD to Begin Remediation for BD Alaris™ System Software
- FRANKLIN LAKES, N.J., July 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the company will begin remediation for the February 4, 2020 BD Alaris™ System 1 recall through a new version of software.
- 07/29/2021
|
3 Dividend Stocks Safe Enough to Bet the Farm On
- You shouldn't invest your life savings into any one stock, but these three have some serious potential.
- 07/29/2021
|
BD Board Declares Dividend
- FRANKLIN LAKES, N.J., July 27, 2021 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.83 per common share, payable on September 30, 2021 to holders of record on September 9, 2021.
- 07/27/2021
|
BD Acquires Tepha, Inc., to Drive New Innovations in Soft Tissue Repair and Regeneration
- FRANKLIN LAKES, N.J., July 27, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.
- 07/27/2021
|
Federal Jury in Dallas Finds Bard's IVC Blood Clot Filter Defective and Dangerous
- DALLAS, July 23, 2021 /PRNewswire/ -- For the fourth time since May, jurors in federal court have found that C.R. Bard's IVC blood clot filter is defective and responsible for injuries and complications.
- 07/23/2021
|
BD Seeks to Transform Patient Experience through Vision of 'One-Stick Hospital Stay'
- FRANKLIN LAKES, N.J., July 20, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has taken a large step forward in transforming the patient experience through a vision of a "One-Stick Hospital Stay," building on its history of innovation and leadership in blood collection and vascular access solutions.
- 07/20/2021
|
BD's (BDX) Digital Marketplace Set to Improve User Experience
- BD's (BDX) latest online marketplace is expected to offer a better user experience to its flow cytometry users.
- 07/12/2021
|
BD Announces Two Future Directors for Diabetes Care Spinoff Company
- FRANKLIN LAKES, N.J., July 12, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that David F.
- 07/12/2021
|
Grab these 3 MedTech Stocks That Outperformed S&P 500 YTD
- Snap up these three top stocks, WST, PAHC and RMD, which continue to show promise amid the pandemic and can turn out to be prudent investment choices.
- 07/11/2021
|
Grab these 3 MedTech Stocks That Outperformed S&P 500 YTD
- Snap up these three top stocks, WST, PAHC and RMD, which continue to show promise amid the pandemic and can turn out to be prudent investment choices.
- 07/09/2021
|
BD Launches Reimagined Digital Marketplace for Flow Cytometry
- FRANKLIN LAKES, N.J., July 7, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial release of a new bdbiosciences.com web and eCommerce site, an entirely "reimagined" digital marketplace designed to provide an enhanced online purchasing experience for users and their procurement teams.
- 07/07/2021
|
The 7 Best Dividend Stocks to Buy for Income Investors In July 2021
- Markets have become choppy due to inflation and uncertainty. These dividend stocks could provide a safe haven in volatile times for the rest of the year.
- 07/02/2021
|
BD To Announce Financial Results For Its Third Quarter Of Fiscal 2021
- FRANKLIN LAKES, N.J., June 30, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report its financial results for the third quarter of fiscal year 2021 on Thursday, August 5, 2021.
- 06/30/2021
|
BD's (BDX) PeritX System Gets FDA's Expanded 510(k) Clearance
- BD's (BDX) receipt of the expanded FDA indication for its PeritX System is expected to lessen the number of hospital trips a patient takes for fluid removal.
- 06/24/2021
|
BD Announces Expanded 510(k) Clearance for At-Home System for Ascites
- FRANKLIN LAKES, N.J., June 23, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the PeritX™ Peritoneal Catheter System for the drainage of symptomatic, recurrent non-malignant ascites.
- 06/23/2021
|
2 Cheap Dividend Stocks You Can Buy Right Now
- There's a good chance your dividend income will rise over the years with these two investments.
- 06/23/2021
|
BD Highlights Five-Year ESG Achievements in 2020 Sustainability Report, Setting the Foundation for 2030+ Strategy
- FRANKLIN LAKES, N.J., June 22, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2020 Sustainability Report, highlighting significant achievements in environmental, social and governance (ESG) factors that supported the company's 2020 Sustainability Goals – a five year strategy that concluded in 2020.
- 06/22/2021
|
Cardiology Space Gains Momentum in 2021: 5 Stocks to Focus on
- These cardiology device stocks Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW), Merit Medical (MMSI), BD (BDX) are expected to continue their run over the next few months.
- 06/18/2021
|
Cybersecurity Gains Prominence in Healthcare: 3 Stocks to Watch
- Here we look at three stocks, VEEV, HSIC and BDX, that investors can keep a watch on the back of their robust cybersecurity measures.
- 06/17/2021
|
BD's (BDX) Rapid COVID-19 Test for US Olympic Trial Swimmers
- BD (BDX) to provide rapid antigen testing for COVID-19 at the U.S. Olympic Team Trials and other competitive swimming events on behalf of USA Swimming.
- 06/16/2021
|
USA Swimming Partners with BD to Provide COVID-19 Screening for the Olympic Trials and Other Competitive Swimming Events
- FRANKLIN LAKES, N.J., June 11, 2021 /PRNewswire/ -- USA Swimming, the national governing body for the sport of swimming in the United States, and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, have partnered to provide COVID-19 testing at USA Swimming events.
- 06/11/2021
|
BD's (BDX) Milestone Pandemic Orders to Support Vaccinations
- BD (BDX) receives 2 billion pandemic orders for needles and syringes to support global COVID-19 vaccination efforts.
- 06/10/2021
|
BD Hits 2 Billion Injection Device Milestone in Support of Global COVID-19 Vaccination Efforts
- FRANKLIN LAKES, N.J., June 8, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pandemic orders for needles and syringes totaling 2 billion injection devices to support global COVID-19 vaccination efforts.
- 06/08/2021
|
BD (BDX) Solidifies Foothold in Healthcare Cybersecurity
- BD's (BDX) authorization as a CNA is expected to allow it to provide customers with timely information about vulnerabilities in BD products available globally.
- 06/07/2021
|
BD Advances Leadership in Cybersecurity Preparedness, Transparency
- FRANKLIN LAKES, N.J., June 2, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has become the first medical technology company authorized as a Common Vulnerability and Exposures (CVE®) Numbering Authority by the CVE Program, further demonstrating the company's leadership in health care cybersecurity.
- 06/02/2021
|
BD (BDX) to Boost Lab Efficacy With BD Kiestra UCA's U.S. Launch
- BD's (BDX) UCA leverages AI to revolutionize the way microbiology labs conduct urine culture analysis.
- 05/31/2021
|
Matrix Asset's David Katz makes the case for Amgen, Viacom and Verizon
- David Katz, Matrix Asset Advisors chief investment officer, and Jerry Castellini, CastleArk Management chief investment officer, join 'The Exchange' to discuss their market outlook as the economy reopens and the names they think will have value in this market environment. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis.
- 05/27/2021
|
BD to Present at Upcoming Investor Conferences in June
- FRANKLIN LAKES, N.J., May 26, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following upcoming virtual investor conferences during the month of June: The Piper Sandler June Med Tech Series Conference on Friday, June 4, 2021 at 1:30 p.m.
- 05/26/2021
|
BD Leverages Artificial Intelligence To Transform Microbiology Urine Testing
- FRANKLIN LAKES, N.J., May 26, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. launch of a Urine Culture Application for use with the BD Kiestra™ lab automation incubation and imaging system that can transform the way microbiology labs approach urine culture analysis.
- 05/26/2021
|
BD Launches Industry First Ready-to-Use Iodine-Based Surgical Irrigation System
- FRANKLIN LAKES, N.J., May 25, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the availability of BD Surgiphor™ Sterile Wound Irrigation System, the first and only ready-to-use aqueous povidone-iodine (PVP-I) irrigation solution that mechanically loosens and removes wound debris.
- 05/25/2021
|
Becton Dickinson To Build Fourth Facility In Spain To Expand Pre-Filled Drug Delivery Business
- Becton Dickinson and Co (NYSE: BDX) will build a €165 million ($200 million) high-tech manufacturing facility in Zaragoza, Spain, that will create up to 600 jobs by 2030. BD plans to begin constructing the new plant in late 2021, and the new facility will be the fourth manufacturing plant for BD in Spain.
- 05/18/2021
|
BD to Build New €165 Million Manufacturing Facility in Zaragoza, Spain To Support Ongoing Strong Growth of Pre-Filled Drug Delivery Business
- MADRID, May 18, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will build a €165 million ($200 million USD) high-tech manufacturing facility in the city of Zaragoza, located in the Aragon region of Spain, that will create up to 600 jobs by 2030. BD plans to begin construction of the new plant in late 2021, and the new facility will be the fourth manufacturing plant for BD in Spain.
- 05/18/2021
|
BD Announces Industry-First CE Marked Assay for HPV Screening from At-Home Self-Collected Vaginal Samples
- FRANKLIN LAKES, N.J., May 13, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the industry's first self-collection claim for HPV screening has been CE marked to the IVD directive 98/79/EC.
- 05/13/2021
|
Becton Dickinson To Spin Diabetes Care Unit In 2022
- , a leading global medical technology company, announced that its Board of Directors have unanimously authorized management to go ahead with a plan to spinoff the Diabetes Care business into an independent, publicly traded company (“NewCo”).
- 05/11/2021
|
Becton, Dickinson & Co. Continues to Shine
- Becton, Dickinson & Co. ( BDX , Financial) delivered another strong top and bottom-line beat when it reported earnings results last week.
- 05/11/2021
|
10 Of The Best Value Picks Among Dividend Aristocrats
- Dividend Aristocrats can be a great choice for investors looking for reliable income and stocks that can outperform during a recession. Not all Dividend Aristocrats are necessarily attractive at the same time, however.
- 05/08/2021
|
Syringe maker Becton, Dickinson CEO on the Covid supply chain
- CNBC's "Power Lunch" team discusses syringe supply and the Covid supply chain with Becton, Dickinson CEO Tom Polen.
- 05/06/2021
|
Becton, Dickinson and Company (BDX) CEO Tom Polen on Q2 2021 Results - Earnings Call Transcript
- Becton, Dickinson and Company (BDX) CEO Tom Polen on Q2 2021 Results - Earnings Call Transcript
- 05/06/2021
|
Becton Dickinson (BDX) Earnings Surpass Estimates in Q2
- Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal second quarter.
- 05/06/2021
|
Becton Dickinson To Spin-Off Diabetes Care Business: Highlights
- While reporting financial results for the second fiscal quarter of the year, during which revenues grew more than 15% to $4.9 billion, Becton Dickinson and Co (NYSE: BDX) also laid out its plans to spin off its diabetes-focused segment. Split Highlights: The split is expected to be completed in the first half of 2022, after which the segment will become a completely separate, publicly-traded company, tentatively dubbed “NewCo.”
- 05/06/2021
|
Becton Dickinson (BDX) Tops Q2 Earnings and Revenue Estimates
- Becton Dickinson (BDX) delivered earnings and revenue surprises of 4.93% and 1.47%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/06/2021
|
Becton Dickinson beats profit expectations, plans to spin off Diabetes Care business
- Becton Dickinson & Co. reported Thursday fiscal second-quarter profit and sales that rose above expectations, boosted by $480 million in COVID-19 testing sales, and announced plans to separate its Diabetes Care business into an independent publicly traded company. The medical technology company's stock was still inactive in premarket trading.
- 05/06/2021
|
BD Announces Intent to Spin Off Diabetes Care Business to Enhance Focus on Innovation and Priority Growth Markets
- FRANKLIN LAKES, N.J., May 6, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized management to proceed with a plan to spin off the company's Diabetes Care business as an independent, publicly traded company ("NewCo").
- 05/06/2021
|
BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?
- BD's (BDX) second-quarter fiscal 2021 results are likely to reflect strong year-over-year growth in revenues from assays in its Life Sciences segment.
- 05/03/2021
|
BD to Present at Upcoming Investor Health Care Conferences in May
- FRANKLIN LAKES, N.J., April 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following upcoming virtual investor healthcare conferences during the month of May: The Bank of America Securities 2021 Virtual Healthcare Conference on Wednesday, May 12, 2021 at 2:45 p.m.
- 04/29/2021
|
BD Announces Enrollment in Post-Market Studies of the WavelinQ™ Arteriovenous Endovascular Fistula
- FRANKLIN LAKES, N.J., April 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that enrollment has begun and the first patients have been treated in the post-market surveillance study, CONNECT-AV.
- 04/29/2021
|
Elizabeth McCombs Appointed Chief Technology Officer at BD
- FRANKLIN LAKES, N.J., April 28, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Elizabeth McCombs as executive vice president and chief technology officer, effective April 26, 2021, succeeding John DeFord.
- 04/28/2021
|
BD Board Declares Dividend
- FRANKLIN LAKES, N.J., April 27, 2021 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.83 per common share, payable on June 30, 2021 to holders of record on June 9, 2021.
- 04/27/2021
|
CerTest Biotec, BD Announce Addition of Saliva to the CE Marked VIASURE SARS-CoV-2 (N1+N2) Real Time PCR Detection Kit for BD MAX™ Molecular Diagnostic System
- ZARAGOZA, Spain and FRANKLIN LAKES, N.J., April 27, 2021 /PRNewswire/ -- CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit for the BD MAX™ Molecular Diagnostic System can now be run on saliva specimens.
- 04/27/2021
|
3 Top Blue-Chip Healthcare Stocks With Healthy Dividends
- Healthcare stocks have some excellent dividend stocks among their ranks, and these three names are among the most reliable to buy. The post 3 Top Blue-Chip Healthcare Stocks With Healthy Dividends appeared first on InvestorPlace.
- 04/26/2021
|
BD Announces FDA 510(k) Submission for BD Alaris™ System
- FRANKLIN LAKES, N.J., April 26, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the BD Alaris™ System, the most widely used infusion pump in acute care hospitals across the United States.
- 04/26/2021
|
USATF Partners With BD To Provide Rapid COVID-19 Testing To Enhance Athlete Safety At Track & Field Events
- FRANKLIN LAKES, N.J., April 23, 2021 /PRNewswire/ -- USA Track & Field (USATF) and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, have partnered to provide rapid COVID-19 testing for USATF athletes at Journey to Gold meets to help get USATF professional athletes back to competition safely through the use of the BD Veritor™ Plus system.
- 04/23/2021
|
Which Stocks Are the Biggest Losers From Sinking COVID Testing Rates?
- Less COVID-19 testing means less revenue for some companies.
- 04/22/2021
|
BD's Commitment to Address Climate Change
- FRANKLIN LAKES, N.J., April 22, 2021 /PRNewswire/ -- In recognition of Earth Day, BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, reinforces its commitment to Advancing the world of health™ by affirming the first phase of its 2030+ sustainability goals – climate change targets.
- 04/22/2021
|
BD Commits $1M To Fight Maternal And Neonatal Tetanus
- FRANKLIN LAKES, N.J., April 20, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $1 million commitment over five years to UNICEF USA in support of UNICEF's work to uphold the rights of all children and help every child survive and thrive.
- 04/20/2021
|
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
- Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/19/2021
|
Becton, Dickinson - Three Reasons It Is A Buy
- Becton, Dickinson is a market leader in multiple medical supply, laboratory, and diagnostic product categories. The company has deleveraged after two major acquisitions and the leverage ratio is now near 2.5X.
- 04/19/2021
|
BD Announces 510(k) Clearance of Pristine™ Long-Term Hemodialysis Catheter
- FRANKLIN LAKES, N.J., April 14, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Pristine™ Long-Term Hemodialysis Catheter, a new hemodialysis catheter with a unique side-hole free symmetric Y-Tip™ distal lumen design.
- 04/14/2021
|
4 Dividend Blue-Chips That Could Save You A Fortune During The Next Market Crash
- Vaccine/Stimulus/Economic Boom euphoria has sent the S&P 500 soaring to 36% historically overvalued levels. The market is now pricing in three years of growth and medium-term return potential is pathetic. Deutsche Bank just warned of a likely 6% to 10% market decline within the next three months.
- 04/12/2021
|
3 Women Healthcare Stocks With Solid Growth Potential Amid COVID-19
- Let's take a look at the three women healthcare MedTech stocks performing well lately.
- 04/09/2021
|
BD's (BDX) $65M Investment to Boost Supply-Chain Strength
- BD's (BDX) $65-million investment in constructing an advanced facility will become integral to the U.S. medical device supply chain.
- 04/06/2021
|
BD To Announce Financial Results For Its Second Quarter Of Fiscal 2021
- FRANKLIN LAKES, N.J., April 5, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report its financial results for the second quarter of fiscal year 2021 on Thursday, May 6, 2021.
- 04/05/2021
|
4 Lucrative MedTech Stocks to Bet On in 2021 Amid Pandemic
- Grab these four top stocks, HRC, OMI, MCK and VIVO, which continue to show promise amid the pandemic and can turn out to be wise investment choices for 2021.
- 04/01/2021
|
BD to Invest $65 Million for Key Supply Chain Infrastructure in Tucson, Arizona to Increase Resiliency of U.S. Medical Device Supply
- TUCSON, Ariz., April 1, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it will invest $65 million to construct a state-of-the-art facility in Tucson, Arizona that will be a hub for the company's supply chain, serving as a final-stage manufacturing and sterilization center.
- 04/01/2021
|
BD Receives Emergency Use Authorization for Asymptomatic Screening for SARS-CoV-2 through Serial Rapid Antigen Testing
- FRANKLIN LAKES, N.J., April 1, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its rapid antigen test to be used for SARS-CoV-2 screening through serial testing of asymptomatic individuals.
- 04/01/2021
|
BD (BDX) Receives FDA EUA for Combination Rapid Antigen Test
- BD (BDX) gets FDA EUA for new rapid, antigen test, which can distinguish between COVID-19, influenza A and influenza B in a single test.
- 03/31/2021
|
BD gets FDA authorization for test that can detect COVID-19 and the flu
- Becton, Dickinson & Co. said it received emergency authorization from the Food and Drug Administration for a rapid, antigen test that can detect SARS-CoV-2 and two types of influenza. The test, which runs on the company's BD Veritor System, takes about 15 minutes to produce results and is expected to be available this summer.
- 03/30/2021
|
BD Announces FDA Emergency Use Authorization for Combination COVID-19, Flu Rapid Antigen Test
- FRANKLIN LAKES, N.J., March 30, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for a new, rapid antigen test that can detect SARS-CoV-2, influenza A and influenza B in a single test.
- 03/30/2021
|
3 Stocks to Capitalize on Promising Dental Supplies Industry
- 3 Stocks to Capitalize on Promising Dental Supplies Industry
- 03/10/2021
|
Becton, Dickinson And Company: Expect More Cash To Head To Shareholders
- Becton, Dickinson and Company is a Dividend Champion with 49 consecutive years of dividend. Shares currently yield 1.35%.
- 03/09/2021
|
BD (BDX) Acquires GSL Solutions for Medication Management
- This acquisition should improve BD's (BDX) advanced medication management capabilities to further cater to the needs of retail pharmacies including those in outpatient settings.
- 03/08/2021
|
4 Medical Technology Leaders Have Upcoming Catalysts That Could Be Huge
- When the market is expensive and overbought like the current one is, it is very important to stay with companies that not only have solid earnings potential but also have upcoming catalysts that can help move the shares higher.
- 03/04/2021
|
Becton, Dickinson & Co.: Ride the Covid-19 Tailwinds
- Leading medical device manufacturer Becton, Dickinson & Co. (NYSE:BDX), or BD, recently reported earnings results that showed the company greatly benefited from Covid-19-related sales. BD provides the testing kits and vaccine injection devices being used to combat the virus.
- 02/25/2021
|
BD (BDX), Scanwell Health Collaborate on At-Home Coronavirus Test
- BD (BDX) plans to develop a lateral flow antigen test and pair it with the Scanwell Health mobile app via the latest partnership.
- 02/23/2021
|
Which Stocks Could Win if the U.S. Requires COVID Tests for Domestic Flights?
- It's possible that some stocks could fly higher with the policy change being considered by the Biden administration.
- 02/20/2021
|
3 High-Quality Health Care Companies With Recession-Proof Dividends
- Health care companies may not be at the front of mind when thinking of stocks with dividends, but these three are winners. The post 3 High-Quality Health Care Companies With Recession-Proof Dividends appeared first on InvestorPlace.
- 02/19/2021
|
4 Dental Stocks to Watch on Likely Industry Turnaround
- The dental equipment market seems ready to grow as it continues to recover from the COVID-19 pandemic slump, making it prudent to look at names like Henry Schein (HSIC) and McKesson (MCK)
- 02/18/2021
|
BD (BDX) Gets EUA, CE Mark for New Molecular Diagnostic Test
- BD's (BDX) new test has the capability to detect SARS-CoV-2 and Influenza A+B in a single test.
- 02/16/2021
|
Becton Dickinson Lauded by Frost & Sullivan for Enhancing Patient Experience with Its BD Intevia™ Autoinjector
- The solution leverages a modular platform technology that allows rapid customization, optimizing time and cost for pharma companies SANTA CLARA, Calif., Feb. 16, 2021 /PRNewswire/ -- Based on its recent analysis of the global autoinjector drug delivery market, Frost & Sullivan recognizes...
- 02/16/2021
|
BD to Present at Upcoming Investor Conferences
- FRANKLIN LAKES, N.J., Feb. 12, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following upcoming virtual investor conferences: The Leerink Virtual 10th Annual Global Healthcare...
- 02/12/2021
|
Becton, Dickinson's COVID-19/Influenza Combo Molecular Assay Wins FDA Emergency Use Nod
- The FDA has granted Emergency Use Authorization (EUA) to Becton Dickinson and Co's (NYSE: BDX) new molecular test for both SARS-CoV-2 and Influenza A+B. The new test has also received a CE mark in Europe.
- 02/12/2021
|
BD Announces Emergency Use Authorization, CE Mark for Combination Molecular Diagnostic to Detect SARS-CoV-2, Influenza A+B in Single Test
- FRANKLIN LAKES, N.J., Feb. 12, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for a new molecular diagnostic...
- 02/12/2021
|
Becton Dickinson plans dual dollar/euro bond offerings to repay debt
- Medical technology company Becton Dickinson and Co. said Wednesday it is planning a dual-tranche bond offering in dollars and euros to raise the funds to repay outstanding debt. In a regulatory filing, Becton said it will offer $1 billion of 1.957% 10-year bonds and 600 million euros of 1.213% 15-year bonds.
- 02/10/2021
|
Covid-19 testing drives Becton Dickinson Q1 revenue growth
- Medical devices company Becton Dickinson beat the top and bottom line in its first-quarter results. Covid-19 testing helped drive its revenue growth to $867 million.
- 02/05/2021
|
Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q1 2021 Results - Earnings Call Transcript
- Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q1 2021 Results - Earnings Call Transcript
- 02/04/2021
|
Becton Dickinson (BDX) Earnings Surpass Estimates in Q1
- Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal first quarter.
- 02/04/2021
|
Becton Dickinson (BDX) Surpasses Q1 Earnings and Revenue Estimates
- Becton Dickinson (BDX) delivered earnings and revenue surprises of 44.90% and 0.13%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/04/2021
|
First-of-its-Kind Randomized Clinical Trial Published in "The Lancet Infectious Diseases" Outlines Potential New Standard-Setting Best Practices for Peripheral IV Catheters
- FRANKLIN LAKES, N.J., Feb. 2, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that new clinical data have found robust evidence that using a vascular care solution can help improve outcomes for patients...
- 02/02/2021
|
Becton Dickinson (BDX) Earnings Expected to Grow: What to Know Ahead of Q1 Release
- Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/28/2021
|
Becton, Dickinson's (BDX) Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Becton, Dickinson and Company (BDX).
- 01/21/2021
|
Medical Device Aristocrats For A High Class Dividend Portfolio
- Healthcare aristocrats benefit from significant medical device contributions. By and large these healthcare aristocrats share favorable quant metrics on Seeking Alpha, albeit with significant variations among the five.
- 01/21/2021
|
Federal, Private Tie-Ups Boost COVID-19 Testing Volume
- The Department of Health and Human Services (HHS) promises over $22 billion of funding.
- 01/19/2021
|
The 2021 Market Outlook And Some New Stock Picks - Ryan Detrick And Eddy Elfenbein Join Alpha Trader (Podcast Transcript)
- Welcome to Alpha Trader. We have a special double bill today in honor of wildcard weekend coming up on the show. Eddy Elfenbein of Crossing Wall Street giving us his top five new stocks for 2021. But first we are pleased to welcome back to the show, Ryan Detrick. He is Chief Market Strategist for LPL Financial. Ryan, welcome back to Alpha Trader.
- 01/14/2021
|
BD (BDX) Posts Upbeat Preliminary Fiscal First Quarter Results
- BD (BDX) projects its fiscal Q1 revenues to surge from the year-ago figure, primarily on the back of high demand for its COVID-19 diagnostic tests
- 01/14/2021
|
Testing Space in Focus Again Thanks to New Wave of Coronavirus
- The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.
- 01/13/2021
|
Final Trades: Zynga, Becton Dickinson & more
- The "Halftime Report" investment committee give their top picks to watch for the second half.
- 01/12/2021
|
The 2021 Market Outlook And Some New Stock Picks - Ryan Detrick And Eddy Elfenbein Join Alpha Trader
- This week's Alpha Trader podcast features hosts Aaron Task and Stephen Alpher speaking with LPL Financial's Ryan Detrick and Eddy Elfenbein, editor of the Crossing Wall Street blog and portfolio manager of the AdvisorShares Focused Equity ETF (CWS).
- 01/12/2021
|
Becton Dickinson stock rallies after upbeat revenue outlook
- Shares of Becton Dickinson & Co. rallied 2.3% in premarket trading Tuesday, after the medical technology company provided an upbeat outlook for its first quarter. For the quarter ended Dec. 31, the company expects to report revenue of $5.3 billion, up 26% from a year ago and above the FactSet consensus of $4.7 billion.
- 01/12/2021
|
BD Provides Updates To Its Fiscal 2021 Financial Outlook And Intends To Comment On Its Preliminary First Fiscal Quarter Revenue Performance During Today's Webcast At The 39th Annual J.P. Morgan Healthcare Conference
- FRANKLIN LAKES, N.J., Jan. 12, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported, preliminary unaudited financial information for the first fiscal quarter ended Dec. 31, 2020. "We have entered fiscal 2021 with...
- 01/12/2021
|
4 Dividend-Paying Undervalued MedTech Stocks for Gains in 2021
- Here we discuss four dividend-paying value stocks, MCK, CAH, BDX and HRC, which though trading cheap now, have solid chances of a rebound in the second half of 2021.
- 01/08/2021
|
7 Coronavirus Stocks to Buy to Make Mass Vaccination Possible
- The Covid-19 vaccine rally isn't just limited to biotech firms. Here are the top coronavirus stocks that are making mass vaccination possible.
- 01/05/2021
|
Becton, Dickinson and Co.: A Fair Value Report
- Are investors getting a shot in the arm or backing into a needle?
- 01/03/2021
|
BD Is Just Another Great Addition To Your Dividend Growth Portfolio
- In previous articles I analyzed Abbott and Medtronic. BD is their somewhat smaller peer, and a company I own.
- 01/03/2021
|
BD to Present at the 39th Annual J.P. Morgan Healthcare Conference
- FRANKLIN LAKES, N.J., Dec. 22, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 39th Annual J.P. Morgan Healthcare Conference via webcast. BD's CEO and president is scheduled to...
- 12/22/2020
|
4 Large-Cap Stocks to Buy by Year's End
- Large-cap stocks have seen wildly varying performance in 2020. And in 2021, these four names should be among the group's best.
- 12/16/2020
|
Becton, Dickinson & Co. Is a Highly Profitable, Recession-Proof Company
- The health care sector is considered a defensive sector as people will seek out treatment for illness and aliments regardless of the status of the economy. Many companies in this sector literally provide products that consumers cannot live without.
- 12/11/2020
|
Becton Dickinson Expects Covid Testing Sales to Hit $1.5 Billion
- When it comes to Covid-19, Becton, Dickinson and Co. (NYSE:BDX) hasn't gained the attention of vaccine developers like Pfizer Inc. (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ), nor those companies with treatments like Gilead Sciences Inc. (NASDAQ:GILD). But the New Jersey-based medical device company has hardly been sitting on the sidelines.
- 12/10/2020
|
New Clinical Trial Data Demonstrates BD Libertas™ Wearable Injector as a Drug Delivery System
- FRANKLIN LAKES, N.J., Dec. 9, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced publication of the results from a 52-subject human clinical trial with the BD Libertas™ Wearable Injector. The subcutaneous drug...
- 12/09/2020
|
10 Upcoming Dividend Increases
- All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. An average increase of 4.06% and a median increase of 3.64%.
- 12/03/2020
|
Becton Dickinson to invest $1.2 billion to expand pre-fillable syringe manufacturing capacity for COVID vaccination
- Becton Dickinson & Co. said Wednesday it is planning to invest about $1.2 billion in pre-fillable syringe manufacturing capacity over the next four years. The Franklin Lakes, N.J.
- 12/02/2020
|
Dividend Changes: November 21-27, 2020
- This weekly article series covers dividend changes. A summary table provides relevant data and key statistics of dividend increases.
- 11/30/2020
|
How to Invest in a Post-COVID World
- Buying stocks that have been hit by a serious but solvable problem, can lead to extraordinary gains when things work out positively. The post How to Invest in a Post-COVID World appeared first on InvestorPlace.
- 11/25/2020
|
FDA Authorizes First At-Home Coronavirus Test
- The Lucira COVID-19 All-In-One test kit should cost under $50.
- 11/19/2020
|
Minimal Dividend Growth Expected From Sysco And Becton Dickinson In Second Half Of November
- There were no big surprises in the dividend growth announcements in the first half of November. All the usual suspects offered up payout boosts. Long time dividend growth companies Emerson and Mercury General provided token increases of 1% to keep their dividend growth streaks going.
- 11/16/2020
|
Becton, Dickinson And Company: Reasonable Return Prospects, With Some Caveats
- Becton, Dickinson's reported non-GAAP earnings exclude a large amount of unusual items, some of which involve real monetary outlays. Over the last 3.75 years, dividends paid out of equity exceed the amount of income flowing into equity, if the excluded unusual items of expense are taken into account.
- 11/13/2020
|
2 Recession-Proof Healthcare Stocks to Buy for 2021
- These stocks outperformed the S&P 500 during the last recession.
- 11/11/2020
|
BD to Present at Investor Virtual Healthcare Conferences
- FRANKLIN LAKES, N.J., Nov. 9, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the following upcoming virtual healthcare conferences: Stifel 2020 Virtual Healthcare Conference November...
- 11/09/2020
|
Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q4 2020 Results - Earnings Call Transcript
- Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q4 2020 Results - Earnings Call Transcript
- 11/05/2020
|
Recap: Becton, Dickinson Q4 Earnings
- Shares of Becton, Dickinson (NYSE:BDX) were flat in pre-market trading after the company reported Q4 results.
- 11/05/2020
|
BD Announces Fiscal Fourth Quarter And Full Year 2020 Results; Provides Fiscal 2021 Guidance
- FRANKLIN LAKES, N.J., Nov. 5, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.784 billion for the fourth fiscal quarter ended September 30, 2020. This represents an increase of 4.4%...
- 11/05/2020
|
BD Receives Order from Dutch Ministry of Health for More than Nine Million 15-minute COVID-19 Antigen Tests
- THE HAGUE, NETHERLANDS and FRANKLIN LAKES, N.J., Nov. 2, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the receipt of an order from the Dutch Ministry of Health for 9.2 million of its rapid, point-of-care,...
- 11/02/2020
|
2 Healthcare Dividend Stocks to Buy No Matter Who Wins the Election
- Too often, high-yield stocks are too good to be true. One metric in particular can help us find the most reliable dividend payers.
- 10/29/2020
|
Were Hedge Funds Right About Becton, Dickinson and Company (BDX)?
- Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren't timid and registered double digit market beating gains. Financials, energy and industrial stocks aren't doing great but many of the stocks that delivered strong returns since March are still going very strong and hedge funds actually increased their positions in these stocks. In this article we will find out how hedge fund sentiment to Becton, Dickinson and Company (NYSE:BDX) changed recently.
- 10/26/2020
|
Global Pain Management Devices Market Forecast 2020-2027 - COVID-19 Impact and Analysis by Product Type; Application; and Geography - ResearchAndMarkets.com
|
Becton Dickinson Trying To Leverage COVID-19 Opportunities While Fixing Some Longer-Term Issues
- BD management has had to deal with new revenue headwinds from COVID-19 while also trying to resolve longer-standing issues like the Alaris pump recalls.
- 09/14/2020
|
Tracking Al Gore's Generation Investment Management Portfolio - Q2 2020 Update
- Generation Investment Management’s 13F portfolio value increased from $14.09B to $17.34B this quarter.
- 09/09/2020
|
Calm Down: This Time Won't Be Different
- The market closed down last week. Investors are getting jittery.
- 09/06/2020
|
Dividend Aristocrat Performance: August 2020
- Components of the S&P 500 that have paid steadily increasing dividends for at least 25 years have outperformed the broader market over time.
- 09/02/2020
|
Dividend Champion And Contender Highlights: Week Of August 30
|
Bullish On Baxter: Cruising Along, Business As Usual; $90 Price Target Set
- Baxter continues to chug on slowly as it has done for the past 10 years, delivering ongoing value to shareholders.
- 08/28/2020
|
Syringe shortage could hamper delivery of Covid-19 vaccine, experts warn
- US companies make roughly 663m syringes a year but the Trump administration has calculated that an extra 850m may be needed
- 08/21/2020
|
Quidel: An Impressive Growth Story For The Long Term
- Quidel is a high growth in vitro diagnostics company which is continuously developing new products. The company's total revenue in the second quarter increased 86% YoY driven by COVID-19 tests.
- 08/19/2020
|
Kristen Stewart to Join BD as Senior Vice President of Strategy and Investor Relations
- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the appointment of Kristen Stewart to the newly created position of senior vice president of Strategy and Investor Relations.
- 08/17/2020
|
10x Genomics Enjoys Investor Support As Stock Rebounds
- 10x Genomics went public in September 2019. The firm provides equipment and software for genetic research purposes.
- 08/14/2020
|
BD to Present at UBS Genomics 2.0 and MedTech Innovations Virtual Summit
- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the UBS Genomics 2.0 and MedTech Innovations Virtual Summit on Thursday, August 13, 2020, at 3:30 p.m. ET.
- 08/13/2020
|
BD and BD Foundation commit $7.8 million to helping community health centers expand innovative care to patients
- BD (NYSE: BDX), a leading global medical technology company, together with the BD Foundation, its charitable affiliate, today committed $7.8 million in monetary grants and product donations over the next three years to support the continued expansion of the BD Helping Build Healthy Communities™ initiative – a unique public-private partnership launched in 2013 and implemented jointly by Direct Relief and the National Association of Community Health Centers (NACHC).
- 08/10/2020
|
Calculating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)
- Today we will run through one way of estimating the intrinsic value of Becton, Dickinson and Company (NYSE:BDX) by...
- 08/10/2020
|
Pharma Companies Have Improved How They Engage with Healthcare Providers During COVID-19, Finds New Research from Accenture
- Pharma companies have improved how they engage with healthcare providers during COVID-19, says Accenture.
- 08/10/2020
|
Brenntag AG (BNTGF) CEO Christian Kohlpaintne on Q2 2020 Results - Earnings Call Transcript
- Brenntag AG. (OTCPK:BNTGF) Q2 2020 Earnings Conference Call August 06, 2020, 08:00 AM ET Company Participants Christian Kohlpaintne - Chief Executive Officer Georg Müller - Chief Financial Officer Conference Call Participants Rory McKenzie - UBS Laurent Favre - Exane BNP Paribas Rajesh Kumar - HSBC Markus Mayer - Baader Helvea Steven Goulden - Deutsche Bank Isha Sharma - MainFirst Bank Chetan Udeshi - JPMorgan.
- 08/09/2020
|
HighRadius Adds New Leader to Drive Finance Digital Transformation in Growing Enterprise Client Base
- HighRadius, a fintech enterprise Software-as-a-Service (SaaS) company specializing in automating the order-to-cash and treasury management processes,
- 08/07/2020
|
Becton Dickinson Earnings Top, But BDX Stock Falls On Weak Sales
- Becton Dickinson earnings beat views, but the coronavirus test maker missed on revenue and gave weak full-year guidance below expectations. Shares tumbled out of a buy zone early Thursday,
- 08/06/2020
|
US STOCKS-Wall Street gains as markets look to aid package, Nasdaq closes above 11,000
- Shares on Wall Street shrugged off a sluggish start and closed higher on Thursday, with the Nasdaq ending the session above 11,000 for the first time as investors hoped for a new fiscal stimulus package. The tech-heavy Nasdaq clinched a new record high in early trading, and closed above the 11,000-mark for the first time after initially climbing above it on Wednesday. The benchmark S&P 500 and blue-chip Dow were about 1% and 7% away from their own peaks scaled in February.
- 08/06/2020
|
US STOCKS-Wall Street gains as markets await aid package, U.S. jobs data
- Shares on Wall Street rose on Thursday but moved within narrow ranges, as investors awaited a new fiscal stimulus package to bolster the country's economy and digested better-than-expected U.S. jobless claims data. The tech-heavy Nasdaq clinched a new record high in early trading, crossing the 11,000-mark for a second straight day but has yet to close above the threshold. The benchmark S&P 500 and blue-chip Dow were about 2% and 8% away from their own peaks scaled in February.
- 08/06/2020
|
US STOCKS-S&P 500 flat as Congress wrangles over stimulus
- The S&P 500 treaded water on Thursday as investors awaited a new fiscal aid package to prop up the economy, with data showing a staggering 31.3 million Americans were receiving unemployment checks in mid-July. The tech-heavy Nasdaq clinched a new record high in early trading. The benchmark S&P 500 and blue-chip Dow were about 2% and 8% away from their own peaks scaled in February.
- 08/06/2020
|
Becton, Dickinson's Debt Overview
- Over the past three months, shares of Becton, Dickinson Inc. (NYSE: BDX) fell by 1.87%. Before having a look at the importance of debt, let's look at how much debt Becton, Dickinson has.Becton, Dickinson's Debt Based on Becton, Dickinson's balance sheet as of May 7, 2020, long-term debt is at $16.81 billion and current debt is at $4.36 billion, amounting to $21.17 billion in total debt. Adjusted for $2.35 billion in cash-equivalents, the company's net debt is at $18.82 billion.To understand the degree of financial leverage a company has, shareholders look at the debt ratio. Considering Becton, Dickinson's $53.52 billion in total assets, the debt-ratio is at 0.4. Generally speaking, a debt-ratio more than 1 means that a large portion of debt is funded by assets. As the debt-ratio increases, so the does the risk of defaulting on loans, if interest rates were to increase. Different industries have different thresholds of tolerance for debt-ratios. For example, a debt ratio of 40% might be higher for one industry, whereas normal for another.Importance of Debt Debt is an important factor in the capital structure of a company, and can help it attain growth. Debt usually has a relatively lower financing cost than equity, which makes it an attractive option for executives.However, interest-payment obligations can have an adverse impact on the cash-flow of the company. Having financial leverage also allows companies to use additional capital for business operations, allowing equity owners to retain excess profit, generated by the debt capital.See more from Benzinga * Insider Sells Becton, Dickinson's Stock * Benzinga's Top Upgrades, Downgrades For July 9, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/06/2020
|
US STOCKS-Wall St struggles for direction as Congress wrangles over stimulus
- The benchmark S&P 500 and blue-chip Dow were about 2% and 8% away from their own peaks scaled in February. Economic data released on Thursday painted a mixed picture as Labor Department numbers showed a first fall in jobless claims in three weeks, while a separate report showed a 54% surge in job cuts announced by employers in July. "The (stocks) treading water might be waiting for tomorrow's actual number... The other most important thing that's going on is the stimulus bill, and the lack of agreement between the White House and the Democratic party as to what the deal ought to include," said Tom Martin, senior portfolio manager at GLOBALT Investments in Atlanta.
- 08/06/2020
|
Becton Dickinson on track to produce 1 bln syringes in 12-18 months
|
Becton Dickinson (BDX) Earnings Surpass Estimates in Q3
- Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in Q3.
- 08/06/2020
|
Becton Dickinson (BDX) Q3 Earnings Beat Estimates
- Becton Dickinson (BDX) delivered earnings and revenue surprises of 7.32% and -1.88%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/06/2020
|
Colliers International Reports Second Quarter Results
- Investment Management, Outsourcing & Advisory demonstrate resilience, diversificationOperating highlights: Three months ended Six months ended June 30 June 30 (in millions of US$, except EPS)2020 2019 2020 2019 Revenues$550.2 $745.5 $1,180.8 $1,380.6 Adjusted EBITDA (note 1) 60.0 87.3 114.4 130.9 Adjusted EPS (note 2) 0.70 1.10 1.25 1.61 GAAP operating earnings 14.5 57.2 33.1 70.6 GAAP EPS (0.26) 0.60 (0.14) 0.63 TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (NASDAQ and TSX: CIGI) today announced operating and financial results for the quarter ended June 30, 2020, which were significantly impacted by the global COVID-19 pandemic. All amounts are in US dollars.For the second quarter ended June 30, 2020, revenues were $550.2 million, down 26% (25% in local currency) relative to the same quarter in the prior year, adjusted EBITDA (note 1) was $60.0 million, down 31% (30% in local currency) and adjusted EPS (note 2) was $0.70, down 36% versus the prior year period. Second quarter adjusted EPS would have been approximately $0.02 higher excluding foreign exchange impacts. GAAP operating earnings were $14.5 million, relative to $57.2 million in the prior year quarter. GAAP EPS was a loss of $0.26 per share, relative to $0.60 per share in the prior year quarter. Second quarter GAAP EPS would have been approximately $0.02 higher excluding changes in foreign exchange rates.For the six months ended June 30, 2020, revenues were $1.18 billion, down 14% (13% in local currency) relative to the same period in the prior year, adjusted EBITDA (note 1) was $114.4 million, down 13% (11% in local currency) and adjusted EPS (note 2) was $1.25, down 22% versus the prior year period. Year-to-date adjusted EPS would have been approximately $0.04 higher excluding foreign exchange impacts. GAAP operating earnings were $33.1 million, relative to $70.6 million in the prior year period. GAAP EPS for the six month period was a loss of $0.14 per share, relative to $0.63 per share in the prior year period. Second quarter GAAP EPS would have been approximately $0.04 higher excluding changes in foreign exchange rates.“Colliers reported better than expected results across all segments and regions during the second quarter despite the unprecedented impact of COVID-19, especially in Leasing and Capital Markets. Fortunately, the majority of our earnings now come from Investment Management and Outsourcing & Advisory – high value-add professional services that are recurring and contractual – providing us with more resilience and service line diversification than ever,” said Jay S. Hennick, Global Chairman and CEO of Colliers International. “Pandemic uncertainty in Leasing and Capital Markets continue to impact our results, though we expect gradual improvement for the balance of the year. During the quarter, we completed a $230 million offering of convertible notes to fortify our balance sheet and completed the acquisitions of Dougherty, a US commercial real estate debt finance, loan servicing and securities platform (now rebranded as Colliers Mortgage) and Maser Consulting, a leading US engineering design and service firm focused on real estate assets and related infrastructure. With a highly diversified and balanced global business, strong balance sheet, entrepreneurial culture, and significant insider ownership, we are confident that Colliers will emerge from this crisis stronger than ever,” he concluded.About Colliers International Group Inc. Colliers International (NASDAQ, TSX: CIGI) is a leading real estate professional services and investment management company. With operations in 68 countries, our more than 15,000 enterprising professionals work collaboratively to provide expert advice to maximize the value of property for real estate occupiers, owners and investors. For more than 25 years, our experienced leadership, owning approximately 40% of our equity, has delivered compound annual investment returns of almost 20% for shareholders. In 2019, corporate revenues were more than $3.0 billion ($3.5 billion including affiliates), with $33 billion of assets under management in our investment management segment.Learn more about how we accelerate success at corporate.colliers.com, Twitter @Colliers or LinkedIn.Consolidated Revenues by Line of Service With the closing of Colliers Mortgage acquisition, Colliers has renamed its Sales Brokerage service line to Capital Markets, which now includes sales brokerage, mortgage origination and mortgage investment banking revenues. In addition, the Company added mortgage loan servicing under its Outsourcing & Advisory revenues. Three months ended Six months ended (in thousands of US$) June 30ChangeChange June 30ChangeChange (LC = local currency) 2020 2019in US$ %in LC% 2020 2019in US$ %in LC% Outsourcing & Advisory $257,044 $281,638-9%-6% $534,334 $540,022-1%1% Investment Management 41,389 46,902-12%-12% 87,214 89,992-3%-3% Leasing 136,768 253,374-46%-45% 301,278 435,158-31%-30% Capital Markets 115,005 163,603-30%-28% 258,008 315,468-18%-17% Total revenues $550,206 $745,517-26%-25% $1,180,834 $1,380,640-14%-13% Consolidated revenues for the second quarter declined 25% on a local currency basis, driven primarily by expected declines in transactional Leasing and Capital Markets activity due to the COVID-19 pandemic. Consolidated internal revenues measured in local currencies were down 26% (note 3).For the six months ended June 30, 2020, consolidated revenues declined 13% on a local currency basis, with the impact of the pandemic beginning in March 2020. Consolidated internal revenues measured in local currencies were down 15% (note 3).Segmented Quarterly Results Revenues in the Americas region totalled $308.9 million for the second quarter compared to $421.4 million in the prior year quarter, down 27% (26% in local currency) on reduced Leasing and Capital Markets activity across the region. Outsourcing & Advisory revenues were flat in the quarter. Adjusted EBITDA was $24.4 million, versus $36.2 million in the prior year quarter. GAAP operating earnings were $3.4 million, relative to $25.6 million in the prior year quarter.Revenues in the EMEA region totalled $99.6 million for the second quarter compared to $151.6 million in the prior year quarter, down 34% (32% in local currency) on lower activity in each service line, including Outsourcing & Advisory which was impacted by delays in executing on-site turnkey project management assignments due to the pandemic. Adjusted EBITDA was $6.3 million, versus $19.0 million in the prior year. GAAP operating earnings were a loss of $3.3 million as compared to $10.8 million in the second quarter of 2019.Revenues in the Asia Pacific region totalled $100.1 million for the second quarter compared to $125.1 million in the prior year quarter, down 20% (16% in local currency) on lower Leasing and Capital Markets activity. Outsourcing & Advisory revenues were up slightly in the quarter, including incremental revenues from the recent Synergy acquisition, now rebranded as Colliers Project Leaders. Adjusted EBITDA was $12.3 million, down from $14.2 million. GAAP operating earnings were $5.1 million, down from $12.5 million in the prior year quarter.Investment Management revenues for the second quarter were $41.4 million compared to $46.9 million in the prior year quarter, down 12% (12% in local currency). The second quarter revenue decline was primarily attributable to a $4.3 million reduction in pass-through revenue from legacy carried interest versus the prior year quarter. Adjusted EBITDA was $17.4 million relative to $19.2 million in the prior year quarter, attributable to the timing of certain European transaction fees, which were elevated in the prior year quarter. GAAP operating earnings were $10.6 million in the quarter, versus $12.2 million in the prior year quarter. Assets under management were $35.7 billion at June 30, 2020, up 2% from $35.1 billion at March 31, 2020 and up 18% from $30.3 billion at June 30, 2019.Unallocated global corporate costs as reported in Adjusted EBITDA were $0.3 million in the second quarter, relative to $1.3 million in the prior year quarter, and were favourably impacted by lower insurance costs and lower variable expenses. The corporate GAAP operating loss for the quarter was $1.4 million, relative to $4.1 million in the second quarter of 2019.Impact of COVID-19 Pandemic The full impact of the pandemic continues to remain uncertain. The Company is updating the working assumption previously provided to reflect: (i) better than anticipated results for the second quarter across all service lines and regions; and (ii) the recently completed acquisitions of Colliers Mortgage and Maser Consulting. The updated working assumption for the full year 2020 (relative to 2019), is as follows: PreviousUpdatedAdd acquisitionsUpdated with acquisitions Revenue-15% to -25%-15% to -25%+5%-10% to -20% Adjusted EBITDA-25% to -35%-20% to -30%+5%-15% to -25% This working assumption is based on the best available information and is subject to change based on numerous macroeconomic, health, social, political and related factors.Transactional Leasing and Capital Markets revenues are expected to remain below 2019 levels, although the scale of decline should moderate in the third and fourth quarters. Investment Management and Outsourcing & Advisory are expected to remain relatively stable for the balance of the year with some variability depending on market conditions.The Company has taken significant steps to adjust costs to expected revenues across all service lines, including reductions to support, administrative and leadership and related costs.
- 08/06/2020
|
Becton Dickinson profit slumps nearly 37% on delayed surgeries
|
BD Announces Results For 2020 Third Fiscal Quarter; Provides Fiscal 2020 Guidance
- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $3.855 billion for the third fiscal quarter ended June 30, 2020. This represents a decrease of 11.4 percent as reported from the prior-year period, or 9.4 percent on a currency-neutral basis.
- 08/06/2020
|
Penn State Microbiome Center and GALT Enter Collaboration to Advance Research
- Researchers will utilize GALT's Prospector high-throughput microbial isolation and cultivation system to generate banks of live microbial isolates.
- 08/06/2020
|
Why Becton, Dickinson (BDX) Might Surprise This Earnings Season
- Becton, Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 08/05/2020
|
STERIS plc (STE) CEO Walter Rosebrough on Q1 2021 Results - Earnings Call Transcript
- STERIS plc (NYSE:STE) Q1 2021 Results Conference Call August 03, 2020 10:00 AM ET Company Participants Julie Winter - Investor Relations Walter Rosebrough - President and Chief Executive Officer Michael Tokich - Senior Vice President and Chief Financial Officer Daniel Carestio - Senior Vice President and Chief Operating Officer Conference Call Participants David Turkaly - JMP Securities Christopher Cooley - Stephens Inc Michael Matson - Needham and Company Lawrence Keusch - Raymond James Matthew Mishan - KeyBanc Capital Markets Presentation Operator Good day, and welcome to the STERIS PLC First Quarter Fiscal 2021 Conference Call and Webcast.
- 08/04/2020
|
What's in Store for Becton, Dickinson's (BDX) Q3 Earnings?
- Becton, Dickinson's (BDX) fiscal third-quarter results likely to reflect robust performance at BD Life Sciences. However, forex is likely to have remained a woe.
- 08/04/2020
|
QIAGEN Reports Full Results for Second Quarter and First Half Of 2020
- QIAGEN reports full results for second quarter and first half of 2020
- 08/04/2020
|
BD releases FY 2019 Sustainability Report
- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2019 Sustainability Report, focusing on performance of the environmental, social and governance factors that support the company's 2020 Sustainability Goals from October 1, 2018 to September 30, 2019 (FY 2019).
- 08/03/2020
|
Samyang Biopharm USA Announces Hyun Jung Helen Lee, M.D., Named to PharmaVOICE 100
- Samyang Biopharm USA, Inc. (https://us.samyangbiopharm.com) a global biotech subsidiary of the Samyang Biopharmaceuticals Corp. (https://samyangbiopha
- 08/03/2020
|
COVID-19 Impacts: Antiseptic and Disinfectant Products Market will Accelerate at a CAGR of about 7% through 2020-2024 | Increasing Number of Surgical Procedures Worldwide to Boost Growth | Technavio
- The Global Antiseptic and Disinfectant Products Market will grow by $ 3.48 bn during 2020-2024
- 08/01/2020
|
Craving Healthcare: A Beginner's Guide And My 7 Picks
- The Healthcare sector has significantly outperformed the S&P 500 in the last decade and with lower volatility – the only sector to do so.
- 07/31/2020
|
Thermo Fisher Long Case: Trajectory Is Clear, Buy On Value
- Strong quarter exit and clear guidance for Q4 2020 on the back of $1.3 billion in COVID-19 related sales YTD.
- 07/31/2020
|
Becton, Dickinson Receiving $24 Million Federal Investment to Ramp Up Coronavirus Test Kit Manufacturing
- Becton, Dickinson (NYSE: BDX) is about to increase production of its SARS-CoV-2 diagnostic solution thanks to the largesse of two arms of the federal government. The healthcare equipment specialist announced Thursday that the Department of Defense (DOD), supported by the Department of Health and Human Services (HHS), is providing it with a $24 million investment for the purpose. The money will be devoted to the production of Becton, Dickinson's Veritor System for Rapid Detection of SARS-CoV-2, a test that the company says can produce results within 15 minutes of being administered.
- 07/31/2020
|
BD Announces $24 Million U.S. Government Investment to Support Scale Up of U.S. Manufacturing of COVID-19 Diagnosic Tests
- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $24 million investment from the U.S. Department of Defense in collaboration with the U.S. Department of Health and Human Services to support the scale up of U.S. manufacturing capabilities for BD Veritor™ Solution for Rapid Detection of SARS-CoV-2 (see demo here).
- 07/30/2020
|
Cross-Sector: Market Data Highlights
|
Ecolab : Second Quarter Reported Diluted Continuing Operations EPS $0.44; Adjusted Diluted Continuing Operations EPS $0.65, -49% | MarketScreener
|
Biotech Bonanza - Second Half Outlook
- Biotech is one of the rare industries whose prospects have improved as the year has progressed. A low interest rate environment, a less hostile regulatory environment, and strong investor interest creates an ideal environment for biotechs to continue outperforming the market.
- 07/28/2020
|
AKKA: First-half 2020 Revenue
- Regulatory News: AKKA (Paris:AKA) (BSE:AKA) (ISIN:FR0004180537): H1 2020 performance Low point in activity reached in May Solid performance of Data Re
- 07/27/2020
|
Rising Risk? Here's What You Can Buy
- Volatility caused by dismal economic data creates opportunities. Our overbought reading is heating up, suggesting you proactively pick entry points.
- 07/24/2020
|
QIAGEN announces publication of Supplemental Reasoned Position Statement for proposed acquisition by Thermo Fisher
- QIAGEN announces publication of Supplemental Reasoned Position Statement for proposed acquisition by Thermo Fisher
- 07/22/2020
|
Kronos Bio Appoints Barbara Kosacz, Chief Operating Officer and General Counsel
- Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to trans
- 07/20/2020
|
Why Becton, Dickinson & Co (BDX) is an Attractive Pick for Investors
- Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Equity Income Fund posted a return of 18.29% for the quarter, underperforming its benchmark, the S&P; 500 Index which returned 20.55% in the same quarter. You should check out Brown Advisory’s top 5 stock picks for investors […]
- 07/17/2020
|
2 Top Pharma Stocks to Buy in a Recession
- When the economy struggles, these two pharma companies take it in stride because they know the rest of the industry depends on them for critical products.
- 07/17/2020
|
Emerging Market and Legal Trends in the Top Five Global Startup Ecosystems
- The recently published Global Startup Ecosystem Report 2020 ranks the top global startup ecosystems by metrics including performance, funding, connectedness, talent, and knowledge to highlight the winning startup cities worldwide.
- 07/17/2020
|
T Rowe Price Equity Income Fund's Top 5 Buys in the 2nd Quarter
- Fund of Baltimore-based firm establishes new holdings in Merck and Volkswagen Continue reading...
- 07/16/2020
|
Colliers International Group Inc. Announces Normal Course Issuer Bid
- TORONTO, July 16, 2020 -- Colliers International Group Inc. (NASDAQ: CIGI) (TSX: CIGI) (“Colliers”) announced today that the Toronto Stock Exchange (the “TSX”) has accepted a.
- 07/16/2020
|
U.S. government agrees to buy Becton's COVID-19 testing devices
- The U.S. Department of Health and Human Services has agreed to buy 2,000 of its BD Veritor Plus Systems and 750,000 of its SARS-CoV-2 antigen test kits, the company said. According to U.S. health experts, broad testing for the virus in the country needs to be ramped up as the White House considers when and how to lift stay-at-home restrictions and lockdowns triggered by the pandemic. "There is absolutely a recognized need for this type of testing," Dave Hickey, president of Becton Dickinson's integrated diagnostic solutions business, said in an interview.
- 07/16/2020
|
Becton Dickinson Covid Test Systems Bought by U.S. Government
- Becton Dickinson's system will 'significantly expand testing ... for the benefit of all Americans,' the government said.
- 07/15/2020
|
Becton, Dickinson Score Fed Contract For Covid-19 Rapid Test Systems
- Becton, Dickinson and Co (BDX) has announced that the U.S. Department of Health and Human Services (HHS) will purchase 2,000 of its BD Veritor Plus Systems and 750,000 SARS-CoV-2 antigen test kits for Covid-19 detection.“The BD Veritor Plus System for rapid detection of SARS-CoV-2 is the latest point-of-care testing advance that will significantly expand testing in distributed locations for the benefit of all Americans,” said Admiral Brett P. Giroir, assistant secretary for Health and COVID-19 testing coordinator. “This development will help identify community spread of the virus by further enabling rapid diagnosis of COVID-19.”BD began shipping limited quantities of its BD Veritor Plus SARS-CoV-2 antigen test kits to distributors last week as it ramps up production capacity. BD is leveraging its global manufacturing network and scale and expects to increase capacity to be able to produce 2 million tests per week by the end of September. The company expects to produce up to 10 million tests from July through September.Earlier this month, the U.S. Food and Drug Administration (FDA) granted BD an Emergency Use Authorization (EUA) for the system. Clinical studies performed at more than 20 sites across the U.S. demonstrated that the test is capable of achieving 84% sensitivity and 100% specificity, which is in line with the performance from similar immunoassay tests.Similar to all immunoassay tests, FDA recommends that negative test results be confirmed by a molecular method to confirm the result, if necessary, for patient management.Shares in BDX are currently trading down 3% year-to-date, and analysts have a cautiously optimistic take on the stock’s outlook with a Moderate Buy consensus. Meanwhile the average analyst price target of $276 indicates 5% upside potential lies ahead. (See BDX stock analysis on TipRanks).Wells Fargo analyst Larry Biegelson recently reiterated his buy rating on the stock, citing the Covid-19 antigen tests. If BDX managed to sell 2 million tests/ week at an average price of $18, this would generate a further $470 million in revenue per quarter, calculates Biegelson. As this is not yet included in his model, it represents potential upside to estimates going forward, the analyst noted.Related News: Boston Scientific Mulls Billion-Dollar Snake Venom Sale- Report Abbott Labs, Edwards Lifesciences Settle Heart Device Patent Disputes Akebia Initiates Vadadustat Study In Covid-19 Patients More recent articles from Smarter Analyst: * Google Snaps Up 7.7% Stake In India’s Jio Platform For $4.5B * Apple Wins $15 Billion European Court Ruling On Irish Taxes * UnitedHealth Reports Earnings Beat With Strong Optum Performance * Sony Increasing Production On PlayStation 5 By 50%- Report
- 07/15/2020
|
U.S. government agrees to buy Becton's COVID-19 testing device
- Becton, Dickinson and Co said on Wednesday the U.S. government had agreed to buy its COVID-19 testing device and kits. The U.S. Department of Health and Human Services has agreed to buy its 2,000 BD Veritor Plus Systems and 750,000 SARS-CoV-2 antigen test kits, the company said. Becton said distribution for the device and kits is set to begin from next week.
- 07/15/2020
|
BD to sell 750,000 coronavirus tests to U.S. government
- Becton Dickinson and Co. said Wednesday that the U.S. government plans to buy 750,000 of the company's COVID-19 antigen diagnostic tests. The purchase will also include 2,000 systems manufactured by BD to run the tests. BD was granted an emergency use authorization from the Food and Drug Administration for the rapid, point-of-care test earlier this month, making it the third of its diagnostics tests to receive emergency authorization. The regulator, also in July,issued an alert about the risk of false-positive results for another one of BD's diagnostic coronavirus tests. BD's stock is down 3.1% year-to-date, while the S&P; 500 has declined 1.0%.
- 07/15/2020
|
BD Supports U.S. Government Efforts to Increase COVID-19 Testing Capacity with Point-of-Care Tests
- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today a commitment from the U.S. Department of Health and Human Services (HHS) to purchase BD diagnostic solutions in expanding access to rapid point-of-care testing for COVID-19 through a broad, decentralized network of testing instrumentation.
- 07/15/2020
|
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
- Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/14/2020
|
Colliers International Group Inc. to Announce Second Quarter Results on August 6, 2020
- TORONTO, July 14, 2020 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (NASDAQ and TSX: CIGI), announced today that results for the second quarter ended June 30th, 2020 will be issued by press release on Thursday August 6th, 2020 at approximately 7:00am ET. The conference call to review these financial results will take place at 11:00am ET on Thursday August 6th, 2020 and will be hosted by Jay S. Hennick, Chairman & CEO, John Friedrichsen, COO and Christian Mayer, CFO. The numbers to use for this call are: 1) toll-free 1-877-402-8911; or 2) for international callers 1-707-927-4894, with the conference ID number 1587213 for all participants.The conference call will also be accessible on our website at Corporate.Colliers.com in the “Events” section. For anyone unable to listen to the scheduled call, the rebroadcast number will be 1-855-859-2056 with conference ID 1587213. The rebroadcast and archive recording of the conference call will be available at the above noted web address for 90 days following the call.About Colliers International Group Colliers International (NASDAQ, TSX: CIGI) is a leading real estate professional services and investment management company. With operations in 68 countries, our more than 15,000 enterprising professionals work collaboratively to provide expert advice to maximize the value of property for real estate occupiers, owners and investors. For more than 25 years, our experienced leadership, owning approximately 40% of our equity, has delivered compound annual investment returns of almost 20% for shareholders. In 2019, corporate revenues were more than $3.0 billion ($3.5 billion including affiliates), with $33 billion of assets under management in our investment management segment. Learn more about how we accelerate success at corporate.colliers.com, Twitter@Colliers or LinkedIn.For further information, please contact: Christian Mayer, CFO Colliers International Group Inc. (416) 960-9500
- 07/14/2020
|
COVID-19 Impact and Recovery Analysis - Disposable Hospital Supplies Market 2020-2024 | Growing Incidences of Infectious Diseases to Boost Growth | Technavio
- The Global Disposable Hospital Supplies Market will grow by USD 39.06 bn during 2020-2024
- 07/14/2020
|
Insider Sells Becton, Dickinson's Stock
- Becton, Dickinson Inc (NYSE:BDX) was trading 1.6% higher from the previous closing price. A Form 4 filing filed with the SEC on Monday, July 13 showed that EVP & Pres Life Sciences Kaltenbach Patrick sold 1,272 shares at an average price of $260.00. The transaction moved the executive's stake in Becton, Dickinson Inc. to 10,340 shares.Why Insider Transactions Are Important? While transactions from an insider shouldn't be used as the sole item to make an investment or trading decision, an insider buying or selling stock in their company can be a good added factor that leads to more conviction in a decision.When an insider buys stock after an important sell off, that can indicate the insider's faith in the success of the organization. Henceforth, if the stock is bought at new highs, it might be because the insider feels that the stock is not overvalued. Insiders who sell stock at new lows could be anticipating some capitulation moment. If the insider sells at new highs, it could point to the intention to "take some profit" and "lock in a gain."Transaction Codes To Focus On Wall Street tends to focus on insider transactions which take place in the open market, viewed inside a Form 4 filing via codes P for purchase and S for sale. If the transaction was an open-market transaction, that means that the insider made a concious decision for the company's stock moving forward.Transaction codes other than P or S are often viewed with less conviction as they are often not tied to a decision by the exec. As an example, transaction code C indicates the conversion of an option. Transaction code A indicates the insider may have been forced to sell shares in order to receive compensation the exec was promised upon being hired by a company.See more from Benzinga * Benzinga's Top Upgrades, Downgrades For July 9, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/13/2020
|
Qiagen N : provides update on Q2 2020 results, announces strong outlook for Q3 and FY 2020, and 2021 perspectives in light of coronavirus pandemic | MarketScreener
|
Colliers International Completes Acquisition of Maser Consulting
- TORONTO and RED BANK, N.J., July 13, 2020 -- Leading global commercial real estate services and investment management firm, Colliers International (NASDAQ and TSX: CIGI), has.
- 07/13/2020
|
IGC Reports Financial Results for the Fiscal Year Ended March 31, 2020
- IGC announces its financial results for the Fiscal Year Ended March 31, 2020.
- 07/13/2020
|
Becton Dickinson Forms $70M Covid-19 Partnership With U.S. For Syringes
- Becton Dickinson (BDX) has formed a $70 million public-private partnership with the U.S. government for the manufacturing of injection devices used for COVID-19 vaccines.As part of the partnership, the U.S. Biomedical Advanced Research and Development Authority (BARDA) will invest an estimated $42 million into a $70 million capital project to further expand BD's operations and production capacity in Nebraska, where it has manufactured medical devices for nearly 70 years.The new capacity, which is expected to be online within 12 months, will grant BARDA priority access to injection devices from the new manufacturing lines to meet mass vaccination needs for COVID-19 and future pandemics.The medical technology company said it finalized an initial order for 50 million needles and syringes to be delivered by the end of December this year for the U.S. government’s COVID-19 vaccination needs. The company added that it continues to work closely with the U.S. government for additional quantities of injection devices under the Operation Warp Speed vaccine program, which seeks to begin supplying millions of doses of a safe, effective vaccine for COVID-19 in 2021."BD's commitment to produce 50 million vaccine injection devices by the end of this year to support the U.S. COVID-19 vaccination campaign is the latest effort in the company's multifaceted global response to this virus," said Rick Byrd, BD’s Medication Delivery Solutions president. "Over the past four years, BD has committed to invest more than $340 million in our Nebraska facilities."BD does not expect the order to have an impact on its ability to meet existing customer requirements for needles and syringes, including the annual flu vaccination and childhood immunization campaigns.The world’s largest manufacturer of injection devices said that in addition to the U.S., it has also received orders from other countries, including Canada and the U.K.The U.S. government order comes as BD earlier this week announced that the U.S. Food and Drug Administration granted emergency-use authorization (EUA) for its portable COVID-19 antigen test that delivers results in 15 minutes.BD will ramp-up manufacturing capacity to 2 million tests per week by the end of September and seeks to produce up to 10 million tests from July through September.Five-star analyst Larry Biegelsen at Wells Fargo, who reiterated a Buy rating on the stock, said that assuming 2 million tests per week would be produced at an average price of $18, the COVID-19 antigen test could generate revenue of about $470 million per quarter, if BD would sell all of its capacity.Shares rose 1.2% to $254.49 in early afternoon trading. The stock is still down 7.6% so far this year and analysts have a cautiously optimistic Moderate Buy consensus on the stock with 6 Buy ratings versus 7 Hold ratings. The $273 average price target indicates 7.7% upside potential in the shares over the coming 12 months. (See BDX stock analysis on TipRanks).Related News: Novavax Spikes 42% Pre-Market On $1.6B U.S. Funding For Covid-19 Candidate Corvus Shoots Up 115% On Start Of Novel Immunotherapy Study In Covid-19 Patients GenMark Soaring In Pre-Market On 118% Revenue Explosion More recent articles from Smarter Analyst: * Moderna Completes Enrollment For Phase 2 Covid-19 Vaccine Study * KKR To Snap Up Global Atlantic For Foothold In Insurance Industry * National General Pops 69% In Pre-Market On $4B Takeover Deal By Allstate * AstraZeneca-Merck Pancreatic Cancer Drug Wins European Approval
- 07/08/2020
|
BD Receives EUA for New Antigen Test to Combat COVID-19
- Becton, Dickinson (BDX) receives EUA from the FDA for a rapid, point-of-care, antigen test to detect SARS-CoV-2 in 15 minutes.
- 07/08/2020
|
BD Unveils BD PurPrep Patient Preoperative Skin Preparation
- By developing fully sterile PurPrep, BD (BDX) is offering health care experts a more complete set of tools to mitigate the risk of intrinsic contamination in antiseptic solutions.
- 07/08/2020
|
U.S. govt to invest $42 mln in Becton Dickinson's injection device production
- Becton Dickinson and Co said on Wednesday the U.S. government will invest $42 million to expand the medical technology company's manufacturing lines for injection devices to support vaccination efforts against COVID-19. The investment is under a public-private partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Health and Human Services Office, Becton Dickinson said. BARDA has invested more than $3 billion in vaccines and funded more than 30 projects as part of "Operation Warp Speed," the White House program aimed at accelerating access to vaccines and treatments for the new coronavirus.
- 07/08/2020
|
BD to get $42 million to manufacture vaccine injection devices
- Becton Dickinson & Co. said Wednesday that it will receive $42 million from the U.S. government to build out manufacturing capacity for vaccine injection devices, to be used during the coronavirus pandemic. The Biomedical Advanced Research and Development Authority awarded the funding as part of Operation Warp Speed, a Trump administration program aimed at having 300 million doses of a COVID-19 vaccine in January. BD, which says it is the largest manufacturer of injection devices in the world, said the total cost of the capital project is $70 million. BD's stock is down 7.5% since the start of the year, while the S&P; 500 has declined 2.6%.
- 07/08/2020
|
BD Partners with U.S. Government on $70 Million Manufacturing Infrastructure Project for Mass Vaccination Campaigns
- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the formation of a strategic, public-private partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response, to develop new manufacturing lines for injection devices that will provide priority access to the U.S. government for hundreds of millions of syringes and needles to support current and future pandemic vaccination efforts.
- 07/08/2020
|
Is Colliers International Group Inc (CIGI) A Good Stock To Buy?
- We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
- 07/08/2020
|
Were Hedge Funds Right About Piling Into Becton, Dickinson and Company (BDX)?
- The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]
- 07/07/2020
|
Becton Dickinson Virus Test Prompts FDA False-Positive Alert
- The FDA issued an alert for one of Becton Dickinson's coronavirus tests due to an increased risk of false-positive results.
- 07/07/2020
|
FDA alerts health care providers about false positives for one of BD's COVID-19 tests
- Shares of Becton Dickinson & Co. were down 0.7% in premarket trading on Tuesday, the day after the Food and Drug Administration issued an alert about an increased risk of false-positive results for one of BD's COVID-19 diagnostic tests. In one study, 3% of the results were false positive for the BD Max System test, which received an emergency use authorization from the regulator in April. "Consider any positive result presumptive from tests using the BD SARS-CoV-2 Reagents for the BD Max System," the FDA said. "Consider confirming with an alternate authorized test." A spokesperson confirmed that BD had received reports of the false-positive results, saying that "the elevated rates represent a small subset of the positive results" and that the company is in discussions with the FDA about the issue. On Monday, BD had announced the launch of a point-of-care COVID-19 antigen test that can detect the coronavirus in 15 minutes, the third of its COVID-19 diagnostic test. BD's stock is down 7.9% since the start of the year. The S&P; 500 has declined 1.5% year-to-date.
- 07/07/2020
|
BD Launches First and Only Fully Sterile Povidone-Iodine and Isopropyl Alcohol Skin Preparation
- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the availability of BD PurPrep™ patient preoperative skin preparation with sterile solution, the first and only fully sterile povidone-iodine plus isopropyl alcohol single-use antiseptic skin preparation (PVP-I; 0.83% available iodine and 72.5% isopropyl alcohol) commercially available in the United States.
- 07/07/2020
|
New APM Study Reveals the Contribution of Projects and Project Management in the Health, Pharmaceutical and Life Sciences Sector
- Association for Project Management (APM), results of a study of the contribution of project management in the UK healthcare sector
- 07/07/2020
|
FDA Authorizes Becton, Dickinson Portable 15-Minute Coronavirus Test
- Healthcare technology specialist Becton, Dickinson (NYSE: BDX) announced Monday that it has been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for an antigen test that can effectively detect the presence of the coronavirus. According to Becton, Dickinson, it is also very fast; the company says it can produce results in 15 minutes. At the moment, according to Becton, Dickinson, the BD Veritor Plus System is in use in over 25,000 healthcare facilities within the U.S. It is used to test for illnesses such as flu.
- 07/06/2020
|
U.S. FDA alerts on false positive result from Becton Dickinson COVID-19 test
- The U.S. Food and Drug Administration alerted clinical laboratories and healthcare providers on Monday about false positive results from one of Becton Dickinson and Co's COVID-19 molecular diagnostic tests. The test, designed to detect viral nucleic acid from the virus that causes COVID-19, is in use in nearly every state across the U.S. at hundreds of laboratories. In one study, the manufacturer found about 3% of the results were false positives, according to the FDA.
- 07/06/2020
|
Covid Report: Medical Giant Surges On Its 15-Minute Coronavirus Test
- Becton Dickinson gained U.S. authorization for its third coronavirus test on Monday, sending BDX stock higher at the close. Gilead Sciences and Mylan also gained remdesivir nods.
- 07/06/2020
|
Miami Mayor Shuts Down Restaurants Except for Takeout and Delivery
- • Miami is closing restaurants for both indoor and outdoor dining again, along with “ballrooms, banquet facilities, party venues, gyms and fitness centers, and short-term rentals,” Mayor Carlos A. Gimenez said in a statement Monday. • The return of Major League Baseball is at risk after the Houston Astros and Washington Nationals canceled their team workouts Monday, citing delays in receiving coronavirus test results. “We cannot have our players and staff work at risk,” Mike Rizzo, the Nationals’ GM said in a statement.
- 07/06/2020
|
Abbott Deal, UnitedHealth Coverage Push Up Tandem Shares
- Stock of San Diego-based medical device company hits one-year high Continue reading...
- 07/06/2020
|
Coronavirus latest: Monday, July 6
- The United States topped over 130,000 new cases of coronavirus over the 4th of July holiday weekend, with Florida and Texas breaking new daily case records. Yahoo Finance’s Anjalee Khemlani breaks down the latest news about the coronavirus on The Final Round.
- 07/06/2020
|
Salesforce.com: Moving Toward Good Health (NYSE:CRM)
- Salesforce.com has a significant presence in the healthcare segment and there are indications of continued strong momentum.
- 07/06/2020
|
Becton Dickinson Cleared by FDA for 15-Minute Virus Test
- Becton Dickinson said it was cleared by the FDA to market a 15-minute coronavirus diagnostic test and will begin shipping the test this week.
- 07/06/2020
|
BD's stock gains on launch of rapid COVID-19 diagnostic test
- Shares of Becton Dickinson & Co. gained 3.6% in premarket trading on Monday after the diagnostics company announced the launch of a point-of-care COVID-19 antigen test that can detect the coronavirus in 15 minutes. It's the third BD COVID-19 diagnostic test to receive emergency use authorization from the Food and Drug Administration during the pandemic. "This will be a game-changer for frontline health care workers and their patients to be able to access a quick diagnostic test for COVID-19, offering results in real-time at convenient locations like retail pharmacies, urgent care centers and doctors' offices," Dave Hickey, president of BD's integrated diagnostic solutions business, said in a news release. BD's stock is down 9.9% year-to-date, while the S&P; 500 has declined 3.1%.
- 07/06/2020
|
Becton Dickinson's rapid antigen test for COVID-19 authorized by FDA, shares rise
- Becton Dickinson shares rose $5.40, or 2.3%, to $250.61 in early trading. The authorization was based on a robust sample size of 226 specimens from sites across the United States, Evercore ISI analyst Vijay Kumar said in a research note. "We think the new antigen test will play a big role in the coming flu season as a rapid, rule out test," Kumar said.
- 07/06/2020
|
Median Technologies Is Awarded the Euronext European Rising Tech Label
- Regulatory News: Median Technologies (Paris:AMLDT), The Imaging Phenomics Company® (ALMDT) announced today that it has been awarded the Euronext Europ
- 07/06/2020
|
Analysis on New Product Launches in COVID-19 Related Markets: Patient Temperature Management Market 2020-2024 | Evolving Opportunities with 3M Co. and Asahi Kasei Corp. | Technavio
- The Global Patient Temperature Management Market will grow by $ 1.09 bn during 2020-2024
- 07/04/2020
|
COVID-19: Significant Shift in Strategy of Global Automated Microbiology Market 2020-2024 | Evolving Opportunities with Abbott Laboratories and Agilent Technologies Inc. | Technavio
- The Global Automated Microbiology Market 2020-2024 will grow by $ 744.20 mn during 2020-2024
- 07/03/2020
|
BD Announces Live Webcast Of Third Fiscal Quarter Earnings Conference Call
- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2020 earnings conference call on Thursday, August 6, 2020, at 8:00 a.m. (ET). BD will issue a press release detailing the quarter's earnings earlier that morning.
- 07/02/2020
|
Digital Microscopes Market to Surpass US$ 1,743.9 Million Globally by End Of 2027, Says CMI | | IT Business Net
- SEATTLE--(BUSINESS WIRE)--#DigitalMicroscopes--According to Coherent Market Insights, the global digital microscopes market is estimated to be valued at US$ 1,124.0 million in 2020, and is expected to
- 07/02/2020
|
The Top-Ranked Dividend Growth Stocks In The Health Care Sector
- This article presents the top-ranked dividend growth stocks in the Health Care sector. To rank stocks, I sort them by decreasing quality scores using DVK Qualit
- 07/02/2020
|
MastOR Secures Seed Funding from Sofinnova Partners to Develop its Laparoscopy Assistance Platform | | IT Business Net
- PARIS, FRANCE / ACCESSWIRE / July 2, 2020 / MastOR, a medical device company developing a surgical robot for laparoscopy assistance, announced today a €3M equity round through a seed investment from t
- 07/02/2020
|
Sofinnova Partners : MastOR Secures Seed Funding from Sofinnova Partners to Develop its Laparoscopy Assistance Platform
|
Boom biotecnológico a la vista: Caixa Capital Risc, Inveready e Ysios anticipan un mayor apetito inversor y nuevas oportunidades
- La pandemia traerá un boom de inversión en biotecnología: los principales fondos españoles dan las claves para invertir en un sector muy especializado.
- 07/02/2020
|
Sofinnova Partners : Announces Two First Investments from its MD Start III Medtech Acceleration Fund
|
Sofinnova Partners Announces Two First Investments from its MD Start III Medtech Acceleration Fund
- Sofinnova Partners announces two first investments from its MD Start III Medtech Acceleration Fund
- 07/02/2020
|
HC2 Holdings Provides Update on Strategic Initiatives | MarketScreener
|
Agilent Technologies Inc (NYSE:A) Holdings Cut by Guggenheim Capital LLC
- Guggenheim Capital LLC cut its position in Agilent Technologies Inc (NYSE:A) by 31.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,478 shares of the medical research company’s stock after selling 23,802 shares during the quarter. Guggenheim Capital LLC’s holdings in Agilent Technologies […]
- 07/01/2020
|
Agilent Technologies (NYSE:A) Stock Rating Reaffirmed by Goldman Sachs Group
- Agilent Technologies (NYSE:A)‘s stock had its “neutral” rating reaffirmed by equities researchers at Goldman Sachs Group in a research report issued on Wednesday, Stock Target Advisor reports. Other equities research analysts have also recently issued research reports about the company. Cfra cut their target price on Agilent Technologies from $89.00 to $85.00 and set a […]
- 07/01/2020
|
Recent Analysts’ Ratings Changes for Chart Industries (GTLS)
- A number of research firms have changed their ratings and price targets for Chart Industries (NASDAQ: GTLS): 6/29/2020 – Chart Industries was upgraded by analysts at Evercore ISI from an “in-line” rating to an “outperform” rating. They now have a $62.00 price target on the stock. 6/24/2020 – Chart Industries was upgraded by analysts at […]
- 07/01/2020
|
Dividend Growth 50: Big Income Growth, Minimal Pandemic Peril
- The DG50 experienced no coronavirus-related dividend cuts during the first half of 2020. Year-over-year growth of the portfolio's income stream was outstanding.
- 06/30/2020
|
Accenture (ACN) Receives a Hold from Wells Fargo - Markets
- Wells Fargo analyst Edward Caso maintained a Hold rating on Accenture (ACN – Research Report) on June 25. The company’s
- 06/30/2020
|
ÖAW nahm 96 neue Stipendiat/innen auf
- Stipendien in Höhe von insgesamt mehr als 10 Mio. Euro wurden an herausragende Nachwuchswissenschaftler/innen vergeben.
- 06/30/2020
|
All About the Berkeley Lights Stock IPO
- For some reason, IPOs are coming out of the woodwork these days. Seems strange when you consider that just three months ago, all hell was breaking loose, and everyone seems to have forgotten about that. In fact, since the first-ever mention of the Woohoo Flu, the Nasdaq has gone up by +13%. Maybe everyone's rushing to IPO before the door slams shut again? It was only several months ago that we wrote about 'How Berkeley Lights Enables Synthetic Biology,' and now they've filed for an IPO, which means we get to take a look under the hood. We'll assume you're
- 06/30/2020
|
Insights & Forecast with Potential Impact of COVID-19 - Breast Biopsy Devices Market 2020-2024 | Growing Prevalence of Breast Cancer Cases to Boost Growth | Technavio
- The Global Breast Biopsy Devices Market will grow by $504.94 mn during 2020-2024
- 06/30/2020
|
Seoul’s startup and tech ecosystem is world class — here’s what you need to know
- The city is already home to 8,708 startups, 85 accelerators, and the country has a total of 10 unicorns. And now, Seoul entered the top 20 startup ecosystems in the world.
- 06/29/2020
|
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
- Individual and institutional investors as well as advisors are invited to log-on to LifeSciencesInvestorForum.com to view presentations
- 06/29/2020
|
Agilent Technologies Inc (NYSE:A) Shares Sold by Skandinaviska Enskilda Banken AB publ
- Skandinaviska Enskilda Banken AB publ reduced its position in Agilent Technologies Inc (NYSE:A) by 1.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 74,672 shares of the medical research company’s stock after selling 1,096 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s […]
- 06/28/2020
|
Agilent Technologies Inc (NYSE:A) Declares $0.18 Quarterly Dividend
- Agilent Technologies Inc (NYSE:A) declared a quarterly dividend on Wednesday, May 20th, Zacks reports. Investors of record on Tuesday, June 30th will be paid a dividend of 0.18 per share by the medical research company on Wednesday, July 22nd. This represents a $0.72 dividend on an annualized basis and a yield of 0.84%. The ex-dividend […]
- 06/28/2020
|
Liverpool hit harder than most by coronavirus but city has hope
- SPECIAL REPORT: We take an in-depth look at how the city plans to recover from the crisis and transform its position in the country
- 06/28/2020
|
Becton Dickinson and Co (NYSE:BDX) Shares Acquired by Verus Capital Partners LLC
- Verus Capital Partners LLC lifted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 65.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 165 shares of the medical instruments supplier’s stock after buying an additional 65 shares during the quarter. Verus […]
- 06/28/2020
|
Dividend Champion And Contender Highlights: Week Of June 28
- A weekly summary of dividend activity for Dividend Champions and Contenders. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
- 06/27/2020
|
Movers And Shakers Of The Week [June 22-27]
- We bring to you the latest edition of movers and shakers of the week in the Indian startup ecosystem.
- 06/27/2020
|
Accenture : Third Quarter Fiscal 2020 Transcript | MarketScreener
|
Gut health and exercise: studies suggest exercise could change microbiome
- Mounting evidence suggests that exercise can modify the types of bacteria that reside within our guts
- 06/26/2020
|
Global Respiratory Syncytial Virus Diagnostics Market 2020-2024 | Evolving Opportunities with Abbott Laboratories and Becton, Dickinson and Co. | Technavio
- The Global Respiratory Syncytial Virus (RSV) Diagnostics Market will grow by $ 585.17 million during 2020-2024
- 06/26/2020
|
Top Holdings Of Dividend ETFs (Part 3: Hidden Gems In June 2020)
- Part 1 of this article presented the top 50 holdings of 47 dividend-paying ETFs, ranked by using a proportional scoring system that favors larger investments an
- 06/25/2020
|
Hutchison China MediTech : Chi-Med Announces US$100 Million Equity Investment by General Atlantic | MarketScreener
|
Chi-Med Announces US$100 Million Equity Investment by General Atlantic
- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE...
- 06/25/2020
|
The Challenges And Opportunities For Life Sciences Industry - ValueWalk
- The life sciences industry, comprised largely of small and middle market companies, is the focus of a new report from the NCMM.
- 06/24/2020
|
Cantel Medical Corp. (NYSE: CMD) Q3 2020 Earnings Call Transcript | AlphaStreet
- Final earnings conference call transcript of Cantel Medical Corp. - CMD stock
- 06/24/2020
|
Wave Life Sciences Ltd (NASDAQ:WVE) Sees Large Drop in Short Interest
- Wave Life Sciences Ltd (NASDAQ:WVE) was the recipient of a large drop in short interest in the month of June. As of June 15th, there was short interest totalling 4,690,000 shares, a drop of 5.8% from the May 31st total of 4,980,000 shares. Based on an average trading volume of 571,400 shares, the days-to-cover ratio […]
- 06/24/2020
|
Assessment of COVID-19's Effect on Hemostats and Tissue Sealants Market 2020-2024 | Use of Hemostats and Tissue Sealants in Surgeries to Augment Growth | Technavio
|
Why Buy These 2 TSX Stocks for Your TFSA Portfolio Now?
- TFSA investors should consider buying these two TSX stocks now for capital appreciation and steady income.
- 06/23/2020
|
Cognizant collaborates with Alphabet-owned Verily to facilitate Covid-19 testing across US
- The program is in operation at over 140 testing sites across 13 states and has supported the US administration with 284,000 COVID-19 tests.
- 06/23/2020
|
Hyundai Motor, Kia Motors and LG Chem Launch Global Competition to Invest in EV and Battery Start-ups | MarketScreener
|
Preis für einen, der Blinde sehend macht - Blick
- Botond Roska, Direktor am Institut für Molekulare und Klinische Ophthalmologie Basel (IOB) und Professor an der medizinischen und der naturwissenschaftlichen Fakultät der Uni Basel, erhält den mit einer Million dotierten Körber-Preis für die Europäische Wissenschaft.
- 06/23/2020
|
Steris PLC (NYSE:STE) Short Interest Update
- Steris PLC (NYSE:STE) was the target of a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 1,360,000 shares, an increase of 7.1% from the May 31st total of 1,270,000 shares. Based on an average trading volume of 736,000 shares, the short-interest ratio is presently […]
- 06/23/2020
|
RWS Holdings plc (RWS) to Issue Dividend of GBX 1.75 on July 17th
- RWS Holdings plc (LON:RWS) announced a dividend on Tuesday, June 9th, Upcoming.Co.Uk reports. Shareholders of record on Thursday, June 25th will be paid a dividend of GBX 1.75 ($0.02) per share on Friday, July 17th. This represents a yield of 0.29%. The ex-dividend date is Thursday, June 25th. The official announcement can be seen at […]
- 06/23/2020
|
Becton Dickinson and Co (NYSE:BDX) Shares Sold by Two Sigma Advisers LP
- Two Sigma Advisers LP lessened its position in shares of Becton Dickinson and Co (NYSE:BDX) by 91.7% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 29,777 shares of the medical instruments supplier’s stock after selling 328,800 shares during the period. Two Sigma Advisers […]
- 06/23/2020
|
Danaher Co. (NYSE:DHR) Plans Quarterly Dividend of $0.18
- Danaher Co. (NYSE:DHR) announced a quarterly dividend on Tuesday, May 5th, RTT News reports. Stockholders of record on Friday, June 26th will be given a dividend of 0.18 per share by the conglomerate on Friday, July 31st. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date […]
- 06/23/2020
|
Grant Thornton names Lisa Walkush to lead firmwide Industry program
- Grant Thornton LLP has named Lisa Walkush as its national managing principal of its Industry program, effective immediately. She will also serve on th
- 06/23/2020
|
LEG, H.I.G. Purchase 1.2M-SF Pharma Campus Outside Princeton
- One of your neighbors posted in Neighbor News. Click through to read what they have to say. (The views expressed in this post are the author’s own.)
- 06/22/2020
|
Research reveals search engine habits of patients and HCPs -
- New research by Life Sciences by Stickyeyes, conducted for pharmaphorum, sheds light on people’s behaviour when searching for oncology information online.
- 06/22/2020
|
Das Kriegsende brachte den tiefsten Einschnitt der Firmengeschichte
(FOTO)
- SCHOTT erinnert an den legendären "Zug der 41 Glasmacher" vor 75 Jahren
- 06/22/2020
|
9,020 Shares in Steris PLC (NYSE:STE) Acquired by CIBC World Markets Inc.
- CIBC World Markets Inc. purchased a new position in shares of Steris PLC (NYSE:STE) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 9,020 shares of the medical equipment provider’s stock, valued at approximately $1,263,000. A number of other hedge funds and other institutional investors have […]
- 06/22/2020
|
Global Silicon Photonics Market (2019 to 2025) - Growing Deployment of 5G Networks Presents Opportunities - ResearchAndMarkets.com
|
Will the launch of Favipiravir mark the turnaround for Glenmark Pharma?
- If the drug proves to be efficacious for Covid treatment, Glenmark will cash in on first mover advantage.
- 06/21/2020
|
The History Of 50 Dividend Aristocrats And What It Means For Your Retirement
- I analyze the dividend growth rates and standard deviations of 50 dividend aristocrats. I take a deep dive at how it can impact retirement for dividend investor
- 06/21/2020
|
Zacks: Brokerages Expect Agilent Technologies Inc (NYSE:A) Will Post Earnings of $0.63 Per Share
- Brokerages predict that Agilent Technologies Inc (NYSE:A) will report $0.65 earnings per share (EPS) for the current quarter, according to Zacks. Five analysts have provided estimates for Agilent Technologies’ earnings, with estimates ranging from $0.49 to $0.73. Agilent Technologies reported earnings of $0.76 per share during the same quarter last year, which would suggest a […]
- 06/20/2020
|
COVID-19 Impacts Demand on Ultraviolet (UV) Disinfection Equipment Market 2020-2024 | Evolving Opportunities With Advanced UV Inc. and American Ultraviolet Inc. | Technavio
|
COVID-19 Impacts Demand on Ultraviolet (UV) Disinfection Equipment Market 2020-2024 | Evolving Opportunities With Advanced UV Inc. and American Ultraviolet Inc. | Technavio
- The Global Ultraviolet (UV) Disinfection Equipment Market will grow by USD 2.06 bn during 2020-2024
- 06/20/2020
|
Assessment of COVID-19's Effect on Biosurgery Market 2020-2024 | Increasing Number of Surgical Procedures to Augment Growth | Technavio
|
Assessment of COVID-19's Effect on Needle-Free Drug Delivery Devices Market 2020-2024 | Technological Advances in Needle-Free Drug Delivery Devices to Augment Growth | Technavio
|
Here’s Why Colliers Group (CIGI) Stock is an Attractive Pick for Investors
- PenderFund Capital Management recently released its May 2020 Investor Letter, a copy of which you can download here. Pender is a growing, independent, value-based mutual fund company with the goal of creating value by generating superior risk-adjusted returns. You should check out PenderFund Capital Management's top 5 stock picks for investors to buy right now, […]
- 06/19/2020
|
Centre revises quarantine period to 1 week for doctors, health workers in COVID-19 facilities
- The earlier May 15 advisory stated that high risk contacts should be quarantined for 14 days, tested as per ICMR testing protocol, actively monitored for development of symptoms and managed as per laid down protocol. .
- 06/19/2020
|
Croda International (LON:CRDA) Stock Price Passes Above 200-Day Moving Average of $4,852.05
- Croda International Plc (LON:CRDA) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4,852.05 and traded as high as $5,184.00. Croda International shares last traded at $5,158.00, with a volume of 229,431 shares traded. CRDA has been the topic of several recent research reports. JPMorgan […]
- 06/19/2020
|
Wave Life Sciences (NASDAQ:WVE) Stock Rating Upgraded by BidaskClub
- Wave Life Sciences (NASDAQ:WVE) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Friday, BidAskClub reports. WVE has been the topic of several other reports. Mizuho reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Wave Life Sciences in a research note […]
- 06/19/2020
|
Assessment of COVID-19's Effect on Needle-Free Drug Delivery Devices Market 2020-2024 | Technological Advances in Needle-Free Drug Delivery Devices to Augment Growth | Technavio
- The Global Needle-free Drug Delivery Devices Market will grow by USD 10.23 bn during 2020-2024
- 06/19/2020
|
Apprentice.io Raises $7.5M in Funding | FinSMEs
- Apprentice.io, a Jersey City, NY-based provider of an intelligent software platform for Life Sciences manufacturing, raised $7.5m in funding
- 06/18/2020
|
Iowa Soybean Research Center has new partner
- Merschman Seeds joins advisory council of soybean research program based at Iowa State University.
- 06/18/2020
|
Centre revises quarantine period to 1 week for docs, health workers in COVID facilities
|
Centre revises quarantine period to 1 week for docs, health workers in COVID facilities
- A decision on extending the quarantine period further by one week will be taken by the nodal officer or head of the department after taking into account the profile of such doctors and other health workers, according to an updated advisory issued on the management of healthcare professionals working in COVID and non-COVID areas of hospitals. The earlier May 15 advisory stated that high risk contacts should be quarantined for 14 days, tested as per ICMR testing protocol, actively monitored for development of symptoms and managed as per laid down protocol.
- 06/18/2020
|
Plants use odour camouflage tricks to 'hide in plain sight'
- Plants have an upper hand in the ecological battle against insects by using odour camouflage tricks to 'hide in plain sight' and avoid being eaten, scientists say.
- 06/18/2020
|
